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Abstract
Idiopathic non-infectious uveitis is the spontaneous inflammation of the eye, which can lead
to blindness if not treated correctly. Due to long-term side effects of corticosteroids, 4 classes
of off-label immunosuppressive treatments are sometimes used (alkylating agents, inhibitors
of T-lymphocyte signalling, antimetabolites and biological modifiers). We conducted a
systematic review and meta-analysis to assess the effectiveness of 3 treatment classes on
uveitis patients with similar characteristics. Results of the systematic review concurred with
the conclusions from the meta-analysis, which found that all immunosuppressive treatments
improved patient vision, with a statistically significant change in logMAR of -0.11 (95% CI
of -0.152 to -0.061, p=0). The subgroup analysis found antimetabolites and T-cell inhibitors
improved patient vision which was statistically significant, with antimetabolites showing a
better change in logMAR of -0.131 (95% CI -0.211 to -0.050, p=0.001. I2=0%). These
findings could inform policy and help develop concrete guidelines for treating uveitis
patients.

Keywords
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Chapter 1
1

Overview of Thesis and Introduction

1.1 Outline of Thesis
The primary objective of this thesis is to summarize the effects of the 3
immunosuppressive treatment groups used to treat idiopathic non-infectious uveitis
patients. We conducted a systematic review and meta-analysis with studies that met our
eligibility criteria. This chapter describes the terminology needed to understand what
uveitis is, how it is treated and how the outcomes are measured for identifying whether
treatments are effective or not. Then Chapter 2 discusses the literature for uveitis patients
and gives a clear case as to why an evidence-based approach is required for this particular
question, which leads into Chapter 3, justifications and objectives for the thesis. Before
discussing the methods, Chapter 4 describes the concepts and terminology that is vital for
describing and interpreting our meta-analysis. Chapter 5 outlines the methods used to
reach our objectives, and Chapter 6 summarizes the results for the systematic review,
quality assessment, meta-analysis, and publication bias analysis. Finally, Chapter 7
interprets the results and lists the strengths and limitations of the thesis, alongside
possibilities for future research.

1.2 Introduction to Uveitis
Uveitis is inflammation of the eye, which can result in patients becoming blind if it is not
treated correctly and it can affect both eyes (bilateral) or it can affect 1 of 2 eyes
(unilateral).1 To understand how to treat uveitis patients, it is important to understand the
anatomy of the eye as well as the mechanisms involved in the inflammation caused by
uveitis. An article published in 2005 presented specific terms and guidelines used to
define the various components of uveitis, which were updated from the 1987
International Uveitis Study Group (IUSG) that had developed criteria based mainly on
anatomy.1, 2 These terms were provided by uveitis specialists whose purpose was to
develop international consensus for the use of terms associated with uveitis in the
literature. The phrase coined for the use of these terms was the Standardization of Uveitis
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Nomenclature (SUN). Two important classifications key to understanding how to treat
uveitis patients were developed for the progression of the disease and the anatomy of the
eye.1, 2 A patient with uveitis may experience, acute, recurrent or chronic uveitis. Table 1
defines each course of disease.
Table 1: Course of Disease
Acute

Episode characterized by sudden onset and limited duration

Recurrent

Repeated episodes separated by periods of inactivity without
treatment ≥3 months in duration

Chronic

Persistent uveitis with relapse in <3 months after discontinuing
treatment

Anatomy
The progression of uveitis can also be associated with the location of the disease within
the eye. Thus, the 2005 SUN guidelines and the 2007 European classifications
anatomically classified locations within the eye as posterior, anterior or intermediate.1, 2
The anatomical location of uveitis is one of the most important clues to the pathogenesis
and treatment that a patient should receive.

Intermediate

Posterior

Anterior

Figure 1: Anatomy of the eye and location of Uveitis
Source: From http://www.vision-and-eye-health.com/uveitis-treatment.html
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1.2.1.1

Anterior Uveitis

Anterior uveitis involves the anterior chamber, which consists of all structures anterior to
the iris, as indicated by the purple box in Figure 1.3 Usually, it is acute in nature and only
1 of the 2 eyes is usually affected (unilateral). About 67% to 90% of patients with uveitis
have anterior uveitis. These patients are easier to treat than patients with uveitis in other
locations. The most common symptoms exhibited by patients with anterior uveitis are
dull pain in the eye, redness of the eye, blurred vision and photophobia.

1.2.1.2

Intermediate Uveitis

As shown in the Figure 1, the yellow box contains intermediate uveitis, which involves
the area where the retina meets the anterior structures of the eye, that is, the pars plana
and ciliary body. Intermediate uveitis is the least common type of uveitis, accounting for
only 7-15% of cases.1, 2 Both eyes are usually affected in patients with intermediate
uveitis, and patients are more likely to have chronic inflammation.1 Furthermore, patients
with intermediate uveitis commonly experience floaters and may experience painless
blurred vision.

1.2.1.3

Posterior Uveitis and Panuveitis

Posterior uveitis involves the retina and choroid, which can be seen in Figure 1
surrounded with an orange box. It is seen in 15-22% of uveitis patients.4 Generally, it is
chronic, recurrent and can affect both eyes. The underlying cause is often the result of an
abnormal immune disease.4 That is, immune cells enter the eye and become active
because they detect tissue that they identify as foreign or a threat to the individual. This
creates a complex immune response that causes inflammation in the eye. Treating
patients with autoimmune or idiopathic uveitis becomes difficult because it is hard to
detect the cause of uveitis in these patients, and thus treatment varies between
ophthalmologists. Posterior uveitis commonly causes blurred vision, floaters, and in some
cases, severe visual loss.5 Some patients develop scotomata, which are small regions of
less sensitive or absent vision.
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Inflammation affecting the entire uvea is called panuveitis. People with panuveitis may
be more likely to experience vision loss from the condition. Symptoms for patients with
panuveitis include floaters, blurred vision or loss of vision.4 Generally these patients are
considered idiopathic in nature, due to their cause being unknown and effecting the entire
eye.

Etiology
In addition to the anatomy of the eye, uveitis is also differentiated by the etiology. Up to
50% of cases have underlying causes that are usually inflammatory (eg, Sarcoidosis),
however there are some causes that are non-inflammatory (eg, syphilis, tuberculosis, and
toxoplasmosis).6 The other 50% of cases do not have a cause are deemed as idiopathic,
but the general consensus is that those are autoimmune cases without a simple category.7
The diagnosis for idiopathic uveitis is done by checking patients for the known causes of
uveitis, if the workup comes back negative then they are considered idiopathic.8

Epidemiology
Even though uveitis is a rare disease, it is still an important cause of blindness.9, 10 The
prevalence of uveitis is estimated to be about 115-204/100,000 persons.11, 12 Uveitis is the
cause of 30,000 new cases of legal blindness every year in the USA, and nearly 10% of
visual loss in the Western world.10

Age Range
Uveitis can affect any age group, from infants and children (juvenile idiopathic arthritis)
to young adults (pars planitis and seronegative arthropathies) to the middle-aged
(sarcoidosis and idiopathic) to the elderly (masquerade syndromes and idiopathic).13-15

Final Remarks
The introduction of the SUN classification in 2005 has made it easier to diagnose patients
with uveitis. Classification by progression, anatomy and/or cause of disease can facilitate
diagnosis and treatment.1 For example, infectious uveitis, like herpes simplex viruses,
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primarily causes acute or chronic anterior uveitis, and is easy to treat.5 However, the
subset of idiopathic uveitis (spontaneous cause) is much harder to treat.8

1.3 Treatments Administered to Uveitis Patients
Treatment depends on the location of the condition, severity, rate of recurrence and
etiology.8 For single episode anterior uveitis, the use of topical corticosteroid
preparations usually result in successful treatment. For moderate amounts of
inflammation involving the intermediate or posterior structures, periocular or even
intraocular steroids can be used successfully.16 For severe inflammation of the posterior
part of the eye, especially in bilateral cases, treatment usually involves systemic
immunomodulation.17 These agents include oral corticosteroids, which can only be used
in a limited role due to their side effects, which include osteoporosis and bone fractures,
aseptic hip fractures, induced diabetes mellitus, personality changes, and metabolic
abnormalities.
Idiopathic uveitis is more complex to treat since its cause is unknown. Treatment for
idiopathic uveitis can vary from steroids to immunomodulators. There is still a lot of
debate regarding what treatment should be used for patients with idiopathic uveitis. Since
1949, corticosteroids have been used to treat active inflammation of the eye.18 Steroids
reduce the inflammatory infiltration. However, there are many side effects from the use
of steroids.19 This has led to advances in the methods by which steroids are administered,
which has helped to lower the side effects.20 For example, periocular route administration
(ie, injection around the eye), has reduced side effects since the steroid’s use is limited to
the inflamed area.20 The ophthalmologist must be comfortable and the injection must be
given accurately. In general, steroids are usually administered in high doses to patients
that have acute uveitis. However, with chronic uveitis, high doses of steroids over a long
period of time can cause severe side effects in patients, thus immunomodulators, such as
alkylating agents (eg, cyclophosphamide), Inhibitors of T-lymphocyte signaling (eg,
cyclosporine), antimetabolites (eg, azathioprine) and biological modifiers (eg, TNFalpha) are more commonly used.16-21 For the purposes of this thesis we will not be
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discussing biologics, but they are a new but more expensive way of dealing with uveitis
patients.
A brief summary of each treatment group is given below.

Corticosteroids (First Line of Action in Uveitis Therapy)
Corticosteroids have been used since the 1950s. They work on multiple signaling
mechanisms to inhibit inflammation, but have many adverse effects.19,20 Ocular side
effects include cataract and glaucoma. The steroid dosage for vision threatening uveitis
typically starts at 1mg/kg.22 This is the first line of treatment given to patients since it can
quickly dampen the immune system and aid patients in recovering from acute, mild or
moderate uveitis. However, steroids are generally only used for 1 to 3 months, after
which the dosage is tapered. Steroids are not continued for chronic uveitis patients, as
long term steroid use has significant side effects, both on the eye and on the rest of the
body (if taken orally).22

Antimetabolites
Patients that continue to experience symptoms while on corticosteroids, or those who
have taken steroids over a long period of time and exhibit adverse effects, are prescribed
antimetabolites. Antimetabolites function by inhibiting nucleic acid synthesis, thereby
hindering the process of DNA synthesis. There are 3 types of drugs included in the
antimetabolite drug class.

1.3.2.1

Azathioprine (Imuran, Azasan)

Azathioprine (AZA) functions as a purine nucleoside analog (basically mimicking the
structures of DNA and RNA building blocks), thus it interferes with the synthesis of
RNA and DNA.23 Azathioprine is orally absorbed and the initial dose of AZA is
1mg/kg/day, up to a maximum dose of 2.5-4mg/kg/day.23-26 Nausea and vomiting are
common adverse effects, especially at the beginning of treatment.24
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1.3.2.2

Methotrexate (Rheumatrex, Trexall)

Methotrexate (MTX) also interferes with DNA production. MTX was introduced first as
treatment for neoplasm in 1958. It basically functions to reduce cell proliferation, causes
death to T-cells, and changes the response of B-cells. MTX was first introduced as a
treatment for ocular inflammation in 1965.27-37 MTX can be given orally, subcutaneously,
intramuscularly or intravenously, and is usually well tolerated.35 The initial dose of MTX
is 7.5-12.5 mg/week, and the maximum dosage usually given is 25 mg/week. The most
common adverse effects include: increased liver enzymes, ulcerative stomatitis and low
white blood cell count, which can lead to lethargy, infection, nausea, abdominal pain and
acute pneumonitis.30-37

1.3.2.3

Mycophenolate Mofetil (cellcept, Myfortic)

Mycophenolate Mofetil (MMF) inhibits the production of B and T cells by causing
deletion of nucleotides important for DNA production.38-51 MMF is taken orally and has
been known to help adults and children. MMF is usually given twice day at dosages
beginning at 500mg, up to a maximum of 1.5 gm. Among the most common side effects
of this drug are high blood sugar, increased blood cholesterol levels and gastrointestinal
tract complications.

Inhibitors of T-lymphocyte Signalling (Calcineurin Inhibitors)
T-cell inhibitors, or calcineurin inhibitors, were originally developed for use in organ
transplantation.16 They are a class of drugs that inhibit the replication and activation of
immune cells by inhibiting calcineurin, which is important in the activation and
maturation of immune cells. Drugs found in this class include Cyclosporine (CsA),
Tacrolimus (Fk-506), and Sirolmus.

1.3.3.1

Cyclosporine, CsA (Gengraf, Neoral, and Sandimmune)

CsA is mostly used as a T-cell suppressant. CsA has an intricate process, but the end
result is the inhibition of the proliferation and maturation of T-cells.52-58 CsA is mainly
given orally, and the initial dose ranges from 2.5-5 mg/kg/day, up to a maximum dosage
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of 10 mg/kg/day [10-12]. Adverse events of CsA consists of nephrotoxicity,
neurotoxicity, hypertension and increases the risk of infections.55

1.3.3.2

Tacrolimus, FK-506 (Prograf, Advagraf, Protopic)

FK-506 is similar to CsA, in that it inhibits certain molecules that are needed for immune
cell production. FK-506 is usually given orally, and the initial dose ranges from 0.15-0.30
mg/kg/day, up to a maximum of about .30 mg/kg/day.59, 62 Side effects can be severe and
include blurred vision, infection, cardiovascular damage, hypertension, and
nephrotoxicity.59-64

1.3.3.3

Sirolimus (Rapamune)

Sirolimus is similar in its effect to the other two drugs in this class. However, the side
effects of Sirolimus are more severe, including lung toxicity and cancer development.65, 66

Alkylating Agents
Alkylating agents were mainly developed for the treatment of cancer, but were later used
in the treatment of rheumatologic diseases.67 Alkylating agents work by damaging DNA
through alkylation, resulting in the inhibition of DNA production and cell death. These
are commonly used if other treatments fail.67,68

1.3.4.1

Cyclophosphamide (Cytoxan, Endoxan, Cytoxan, Neosar,
Procytox, and Revimmune)

Cyclophosphamide is derived from mustard gas. It alkylates one of the bases in DNA,
which leads to suppression of the immune system. It is orally and hepatically metabolized
in the liver. Initially, patients are given about 1-2 mg/kg/day, up to about 3 mg/kg/day.70
Adverse reactions include nausea and vomiting, bone marrow suppression, stomach ache,
diarrhea, and lethargy.69-73Fertile aged patients will lose their fertility and so these drugs
are not used in patients under 40, unless there is no alternative.
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1.3.4.2

Chlorambucil (Leukeran)

Chlorambucil was created in 1953 as a less toxic substitute for cyclophosphamide, which
functions using a slightly different mechanism. Chlorambucil is orally administered at
initial doses of 0.1mg/kg/day, to maximum of 0.2 mg/kg/day. Bone marrow suppression
is the most commonly occurring side effect of chlorambucil.74-79

Final Remarks on Treatments
In reviewing the various treatment groups, it becomes apparent that there are a number of
treatments that one can administer to uveitis patients. However, because the treatments
are given off-label there are no specific guidelines for the use of these treatments in
uveitis patients.65 Originally, these treatments were given and prescribed primarily to
patients with rheumatoid arthritis.16 Due to their immunosuppressive nature, they were
eventually given to patients with uveitis, as the idiopathic cases were mainly
autoimmune. Furthermore, the known side effects for immunosuppressive treatment are
taken from studies on patients with rheumatoid arthritis instead of patients with uveitis.
In Canada, patients with idiopathic uveitis are referred to a uveitis specialist. These
patients tend to have similar characteristics when they present with idiopathic uveitis.
Knowing which treatment will be most effective should also be taken into consideration
alongside the age, severity of disease, and location of disease. Therefore, this systematic
review will compile the literature on the various types of immunosuppressive treatments
and create an environment in which they can be compared amongst each other when used
to treat a patient with idiopathic non-infectious uveitis.

1.4 Outcomes Measured for Uveitis Patients
Once the treatment has been administered, there are a few ways to measure the efficacy
of the idiopathic uveitis treatment. These measures include inflammation grade, Visual
Acuity (VA), steroid discontinuation rate, uveitis relapse rate, and the adverse events that
patients may experience with the treatment. A brief summary of each measure is given
below.
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Anterior/Posterior Inflammation Grade
Figure 2 below shows a table from the 2005 SUN paper, which allows uveitis specialists
to numerically quantify the severity of Uveitis.1

Figure 2: The SUN classification for severity of uveitis*
*Table taken from SUN classification for Uveitis (1)

Severity of disease is measured by a grade that can range from no inflammation (ie, 0) to
intense inflammation (ie, 4+). It is usually measured twice, before treatment and after
treatment, to see if the treatment resulted in any difference in the severity.1
Before SUN was established in 2005, there were at least 4 other major systems used to
measure inflammation grade. These systems are similar to SUN, but some of the
differences make it difficult to compare the systems to one another.1 Thus, SUN was
established in order to standardize the way the inflammation grade is measured, which
allows studies to be compared with one another. However, some of the studies included
in this thesis were conducted before SUN was introduced, which means their systems of
measuring inflammation will have been less standardized. Also, there is no correlation or
conversion that can be drawn between pre-SUN studies and post-SUN studies. Thus, it is

11

difficult to compare the inflammation grade data and standardized the data from studies
using different scales, making it a less viable option to do a meta-analysis on.

Visual Acuity
Visual acuity (VA) describes the sharpness of vision, which is measured by the eye's
ability to resolve and recognize letters of varying sizes, through a VA test chart. This
estimate is an essential indicator of ocular health and is used to measure the effectiveness
of treatment in studies.
In order to understand which measure of VA is best for mathematical and/or clinical
settings, it is important to understand which VA test charts are used and how they
compare. There are many variations of test charts used in the clinical setting when
evaluating vision. But their variations have been adapted from mainly two chart designs,
the Snellen chart design and the Bailey–Lovie chart design (also called logMAR
charts).80
The Snellen chart design has been around since 1862 and is still used to this day in a
clinical setting.80 The basics behind the Snellen chart is that there are eleven lines of
block letters, where the first line consists of a large letter, and subsequent rows have
increasing numbers of letters that decrease in size. The distance that the eye perceives the
chart is important as well, with patients being 6 meters or 20 feet away or using a mirror
to mimic the distance in clinical settings that do not have the spatial capacity to distance
the patients 20 feet away. Important to note is that visual acuity is indicated by the
smallest row that can be read accurately and the standard reference that is considered
“normal” visual acuity for healthy eyes is 20/20 or 6/6, however note that generally
healthy individuals have vision that is greater than the reference VA.80 6/60 or 20/200 is
considered “legally blind” and this acuity represents the largest letter on the Snellen
chart.80 However, due to the charts lack of precision and high test-retest reliability when
dealing with patients with low vision, it is not used in clinical trials.81 The test-retest
reliability is defined as the score of VA tested multiple times on the same chart with the
same patient. With Snellen chart, there can be a discrepancy of up to 1 to 2 rows, from
one test to the next and would not be considered vision lost or gained but rather this
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discrepancy would be solely based on chance.81 Also, the Snellen chart follows a
geometric sequence which is not linear and makes its use in calculations very difficult.
In 1976 Bailey–Lovie developed a new design that would negate the limitations of the
Snellen chart, by being more precise and reducing variability (with logMAR chart the
test-retest reliability is ±0.07 logMAR to ±0.16 logMAR compared to the Snellen chart of
±0.29 to ±0.33 logMAR unit).81 The charts that were developed with the ideas from
Bailey–Lovie, are classified as “logMAR charts”, since the charts provide VA on a
logarithmic scale.82 With logMAR charts, the measure is more precise as the
ophthalmologist can measure vision letter by letter on the chart, rather than row-by-row
as on the Snellen chart, with each letter having a value of 0.02 logMAR.82 The logMAR
charts use a 5 letter per line scheme measuring the acuity letter by letter, which allows for
more accurate measure of visual acuity then the Snellen method. A Snellen score of 6/6
(20/20), corresponds to a LogMAR of 0. Positive logMAR values indicate vision loss,
while negative values denote normal or better visual acuity.83 So in other words the
logMAR takes the logarithm of each value and converts the geometric scale (Snellen) to a
linear scale (logMAR).84
With this said, it is important to note that in earlier case series, due to the logMAR charts
having increased testing time and the complexity of scoring, logMAR was not typically
used for routine eye examinations, and Snellen charts were used to measure VA instead.83
And these case series studies conclude with either “lines lost” or “lines gained” which are
not scientifically relevant.84 However, as mentioned above due to the precision of the
logMAR scale, it is used in clinical trials and cohort studies that are planned out to
measure VA, because it offers a scientific equivalent for amount of “lines lost” or “lines
gained.”84
Taking this into account, for our thesis, it was important to choose one scale that can be
effective at allowing for comparisons and analyses to be made on VA.85 For such a task
the Snellen scale cannot be used to assess the acuity data accurately from study to study,
especially in the low-vision range, due it’s a geometric nature and lack of precision,
however logMAR can since it is linear in nature.84, 85 Also, it is more precise and reliable
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to reach a scientific conclusion then the Snellen method.83-85 However, we must be
confident that we can convert from one scale to the other. There have been studies that
have indicated that one can interchangeably convert from one scale to the other, because
of a high correlation between the scales85, though one should be cautious of the
conversion as one method is not as reliable as the other and this could lead to
methodological heterogeneity between studies.86

Improved/maintained VA or inflammation grade
For descriptive purposes it is also important to include data from studies reporting on
percentage of patients that maintained/improved inflammation grade or VA. For the
definition of maintained or improved inflammation grade, it is the percentage of patients
that remained at the same inflammation grade or improved in inflammation grade (ie.
having less severe uveitis) after being treated. The two categories are reported together in
studies because they demonstrate a positive effect of having been given treatment.

Steroid Discontinuation Rate
One of the rationales for using immunomodulators is to spare the use of other agents,
such as systemic steroids, which have a wide range of adverse effects on the body. Thus,
some studies measure the effectiveness of treatment using the rate at which steroid use is
discontinued in patients, or if the dosage of steroid is reduced, after immunomodulatory
treatment.

Reason for Discontinuation and Discontinuation rate
Reasons for immunosuppressant discontinuation and the discontinuation rate helps
illuminate the relationship between treatment efficacy and rate at which a treatment is
discontinued. A treatment could be effective in treating uveitis, but the adverse events
could be problematic, for example, another aspect of the patient’s health could be worse
after taking CsA (ie, liver dysfunction).16
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Adverse Events
Adverse events are an important indicator of which treatments are effective and
advantageous for treating patients with uveitis. Adverse events are usually provided for
descriptive purposes.
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Chapter 2
2

Literature Review

The literature review has been organized by the level of evidence. First the individual
studies that have been done on immunosuppressive treatments given to uveitis patients
are discussed briefly. There have also been narrative reviews and a systematic review
carried out on this issue, but not necessarily specific to idiopathic uveitis patients.
Nonetheless, in this literature review, the various narrative reviews and the systematic
review are summarized, as well as some limitations are discussed as well. Then we
discuss randomized control trials (RCTs) that are beginning to emerge and we conclude
with literature pertaining to the cost of immunosuppressive treatments.

2.1 Individual Observational Studies
Most of the studies conducted on treatments for uveitis were case series. There were
various definitions of success amongst the studies. Effectiveness, in most studies, is
measured in terms of control of ocular inflammation, visual acuity, adverse events, and
steroid sparing success.
In Table 2, 4 studies are presented to showcase the efficacy of 4 different treatments and
the variety of studies encountered. While the presented studies may be valid in their own
right, they do not specifically look at the patient population we are investigating, rather
studies look at the entire uveitis or a subset of the population. For example, Bietti et al
(1976)87 look at the uveitis patients that have Bechet disease, which is a type of uveitis
with a known cause or Doycheva et al (2007)39 specifically look at the children
population with uveitis. Basically, the idea presented across with Table 2 is that studies
are diverse with their choice of patient population, however, there are studies that look at
a specific patient populations. Thus, organizing and systematically retrieving and
reviewing the literature would help paint a better picture of efficacy specific to idiopathic
uveitis patients. In addition, a meta-analysis can be conducted to obtain a standardized
efficacy (pooled analysis), measured in units of effectiveness that can be compared across
studies and used in a cost-effectiveness analysis as well.
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Table 2: Some Observational Studies and Their Findings
Treatment

Author

Study and Sample Size

Inflammation Grade change within 1 year

Methotrexate

Davatchi et
al, 200329

Prospective cohort Study,
comparative
n=23 Behçet patients associated
chronic uveitis; historic series: 297
Behçet associated uveitis

Decrease in Inflammation Grade, used
with low dosage of steroids

Azathioprine

Bietti et al,
197687

Case series
n=23 Behçet patients associated
posterior uveitis; women 21.7%.

Cyclosporine

BenEzra D.
et al, 198853

Randomized Control Trial (RCT)
n=40 Behçet patients

Did RCT study comparing cyclosporine to
Chlorambucil/steroid: Found cyclosporine
to be more effective in 3 year follow-up,
but greater side effects

Mycophenolate
Mofetil

Doycheva et
al, 200739

Case series
n= 17 patients with chronic uveitis in
children (32 eyes); mean age 8;
women 41.2%.

Improvement in the overall inflammation
grade, but limited due to small sample
size.

--

2.2 Review of Narrative Reviews on Uveitis
Studies have been conducted on the majority of idiopathic uveitis treatments. These were
mainly in the form of patient records, case series, and some retrospective and prospective
cohort studies. This indicates that the quality of the literature is low to moderate in
regards to treating patients with idiopathic uveitis. Many narrative reviews have also been
conducted in this subject area. These reviews tried to establish the use of
immunosuppressive treatment using the literature, however, since subjectivity and a lack
of transparency are inherent in the narrative review approach, these reviews were not
systematic, and thus have significant disadvantages. Detailed explanations of the findings
for each review are examined below, to present a better picture for the justification of a
systematic review and meta-analysis.
The format of these reviews are generally the same; an introduction of the topic is given
and a description of each treatment is provided, using studies that they deemed
appropriate for each treatment group. Most of the reviews conclude that more needs to be
done to understand which treatment is best for treating patients with idiopathic uveitis.
Also worth noting is that some reviews generalize the disease as ocular inflammation,
instead of the specific disease types, which limits their usefulness in drawing conclusions
for any one particular disease, such as idiopathic uveitis.
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A Cross-sectional Study of the Current Treatment Pattern in
Non-infectious Uveitis Among Specialists in the United States
Nguyen et al (2011)88 looked at the uveitis treatment patterns of 60 ophthalmologists,
comparing their behaviours to the requirements suggested by guidelines that were
developed by an expert panel in 2000.16 The study looked at the actual practice patterns
of physicians treating uveitis, with a particular focus on steroid usage in patients. The
expert panel established that steroids were the only agents approved for the treatment of
uveitis by the Food and Drug Administration, and steroids were the most frequently
prescribed treatment in the study population. The panel recommended that patients be
treated and maintained with less than 10 mg/day of prednisone, which would allow for
lower severity of the disease and, more importantly, would lower the frequency of side
effects. However, this study found that steroid doses greater than 30mg were used in
about 60% of patients for more than 1.5 years, and only 12% of patients were treated with
immunomodulators. Furthermore, 3 out of 4 physicians were not aware of the treatment
guidelines for uveitis.
The study by Nguyen et al (2011)88 concluded that there is need for education about the
guidelines for uveitis treatment in the medical community. Even though the guidelines
(ie, narrative review) are not based on a systematic approach, but rather an expert panel,
there is a need for greater awareness on the subject so more patients can access the
recommended type of treatment. Guidelines based on evidence would be more helpful for
policy makers and for every day practice by physicians.

Immunomodulatory Therapy for the Treatment of Ocular
Inflammatory Disease: Evidence-based Medicine
Recommendations for Use
The goal of this study was to provide comprehensive guidelines for the use of
immunosuppressive treatment for specific ocular inflammatory diseases. In order to
accomplish this, Kim and Foster (2006)89 summarized the current evidence in the
literature.
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Recommendations for the use of each treatment group depended on the strength of the
recommendations (either supporting or refuting a specific therapy) and on the quality of
the evidence (type of scientific evidence or trial).89 Table 3, which explains the
recommendation classifications, was taken from the study.
Table 3: Recommendation of Quality Levels adapted from Kim and Foster (2006)89

Table 4, on the following page, summarizes what Kim and Foster (2006)89 found in the
literature for each treatment group.
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Table 4: Findings from Kim and Foster (2006)89
Treatment

Initial
Dose

# of
studies
in this
review
7

Methotrexate

7.5mg
once
per
week

Azathioprine

1 to
3mg/
kg/d

7

Mycophenolate
Mofetil

1g
twice
daily

5

CsA

2 to
5mg/
kg/d

Cyclophosphamide 1 to
3mg/
kg/d

Adverse
events

Improved Decreased
Steroid- Recommendation
visual
inflammation sparing
acuity
response

10-25% –
fatigue,
nausea,
stomach
ache, and
anorexia
Discontinuati
on due to
gastrointestin
al side effects
– 15% to 30%
Gastrointesti
nal side
effects – 31%

90%*

76%*

56%*

B2 – Is useful in
treating patients that
may be intolerant to
steroids

--

--

--

--

65%*

54%*

27

Renal toxicity

--

--

--

10

Infections

--

68%*

55%

B1 – Is appropriate to
use with some uveitis
conditions and can be
used with low-dose of
steroids.
B2 – MMF could be
used if patients have
failed combination
treatment
B1 – Low-dose CsA
can be considered
first line defense with
or without steroids.
C2

*values obtained from 1 study

Kim and Foster (2006)89 used the studies from their literature review to formulate their
recommendations. The most studied treatment in their review was CsA, which 27 studies
examined. From their review, it is clear that both Azathioprine and CsA are considered
effective in treating patients with ocular inflammatory disease. In some cases, they also
indicate the percentage of patients that experienced controlled inflammation or better
visual acuity as a result of the treatment. Another key factor the review examined is the
percentage of patients that were able to decrease their use of steroids as a result of the
treatment.
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2.2.2.1

Limitations

Though the study by Kim and Foster (2006)89 reviewed the treatments for ocular
inflammatory disease in general, it did not specify which treatment group could be more
helpful for specific disease types (eg, idiopathic uveitis). Furthermore, they did not
include any methods or explanation for the criteria or suitability of the studies chosen in
each treatment group, which could create a bias towards any number of variables. A
systematic approach would help mediate these biases.
This review also had a broad range for disease type and did not specify which disease
each study looked at. The results for the different disease types were combined, and
conclusions were drawn for the overall effectiveness of each treatment for ocular
inflammatory disease in general. This could lead to doubt in the results, and the findings
could be inaccurate for patients with idiopathic uveitis. Consequently, because they
combined patient characteristics, this review cannot be used to directly draw conclusions
about the efficacy of the treatments for any specific disease.

Review of Immunosuppressive Drug Therapy in Uveitis
Dunn’s review examined the need for immunosuppressive treatment for uveitis patients,
noting that the results for efficacy and safety of such treatments are often limited by the
small sample size, weak study quality, absence of control participants, and changes in
natural course of uveitis.90
In this review, a literature search was conducted to examine studies published from 2001.
The summary of each treatment is similar to the review by Kim and Foster (2006)89.
However, Dunn (2004)90 only used 2 to 3 studies for each treatment group to evaluate the
effectiveness of each treatment. This could lead to bias, as the studies chosen could be
positive in nature and the patient population may not be homogenous. Also, as with the
previous review, no concrete evidence was shown regarding which treatment was better
for treating patients with uveitis or which treatment was best able to reduce inflammation.
This may be explained by the lack of homogeneity in the studies in respect to the
treatment group, patient population, or disease characteristics. Dunn noted that it is
difficult to know the treatment variables, because the studies were limited by the
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difficulty in enrolling large numbers of patients in clinical uveitis trials, and the absence
of a “gold standard” treatment with which to compare the other treatments. These
limitations can hinder the ability to determine which treatment is best for specific disease
types (eg, idiopathic uveitis). Dunn’s review stated that standardized diagnostic criteria
for various types of uveitis, as exists for rheumatologic diseases, would help in the
development of clinical trials for drug treatment.90 The study also tried to provide
methodology that could help in deciding which treatment is most effective. However,
since there is quite a bit of literature that is reviewable, one could simply conduct a
systematic review/meta-analysis to add knowledge to this field.

Cutting-edge Issues in Autoimmune Uveitis
Levy et al (2011)91, like the others, emphasized the need to investigate the different
treatments and analyze their effectiveness, as well as their side effects, to better
understand how to treat patients with uveitis. The review also suggested that newer ways
to determine the effectiveness of treatments are needed in order to make the best
judgement about which treatments work the best for these patients. Once again, this
review was very general regarding patient characteristics, and the studies they used to
summarize the treatments include the entire patient population with ocular disease.91

Use of Immunosuppressive Agents in Uveitis
Lustig and Cunningham (2003)92 examined the studies from the 5 years preceding the
study's publication date. This review looked at a few studies for each different uveitis
treatment (on average, 3-4 studies/treatment), and discussed similar studies to the
previously mentioned reviews. As with the other reviews, this could result in bias when
summarizing the findings to specific patient characteristics.92
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Table 5 below contains a summary of each treatment described by this review.
Table 5: Findings from Lustig and Cunningham (2003)92
Treatment

Initial
Dose

# of
studies
in this
review

Adverse events

Improved
visual acuity

Decreased
inflammation

Steroidsparing
response

Cost/
year
US$?

Methotrexate

7.5 mg
once per
week

3

Serious side
effects in 8.1% of
patients

90%*

76%*

56%*

763

Azathioprine

1 to
3mg/kg/
d

3

25%- leukopenia,
abnormal LFTs,
malaise and
dizziness

--

--

47%

763

Mycophenolate
Mofetil

1 g twice
daily

5

Gastrointestinal
side effects- 31%

94%

65%*

54%*

8748

CsA

2 to 3
mg/kg/d

4

Study 1: Serum
creatinine, 53%

Study 1: 82%*

Study 2: 76%

--

3252

After 6 months

Study 3: 50%

Study 3: 17%,
included renal
toxicity

Study 2: 92%
Study 3: 69%

Tacrolimus

0.15 to
0.3
mg/kg/d

2

--

69%

69%

--

13,164

Cyclophosphamide

1 to 3
mg/kg/d

10

Opportunistic
infections

--

--

--

3600

While this review examined similar studies to those presented above, the key difference
is that they also examined the costs associated with the different treatments. The costs
noted in table 5 are based on approximately 1 year of therapy for an individual of an
average weight of 70kg, using the lowest price from the website, www.cvs.com, or the
Drug Topics Redbook 2003.92 From the table, it can be seen that methotrexate and
azathioprine were the cheapest, while tacrolimus was the most expensive, with the lowest
reported efficacy at 69% of patients experiencing improved visual acuity and decreased
inflammation. CsA was the most effective in treating visual acuity, ranging from 82% to
92% improvement.

23

Overall, Lustig and Cunningham (2003)92 concluded that the choice of
immunosuppressive agents is complex and dependent upon the cause and severity of
uveitis, and the patient's prior response to immunosuppressive treatments.

Update on the Principles and Novel Local and Systemic
Therapies for the Treatment of Non-infectious Uveitis
Although, similar to the other reviews, this review went further in trying to create gold
standards and determine treatment regime for patients who present with non-infectious
uveitis.93 Gallego-Pinazo et al (2013)93 summarized that patients who come in with
uveitis that have relapsed should start treatment as follows:
1. Oral corticosteroids at low doses: Prednisone, 5-10 mg/day.
Prevention of cortisone side effects: Vitamin D + Calcium and Bisphosphonates.
Cyclosporine A, 3-5 mg/kg/day in patients under 40 years of age. Methotrexate would be
a good alternative to CsA.
2. Azathioprine or Mycophenolate, which are the third therapeutic stage if inflammatory
episodes continue. Tacrolimus is an alternative to these, remembering not to combine it
with Cyclosporine.
3. In the event of relapses despite prior treatments, Adalimumab is the treatment of
choice, although there are other options (infliximab, tocilizumab, rituximab).
4. Finally, although it is preferable to avoid its use, is the combination of alkylating
agents such as Chlorambucil or Cyclophosphamide.
The study further explained that after the use of corticosteroids, patients should be given
CsA, and if that is not effective, azathioprine or mycophenolate should be prescribed.93
The fact that there are so many narrative reviews on the treatments for uveitis indicates
that there is a need for a better understanding regarding the appropriate treatment for
patients. This is underscored by the number of reviews that try to describe which
treatment is the most effective. Although this type of review can be beneficial, without a
definitive consensus on which treatment is best, it is hard to extrapolate anything concrete
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from the reviews. However, it is still interesting to see which treatments experts would
recommend and in which order. They also indicate at which stages different treatments
should be given, which is important for policy building, however, a more systematic
approach is needed to extract the data from the literature and formulate quantifiable
results.93

2.3 Prior “Guidelines” on Uveitis
As mentioned previously, the more chronic the uveitis, the more likely it is to be
associated with poor visual prognosis.93 However, no specific guidelines for uveitis and
its management have been consensually proposed. While the term guideline has been
used loosely and often without any justification, epidemiologically speaking, these
guidelines are narrative reviews. For the purpose of the literature review, the studies that
have had influence and are referenced the most by other studies as guidelines in the
ophthalmology world, are included within this section.
From the literature search, one specific proposed guideline that tried to encapsulate the
data, was offered by Abad et al (2009)94 They attempted to describe and recommend the
management of uveitis using the experience of ophthalmologists. Their definition of the
“management of uveitis” consisted of the diagnostic procedure and types of antiinflammatory treatments. Their treatment recommendation included the importance of
identifying any underlying systemic diseases (ie, cause of uveitis). For each treatment
group they examined the literature for the mechanism of action, pharmacokinetics, nonophthalmic use, clinical experience for inflammatory eye disease, dosage and
administration, and side effects and monitoring.94 However, Abad et al (2009)94
concluded that a higher level of evidence is essential in order for there to be uniformity in
clinical practice.
In 2000, Jabs et al16 also provided recommendations for the use of immunosuppressive
drugs in the treatment of patients with ocular inflammatory disorders. They had a 12person panel of physicians with expertise in ophthalmologic, pediatric, and
rheumatologic disease, in research, and in the use of immunosuppressive drugs in patient
care.16 This study included the results not only from uveitis studies, but also from all
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patients with ocular inflammatory disorders. The panel looked at all the studies from
1999 to 2000 that they could find through a literature review. Recommendations were
evaluated according to the strength and quality of available evidence. Jabs et al (2000)16
concluded that the presence of corticosteroid side effects supports the rationale for using
immunosuppressive drugs in the management of these patients.
Because of the potential for side effects, Jabs et al (2000)16 indicated that treatment must
be tailored and regularly monitored. The careful use of immunosuppressive drugs for the
treatment of ocular inflammatory disorders can benefit patients by providing either better
control of the ocular inflammation or a decrease in the corticosteroid side effects. The
study specifically recommended that the immunosuppressive be commenced if a dose
greater than 10mg of prednisone was required for control of chronic inflammation.

Limitations
The two studies summarized above (Abad et al94 and Jabs et al16) both presented logical
arguments in their conclusions; however, a more systematic approach is needed to
encapsulate the evidence. Their conclusions were not methodologically systematic, and
their guidelines even state that the recommendations do not constitute treatment
guidelines, but aim to improve the uniformity of clinical practice for the management of
uveitis until higher levels of evidence are obtained. Thus, one cannot definitively
conclude how to treat patients from the findings presented in these guidelines.

2.4 Previous Systematic Review on the Effectiveness of
Immunosuppressants in the Treatment of Autoimmune
Posterior Uveitis
In 2011, Pato et al95 used a more systematic approach to review the literature from 1961
until 2007, using Medline (from 1961) and EMBASE (from 1980). The purpose of this
review was to try to fill the gap in the literature and provide recommendations for the use
of immunosuppressant treatment, since no clear recommendation for the management of
uveitis patients had been done.
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There were a total of 4235 studies in their initial search. After applying the
inclusion/exclusion criteria, which consisted of study type (which allowed any type of
study), disease (which was autoimmune non-infectious uveitis), treatment, and outcome
measures, they had a total of 265 articles. From the 265 articles, 90 studies pertained to
immunosuppressive treatments. The majority of the studies were prospective studies and
case series, with minimal RCTs. The authors summarized the findings of each study in a
table, which can be found in their supplementary notes. However, they only summarized
the most frequent etiology, the average dosage, and what outcome variables were
frequently measured for each treatment studied. As explained below, this does not
provide information as to which treatment is more effective in treating patients with the
specific type of uveitis we are concerned about in our study.
Pato et al (2011)95 tried to formulate a more specific set of guidelines using the
information they found, however, the conclusion of the study was that, overall,
immunosuppressants are effective at treating patients with uveitis. Due to the limitations
described in 2.4.1, they found no superiority for any individual treatment.

Limitations
When interpreting the summarized data in Pato et al (2011)95, one must take into account
the limitations of this systematic review. The first limitation is that they only searched 2
databases, which makes it possible that some articles were omitted. This would have
restricted their findings if they had conducted a meta-analysis, but the main limitation of
their study is that they were not able to conduct a meta-analysis. Consequently, since they
did not extract data, but just noted what each study measured for their outcome variable,
Pato et al (2011)95 could not draw any definitive conclusions; they could only summarize
some of the findings. Furthermore, they were unable to analyze the data because there
was no homogeneity in the studies. The authors mentioned that they were unable to
recommend a drug of choice for each type of uveitis, because the studies included were
of low quality and the outcome measures that were used to describe the results were
highly heterogeneous. Visual acuity (VA) was used in most of the studies, but there was
no uniformity in terms of the scale used to measure it. This could have been converted to
a standard scale, but no attempt to do so was made. The inflammation grade and number
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of relapses were other variables frequently used to assess effectiveness. In general, there
was great diversity in terms of diseases involved and the outcome variables used.
Pato et al (2011)95 recommended that the measured outcome variable should be
standardized, which would allow for an objective evaluation of the efficacy of drugs, and
in turn, would provide more meaningful comparisons between drugs. However, doing
something of this nature would require a major change in how ophthalmologists conduct
their studies, and would require them to unify and publish their case series and chart
reviews, with similar measures of outcome. Furthermore, in the case of VA, the
measurements could be converted and standardized in the logMAR scale. So, it would
have been possible to compare the different studies if the authors of the systematic review
had decided to do the conversion. However, the same cannot be said for inflammation
grade, as there is no standard conversion between the different scales.
The quality of the various studies was generally low to moderate. This does not indicate
whether drugs are effective or not, it just means that the evidence presented in the
different studies was inadequate due to poor study design of the original articles. Even
though the authors prioritized RCTs, the number of RCTs in this field is minimal,
because the number of patients with uveitis who need treatment is small, and diagnoses
associated with uveitis are varied.
Other limitations of this key study include heterogeneity in the outcome variables as well
as heterogeneity in the type of uveitis. Although many of the studies measure VA, there
is wide variability regarding other outcome variables. The authors also indicated that
there was no uniformity in relation to the procedures or scales used to measure the
outcome variables. For example, to measure VA, some authors used the Snellen chart,
others the logMAR scale, and others described “improvement” without a quantity. This
heterogeneity in the outcome of measure limits the findings and makes it difficult to
assess which treatment is best for patients. However, the study’s suggestion to alleviate
this limitation is to create a more standardized method to measure outcome variables,
allowing studies of different treatments to be compared.
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The limitations of this study hampers what could been a pioneer in the literature on
uveitis. However, these limitations could be overcome by creating inclusion/exclusion
criteria that limits the heterogeneity found in the literature. One could potentially do this
by limiting the type of uveitis and creating criteria that allows a more homogenous
population to be examined from study to study. As for the outcome variables, there may
be ways to analyze the data that are heterogeneous in nature, for example, by converting
the different scales for VA to a standardized logMAR scale.
All in all, the end result of Pato et al (2011)95 is a study that simply summarizes the
literature. This systematic review was used to establish a good reference of studies within
the subject area, but the heterogeneity within the patient population makes it harder to
reach a conclusion. However, it is commendable that an attempt was made to
systematically collect studies in the field of ocular inflammation.

2.5 Randomized Control Trials (RCTs)
Recently there have been RCTs that have been proposed to evaluate the effectiveness of
various treatment methods for uveitis patients. These treatment methods include the
immunosuppressive treatments described in this study but are not the focus of most
RCTs. The RCTs are more focused on biologics, and as discussed in section 1.3, they are
a new but more expensive method for treating patients. However, since they are a newer
way of treating patients, there is more focus on the use of biologics and their
effectiveness on uveitis patients.
Using the online service Clinicaltrials.gov96, there have been no RCTs done specifically
on idiopathic uveitis patients, however there have been studies done solely on uveitis
patients. The Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group
(2015)97 looked at uveitis patients being treated with immunosuppressive treatment
alongside steroids, these patients were compared to a new therapy. There were a total of
255 patients, and the results indicated that this novel therapy helped improve vision more
than the immunosuppressive treatments. However, it should be noted that this study
looked at any immunosuppressive treatment, and as noted in the trial, the
immunosuppressive treatment was given as decided by the individual ophthalmologist.
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This study indicates that there is still a gap in terms of which immunosuppressive
treatment one should receive. This further boosts the idea that we should have some
reference or resource that one can use to help build a more appropriate RCT, with
specific immunosuppressive treatment.
According to Clincialtrials.gov96, there are roughly 5 new RCTs recruiting patients for
uveitis, with some specially examining the immunosuppressive treatments that we are
examining in this thesis. The earliest completion date for one of the RCTs is 2018, so
with the results and conclusions of this study, it could help the RCTs have a better picture
of the treatments, with a more evidence-based approach to existing literature. However, it
is important to note that none of the RCTs look at specifically idiopathic uveitis patients
but rather on the uveitis population as a whole, this is something that sets this study apart
even from the RCTs.

2.6 Previous “Economic Evaluations”
There have been no specific cost-effectiveness analyses conducted regarding treatments
for uveitis. Though, as discussed earlier, there was one study that included the costs of
treatment, it was not the focus of the study. There is only one other economic evaluation
study that examined the costs of the treatments for uveitis, which is summarized below.
Aside from these 2 studies, no other economic evaluations related to the treatments for
uveitis have been done.

Informal Health Care — Expert Opinion
Heo et al (2012)21 examined the costs of treatment, however, they did not state where the
cost data was taken from or how it was calculated. They estimated the annual medical
spending on a uveitis patient with varying treatments. Table 6 below illustrates the data
that was captured from this review:
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Table 6: Cost of Treatments based on Heo et al (2012)21
Treatment

Cost (per year)

Methotrexate

$68

Azathioprine

$92-132

Cyclosporine

$1948-3400

Mycophenolate Mofetil

$3600

Adalimumab

$15,000

*costs depend on the frequency of use and dosage (not shown in the review)

This study demonstrated that biologics have a significantly higher cost compared to
standard therapy, which creates a barrier for the use of biologics in treating uveitis.
However, this review did not conduct a cost-effectiveness analysis. Although the authors
mentioned that cost-effectiveness is low for biologics, they did not provide any measure,
such as a relative/standardized effectiveness unit (QALY). They also failed to mention
where they retrieved the data from, which could potentially lead to bias in the cost data.

Limitations
Overall, this review was not very elaborative on how one treatment is comparable to
another in terms of cost-effectiveness. Though the cost data is provided, it is still very
questionable as to where the data was obtained. However, the study does look at the costs
of treatment per year, and it attempts to investigate which treatment should be more
readily used based on cost.

2.7 Cost and Effectiveness Based on Data Collected Through
Surveys
Survey Given to the American Uveitis Society
In this study, Esterberg et al (2012)98 conducted a survey to determine uveitis specialists’
practice patterns, preferences, and perceptions of therapies other than corticosteroids for
initial use in chronic non-infectious uveitis. They distributed the survey to 205 members
of the American Uveitis Society, of which 45 responded and among which 3% were
Canadian uveitis specialists. The survey asked about the effectiveness of treatments using
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an effectiveness rating (0 to 4), which was defined as the ability to control ocular
inflammation and successfully taper corticosteroids to a maintainable dose. The survey
also asked which factors limited the specialists’ use of a specific treatment; one such
factor was cost.
Table 7: Main Results from Esterberg et al (2012)98
Treatment

Favourable for first line
of treatment for Anterior
Uveitis

Mean Anterior Effectiveness
Rating (p<0.001)*

Too expensive- Reason for not
pre-scribing a specific
immunomodulatory treatment+

Methotrexate

0.6

3

Azathioprine

0.07

2

0%

Cyclosporine

0.05

2

13%

Mycophenolate
Mofetil

0.13

3

40%

Adalimumab

0.06

4

56%

Reference group, least costly

*Effectiveness Rating: Was determined in the survey by each individual Uveitis Specialist (1=not effective,
2=somewhat effective, 3= mostly effective, 4= very effective).
+Cost was another subjective measure, which was asked in the survey to distinguish reasons why a specific
treatment was favoured over another.

The reason this study was included in this literature review was to look at the data
provided by uveitis specialists and examine how subjective the treatment given to a
patient is. In this study, the authors looked at the treatments with respect to the specific
anatomy of the disease, with results for anterior uveitis shown above in Table 7. Based on
this data, uveitis specialists considered methotrexate the primary treatment for uveitis
among the immunomodulators (Column 2: methotrexate is considered favourable for first
line of treatment among 60% of respondents), even though its effectiveness is not the best
(Column 3). A large reason for this can be attributed to the cost of the treatment, as
methotrexate is the least costly of the more effective treatments. This demonstrates that
cost is a key factor in the choice of treatment by uveitis specialists. However, this choice
is very subjective and should be examined in a more systematic way to create a concrete
basis for choosing one treatment over another.

Limitations
This study examined the patterns of which treatments uveitis specialists would choose to
treat patients with uveitis. Though the respondents indicated they would use
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immunosuppressive treatments 100% of the time once the 10mg/day corticosteroids
treatment was exceeded, the primary cause of concern is the study’s small sample size
(only 45 respondents). This concern is further highlighted when these survey results are
compared with the results from a survey conducted on the ophthalmology population in
the USA, which found that steroid-sparing immunosuppressive treatments were rarely
used, and an average prednisone maintenance dose of 34mg/day was reported.98 Thus,
one must ask if more concrete evidence-based guidelines are necessary to maintain
uniformity in uveitis care, in order to ensure that patients with similar characteristics are
treated similarly from tertiary care to population based primary care.

2.8 Conclusion
The primary conclusion is that treatment choice is dependent on the uveitis specialist, and
can vary depending on their opinion. However, with the help of a systematic review, a
more concrete basis for decision-making can be used to create guidelines that all uveitis
specialists can follow to make the treatment of uveitis more uniform. Furthermore, this
would enable better judgement when considering the costs and effectiveness of different
treatments. This leads into Chapter 3, the justifications and objectives of our study.
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Chapter 3
3

Justification and Objectives

3.1 Justification for This Study
Having summarized the entirety of the relevant literature in Chapter 2, the rationale for
this thesis becomes apparent. The lack of comparability within and between studies
requires specific steps to allow for the accurate assessment of the effectiveness of uveitis
treatments.
As mentioned above, the lack of existing RCTs in the subject area, due to sample size
constraints and heterogeneity in etiology and measure of outcome, makes the case
stronger for conducting a systematic review and meta-analysis. The required information
can be gathered from existing literature and used to determine which treatment is best for
treating patients with uveitis. However, there have been new developments in the field,
and new RCTs are underway.
All treatments being studied have been shown to be effective in treating patients with
severe idiopathic posterior uveitis. However, the literature mainly consists of chart
reviews or case series with very limited sample sizes, and a mixed group of individuals in
each study (ie, mixture of patients with different severity of disease, cause of disease, and
difference in location).
Moreover, no one standard definition of success is used in the literature; effectiveness is
measured in terms of visual acuity in some studies, inflammation grade in others, and
corticosteroid-sparing rate in others. This leads to comparability issues, which makes it
hard to compare separate studies and their various treatments. It also makes it unclear
which treatment is more effective at treating patients with similar disease attributes.
Creating a more specific set of inclusion/exclusion questions will make it easier to
compare different studies that contain more homogenous patient populations.
The Canadian Uveitis Society (CUS) is the key stakeholder in this study. The leaders of
the Canadian Uveitis Society are also members of the Canada Ophthalmology Society
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(COS), and they can put guidelines in place that shift the way all ophthalmologists treat
patients with this disease. The establishment of these guidelines is important for uveitis
treatment in Canada, as the treatment given currently depends on the ophthalmologist.
Having clear guidelines in place would result in the best possible outcome for patients
with idiopathic uveitis.

3.2 Case for Why a Meta-analysis is needed
As indicated in Chapter 2, there have been many reviews on this subject area, dating back
as far as 1985. There are so many review articles with exactly the same studies, and most
of them come to similar conclusions, emphasizing the importance of forming evidencebased guidelines that accurately assess which treatment is ideal for treating the desired
patients.
From the literature review in Chapter 2, it is clear that observational studies individually
are not powerful enough, in part because they do not include a large enough sample of
patients and in part because of the heterogeneity in the patient and outcome
characteristics. In addition, the reviews and guidelines offered in the observational
studies are not able to draw conclusions, as the literature does not have a standardized
way to measure effectiveness of treatments. This gap in the literature prompted the
systematic review that attempted to encompass all the available data about treatments for
uveitis patients, specifically those with idiopathic posterior uveitis. However, due to the
heterogeneity in the study outcomes and patient characteristics, a conclusion regarding
the best treatment could not be determined. This begs the question, if a more specific
group of patients with a main outcome of measure are studied, could we form a more
concrete conclusion that might allow us to create guidelines and policy? This thesis was
undertaken to answer this question, using a systematic review and meta-analysis. Other
means to find the best treatment, such as RCTs, were not an option at this time, since it is
not possible to gather the required patient sample size with similar patient characteristics
and administer an array of treatments in a short amount of time.
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3.3 Thesis Objectives
Objective 1 – Systematic Review
To systematically review the literature to summarize the effectiveness and adverse events
of the different treatments used for patients with non-infectious idiopathic uveitis. For
descriptive purposes, the outcomes that summarize the effectiveness of the treatment
groups is outlined in section 1.4.

Objective 2 – Meta-analysis
a) To systematically identify, review, and quantitatively synthesize the evidence
available pertaining to the pre- and post-change in VA after different
immunosuppressive treatments are administered.
b) To explore and categorize other factors that may contribute to differences seen in VA
after treatment is administered to patients, including location of disease, age, previous
treatment given, and primary immunosuppressive treatment given.
c) To systematically identify, review, and quantitatively synthesize the evidence
available pertaining to the pre- and post-change in inflammation grade after different
immunosuppressive treatments are administered. This can be done if there are enough
studies that have the same standardized scale for inflammation grade.

3.4 Patient Characteristics
An important component to this study is the ability to specify and focus on the patient
population that is most in need of a specific immunosuppressive treatment. This patient
population consists of:
1) Patients of any age.
2) Patients that have either posterior, intermediate or panuveitis (anterior uveitis
responds to simple steroid treatment, since it is mainly acute uveitis, and thus
studies looking solely at anterior uveitis patients will be excluded).

36

3) Patients that have chronic non-infectious idiopathic uveitis.
4) Patients that were given oral immunosuppressive treatment by an
ophthalmologist.
The studies included will also have a percentage of patients with other disease types, or
where the location of the disease could include anterior uveitis patients, however, this is
only if the majority of the patients in the study were patients with intermediate or
posterior non-infectious idiopathic uveitis. This will ensure that the patient population is
similar, so the various studies will be more comparable to each other.

3.5 Primary Outcome of Interest for Meta-analysis
For the completion of Objective 2a and b, as outlined in section 3.3.2, efficacy of
treatments will be measured by visual acuity (VA), measured in logMAR.82-84 The unit of
measure for effectiveness is the difference between pre-logMAR and post-logMAR once
treatment is given and the weighted mean difference of logMAR will be the effect size.
This will be used to pool the data from the various studies and allow for comparability
among the treatment groups, using subgroup analysis.82-84 As discussed in detail in
section 1.4.2, the reason this measure is used is because the different scales used in other
studies can be easily converted to logMAR, so comparability exists and logMAR scale
gives a more precise and accurate assessment of change in vision.80 For a more detailed
discussion of logMAR and VA, see section 1.4.2.
Secondary Outcome: Inflammation grade will also be pooled from the various studies if
there is enough data available. This secondary outcome will provide a means to measure
the change in pre- and post-inflammation grade (based on a 0 to 4 scale), indicating
whether an increase or decrease in inflammation occurred after treatment. The
inflammation grade measures severity of disease. The measure of inflammation ranges
from 0 to 4+. Patients with a grade 3 or more are considered to have severe uveitis. If the
treatment shows a mean change in inflammation of 2 grades or more, then the treatment
is deemed effective.1 See section 1.4.1 for more detail.
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Chapter 4
4

Literature Review for Methodology

4.1 Overview of Meta-analysis
Before we go into the methodology, it is important to understand how to conduct a metaanalysis and know some of the terminology that is used within a meta-analysis. Thus, this
chapter will do a brief introduction of the methodology used in this thesis and how to
interpret a meta-analysis.
A meta-analysis can be conducted on an area of research where the studies have low
power due to small sample size or intervention effect. When the studies are combined, the
estimated intervention effect becomes more precise, and power is increased if the studies
have similar variability and similar effects. However, when the results of the combined
studies show inconsistency/heterogeneity, represented as 𝐼 2 , then measures must be taken
to assess where the heterogeneity originates. There are 2 methods that can be used to
assess heterogeneity; the first is a subgroup analysis, and the second is meta-regression.
Subgroup analysis allows you to measure the variability using subgroups that may be
present in the collected data, which could account for the heterogeneity. Meta-regression
uses regression to evaluate if a relationship exists between 1 or more covariates
(moderators) and the effect size in the studies.

4.2 Mechanics of Meta-analysis
Once the summary data is collected, an understanding of the mechanics of meta-analysis
will allow one to assess the data smoothly and accurately. The first step is to understand
how the summary data can be used to obtain an effect size for each study.

What is Effect Size?
Effect size is what encodes the relationship of interest into a common index.99
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It is important to determine an index of how the effect size will be measured. The effect
size can be presented in many ways; it depends on the data that is extracted. Some effect
size indexes include standardized mean difference (SMD), correlation coefficient, and
effect size based on binary data (ie, risk ratio or odds ratio).100 Choosing the index is
straightforward, as the summary data in general will dictate the index. For example, if the
data are based on a standardized meaningful outcome, then using a raw mean difference
(WMD) could be beneficial as the outcome is standardized and is on a meaningful scale
that is widely used, like blood pressure.100 However, in the case of other indexes like
binary, where there are many choices like odds ratio, relative risk, risk differences, or
number needed to treat, it becomes rather controversial to choose an index and care must
be taken in order to pick the index for the meta-analysis.101

Precision
Variance, standard error, and confidence intervals are all measures of precision. How
precise the effect size of a study is depends on a variety of things, however, the rule of
thumb is the greater the sample size, the narrower the confidence intervals and the more
precise the effect size is. As the sample size is reduced, it loses power and the confidence
intervals become larger, and therefore the overall precision is lower.99 This relationship is
important for identifying error within studies, which is needed to calculate the summary
effect size and confidence intervals found in a forest plot. In addition, study design could
affect the precision as well. For example, a cluster trial would have larger variance then a
study with 2 independent groups, since an entire cluster of participants is assigned to one
condition or another. It is important to understand that both sample size and study design
can affect precision, which is intrinsic to that study.
The forest plot consists of the reviewed studies and their effect sizes, their precision,
which is indicated by confidence intervals, the inverse of the study’s variance by the area
of the box, and the inverse of the study’s error indicated by any side of the box.
Another key component of a meta-analysis is the variance or error that is within each
study.100 In this study, the variance of the difference was calculated in STATA by using
the individual standard deviations for the pre-post logMAR.
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True Effect Size and Summary Effect Size
True effect size is the effect size in the underlying population for that study, and it is the
effect size that we would observe if the study had an infinitely large sample size (thus, no
error within or between studies if assuming random effects model). A study’s observed
effect size is the effect size that is actually observed. The summary effect size is the
calculated weighted mean of the observed effect sizes of all the studies combined. The
true overall effect size is the summary effect if all the studies had a common effect size
(ie, true effect size). These calculations were done using Stata.102 Below, we explain the
different models available to compute the summary effect size, the precision associated
with each model, and which model was chosen for our study.

How to Measure a Summary Effect Size (Fixed vs. Random
Effects Model)
When computing the summary effect size and assessing heterogeneity, it is important to
note that the same methodology is used no matter which index is chosen.103 For the metaanalysis, there are 2 models for computing the summary effect size. One is the fixed
effects model and the other is the random effects model.103 Fixed effect assumes that the
true effect size is the same with every study and the only variance that is present is due to
within-study variance.103 For example, if all the studies were conducted the same way,
and all the factors that could influence the effect size were the same in all the studies,
then the true effect size would be the same in all studies. Under the fixed effects model,
all the studies share the same true effect sizes, so the observed effect size varies from one
study to the other only because of the random error intrinsic in each study. The difference
seen between the observed effect size and the true effect size (Xi), is contributed by the
error (Ei), thus the observed effect size (Yi), is simply:
Yi = Xi + Ei
We assume that the error is placed in a normal curve about the true effect size for each
study, with the width based on the variance in that study. Performing a meta-analysis
when calculating the summary effect size using the fixed effects model, we take into
account the variance by taking the inverse variance, which is the weight of that study, and
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multiplying it by the observed effect size.103 In our study, we assigned weights so we
could minimize the within-study error; in other words, we tried to obtain a more precise
estimate of the population effect. The next step is to take the sum of the product and
divide it by the sum of the weights. Then, to determine the variance of the summary
effect, we take the reciprocal of the sum of the weights. The null hypothesis that the z-test
is trying to test is that the common effect is zero for the differences, or 1 for ratios.
Though the basis for the summary effect size calculation in a fixed effects model
accounts for within-study error, it is not a valid reason to assume that all the studies will
have the same true effect size.99 Unless certain, there is another model, which allows the
true effect size to vary from study to study. The random effects model assumes that there
may be between-study variations as well as within-study variation.104 This model is
usually more valid, because studies may differ in study design, type of intervention, age,
or another factor, and effect sizes are assumed to be different among the different
studies.103 For example, the effect size might be higher (or lower) when the participants
are older, more educated, healthier, or when a more intensive variant of an intervention is
used, and so on. Because the studies will differ in the combination of participants and
types of treatment, there may be different effect sizes for the different studies. A key
assumption of the random effects model is that the true effect is normally distributed.104
For our study, we calculated the between-study variance and included that in our weight
before doing any further calculations. Dersimonian and Laird (1996)105 have presented a
method to calculate between-study variance, or the heterogeneity. This will be discussed
in the next part of the thesis.
However, the main equation for the random effects model and the change from fixed
effects model is the addition of the between-study variance, as shown below:
Yi = X+ E + B
So, the observed effect Yi is the true mean (X), the deviation of the study’s true mean
(E), and the deviation of the study’s observed effect from the studies’ true effect (B).103
Weight assigned to each study via the random effects model is:
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Wi*= 1/Vyi*
Where, Vyi* is the within-study variance for study i (Vyi), plus the between-studies
variance (T2),
Vyi* = Vyi + T2
And the weight is reciprocal of the Vyi*.
The weighted mean is calculated the same way as in the fixed effects model, taking the
sum of the weight (Wi*) and the effect size (Yi), and then dividing that by the sum of the
weights. The variance of the summary effect is estimated as the reciprocal of the sum of
the weights.
Thus, the goal was to use the weight of the studies to minimize both sources of study
variance. The random effects model suggests that the studies in the analysis represent a
random sample of effect sizes from all the effect sizes that could have been observed.
Not only does the random effects model take the weight of the study into consideration,
but it also considers the weight of the variance between one study and the other studies in
the meta-analysis. In contrast, the fixed effects model uses the weight of the studies by
considering sample size and only the within-study variance. If the variances between
studies is large and the fixed effects model is used, then a study with a larger sample size
will be assumed to possess greater precision. In reality, it means that 1 study might
dictate the summary effect size. With the random effects model, that larger study will not
be given as much weight depending on the between-study variance compared to the other
hypothetical studies. Thus, it is more accurate to use the random effects model in the case
of notable or a priori predictions of the heterogeneity of studies.
In the fixed effects model, more weight is given to studies that are more precise, because
it is assumed that the true effect size is the same among all the studies. However, in the
random effects model, we are looking for the mean of the distribution of the effect sizes.
Since each study provides information about a different effect size, we want to make sure
every effect size is taken into consideration when determining the summary effect size.
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Consequently, small studies are given more weight and large studies are not given as
much weight, which allows for more balance. Extreme studies lose influence when we
move from the fixed to the random effects model. Confidence intervals will be larger, as
there are 2 errors associated with the model, unless the between-study variance (T2) is
zero, then the fixed and random effects model will be the same.
Conceptually, it is important to note that if the sample size reaches infinity, it would
make the error in the fixed effects model narrower. However, in the random effects
model, there would need to be an infinite amount of studies for the error to narrow. The
null hypothesis in the fixed effects model is that there is zero effect in every study,
whereas in the random effects model, the mean effect is zero.

Heterogeneity
In order to understand the implications of our study, it is important to observe if there is
consistency in the studies or if there is heterogeneity in the true effect sizes. This is not to
be mistaken with precision since that term is solely used for within-study variance,
whereas heterogeneity is used for the variation found in true effect sizes.104 If there is
heterogeneity, can we pinpoint what is causing it? In a random effects model, we allow
that the true effect size may vary from study to study, and suggest that there will be
heterogeneity; therefore, heterogeneity can be defined as between-study error. However,
how do we identify it in a meta-analysis?

4.2.5.1

What is heterogeneity

In the context of a meta-analysis heterogeneity is defined as statistical heterogeneity or
inter-study variance. In a meta-analysis it is assumed that statistical heterogeneity is a
consequence of clinical or methodological variation. Clinical variation is heterogeneity
due to differentiations in interventions or patient characteristics. These variations can
affect the between study variance and true treatment effect will be different study to
study. This can be reduced by having stringent inclusion/exclusion criteria, which would
allow for similar patient characteristics from study to study. There would still be clinical
variation with the type of treatment given, since there are many in our study.
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Methodological factors, such as how the outcomes are measured and defined could lead
to differences in the observed treatment effects. For example, having different scales to
measure VA could lead to methodological heterogeneity as one study could measure
using Snellen and another via logMAR. Thus being aware of the kind of heterogeneity
that could be present is important, and would allow one to choose the appropriate model
to conduct their meta-analyses. If we know that there will be heterogeneity, then a
random effects model would be chosen and would allow for between-study error.
However, we need to know how to identity it and measure it statistically.

4.2.5.2

How to identity and measure heterogeneity

There are many methods to identify heterogeneity. One is to look at the forest plot and
examine how the studies are dispersed from one another, but in order to objectively
identify heterogeneity, we must separate the true variance (between-study variance) from
the random error (within-study variance). For the purposes of this thesis, it not important
to understand how the calculations are done, but to understand conceptually how
heterogeneity is identified.
One method to identify heterogeneity is the Q method, which is the dispersion that is
excess to the within-study error and is standardized, which means it is not affected by the
metric of the effect index, but it suffers from low power if there are too few studies.99, 103
The null hypothesis using the Q can be rejected when the p value is set at less than the
alpha, which is set to 0.05. Q will follow a chi-squared distribution with degrees of
freedom equal to k-1. This is called the homogeneity test; if we reject the null hypothesis,
then the distribution of the effects is heterogeneous.
However, the Q statistic could be used to compute a ratio or dispersion on the same scale
as the effect index itself. One such way Q is calculated is the method of moments or the
DerSimonian and Laird method, which converts the Q to the same scale as the effect
index.103 This method calculates the between-study variance found in the random effects
model and the standard deviation of the summary effect size. This between-study
variance is represented by T2. The T2 is used in the random effects model and is defined
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as the between-study variance that is not explained by excess error found in the study. It
is used to describe the heterogeneity found in the studies in most meta-analyses because it
is easy to calculate, however, it is not the best way to discuss the variance, since it is on
the same scale as the effect index and cannot make comparisons to other indexes. A new
method is used to describe the heterogeneity using ratios with Q value; this value is
represented as I2. It allows one to make a conclusion about whether any of the total
variation that we see is due to the true variation or heterogeneity. This is a way to identify
heterogeneity, and the reason it is often used to talk about heterogeneity is because it is
not sensitive to the number of studies, unlike the method of moments, and it is not
sensitive to the metric of the effect size.
Once the heterogeneity is identified, we can further explore where the heterogeneity
could be coming from. For this, there are 2 methods: subgroup analysis and metaregression.

Subgroup Analysis
Subgroup analysis is the set of studies divided via a particular subgroup, such as
treatment classes. Subgroups can be used to determine whether the heterogeneity can be
explained by a particular subgroup. However, there is a lot of debate concerning the test
of heterogeneity with any method in a subgroup, as subgroups may be too small to be
significant or it may be unreasonable to make a comparison from one group to another
(for example, 1 subgroup could contain only 2 studies, while another subgroup contains
more then 10). The use of fixed effects models with subgroups has been debated for some
time. However, the use of random effects models with subgroups has recently been
applied, with certain assumptions. For example, if we assume that each study within the
subgroup shares a common effect size, then we can apply a fixed effects model, but if we
do not make that assumption, then the random effects model can be applied. With the
random effects model, if we assume that the between-study variance is the same for all
subgroups, then we compute the T2 for the subgroups, pool them together and use the
same estimate for all subgroups. If not, then we use a separate T2 for each subgroup.
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For the purposes of our thesis, if any between-study variance existed, for practical
reasons (which will be explained below), it was assumed that it was the same. Some
heterogeneity authorities do not believe that subgroup analysis is a strong measure for
comparing the different subgroups due to the low number of studies per subgroup.100,101
One rule of thumb is that if there are fewer than 5 studies per subgroup, there is an
assumption that the between-study variance is the same for all subgroups.101 Thus, the
fixed effects method is used for subgroups; this is one of the only valid methods to test
for heterogeneity, as using random effects would make the test of power even lower.101
When there are a low number of studies within a subgroup, it may be wise to just conduct
a pooled meta-analysis. However, it reasonable to use the random effects model if each
subgroup has more than 5 studies.100, 104

Conducting a Univariate Meta-regression with Multiple
Covariates
Meta-regression in a meta-analysis assesses the relationship between study-level
covariates and effect size. Meta-regression is similar to regression conducted in primary
studies, the key difference being that each study is weighted, depending on which model
is selected (fixed vs. random effects). Knowing which model to pick is important, as it
will affect the results (more even weights among studies when using the random effects
model, and larger studies do not impact the summary effect size or the regression line).
Under the null hypothesis, using the random effects model, the mean is the same for all
values of the covariates.105 When conducting a random effects model meta-regression, it
is important to understand some technical issues, the first being that Z-distribution is only
appropriate for the fixed effects model, where the source of error is within-study.7 For the
random effects model, the dispersion across the studies should be accounted for using the
t-distribution. There are many methods to accomplish this, the most well-known and
accepted is from Knapp and Hartung (2003).107 Two modifications are made to the
standard error for the random effects model. The first is the between-study variance
component, which is multiplied by a factor so it corresponds to the t-distribution rather
than the Z-distribution. The second is that the test statistic is compared against the tdistribution, which expands the width of the confidence intervals and moves the p-value
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away from zero. Another method, by Higgins and Thompson (2004)108, is to bypass the
sampling distribution and use a permutation test to yield a p-value. Using this test, a zscore that corresponds to the observed covariate is computed, then the covariate is
randomly distributed among the studies to see what proportion yield a z-score that
exceeds the one that was obtained.107 This is the true p-value.

Final Remarks for Meta-regression or Subgroup Analysis
The absence of statistical significance should never be interpreted as evidence that an
effect is absent. This is important to keep in mind since power to detect heterogeneity in
effect sizes or between covariates or subgroups is very low. In other words, failure to
obtain a statistically significant difference among subgroups or covariates should never
be interpreted as evidence that the effect is the same across subgroups or that there is no
relationship between the covariate and the effect size. Also, the reverse is true, even with
a statistically significant relationship between effect size and subgroups or between effect
size and covariates is observational and cannot be used to prove causality. This holds true
even if all studies in the analysis are RCTs. Some studies employ a strategy of starting
with the fixed effects model and then modifying to use the random effects model if the
test for heterogeneity is insignificant for meta-regression or subgroup analysis. This
approach has significant disadvantages; instead, the model that is initially chosen should
be based on knowledge of the subject matter.

Power vs. Precision
To ensure that a study has good statistical power (a sufficiently high likelihood of
yielding a statistically significant result), observe whether a meta-analysis has sufficient
statistical power to test the null hypothesis of no effect.99 Although it is not always
mandatory to conduct a power analysis for a meta-analysis, especially one with multiple
treatment groups, it can help determine whether a study is likely to yield statistically
significant results. This is particularly important in primary studies. In meta-analysis, it is
more appropriate to look at the effect size and its precision, as that provides a clearer
indictor regarding whether or not the result was significant.
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Publication Bias
Publication bias can have a pronounced effect on the results of a study, as some studies
could have been overlooked in the screening phase, which could lead to bias that is
known as publication bias. The consequences of publication bias include precision and
validity. There could also be bias due to larger studies being included and smaller studies
not being included because they are not as easy to find. One way to mitigate the precision
issues related to publication bias is to use a random effects model to ensure that all
studies are evenly weighted, but this doesn’t take into account the amount of publication
bias that might exist or how the data would look if those theoretical studies were not
missing.
There are methods that have been established to determine if publication bias has taken
place, and some methods can even adjust for the bias. A funnel plot is used by these
methods to detect any asymmetry, and to examine whether the asymmetry is due to
chance. There are also tests, such as Begg and Mazumdar (1994)109 and Egger et al
(1997).110 However, these methods do not provide estimates about the number or
characteristics of the missing studies, nor do they provide an estimate of the underlying
(biased) effect. One such method, developed by Duval and Tweedie (2000), 111 does
address these issues.
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Chapter 5
5

Methods

We conducted this review in accordance with the Meta-analysis of Observational Studies
(MOOSE) recommendations and the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines (completed checklists in Appendices A and B).

5.1 Literature Search
A comprehensive and pre-planned search strategy from 6 databases (MEDLINE,
EMBASE, Cochrane Library, CINAHL, Scopus, BIOSIS and Web of Science) was
created to obtain the maximum return of relevant studies related to our question. Free text
key words and medical subject headings were tailored to each of the electronic databases.
The search strategy was performed in collaboration with a medical librarian with
searching expertise, ophthalmologists within the Canadian Uveitis Society, and
information specialists. The search strategy consisted of the terms listed in Table 8
below.
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Table 8: Concepts, keywords, and phrases for search strategy
Keywords/Phrases
the concept of:
idiopathic uveitis

the concept of:
immunosuppressive
treatments
Pharmaceutical Family
Antimetabolites:

Idiopathic uveitis
Chronic uveitis
Non-infectious uveitis
Ocular inflammation
Ocular inflammatory disorders
Intraocular inflammation
Immunosuppressive drugs
Immunosuppressive therapy
Immunomodulators
Generic Name
Azathioprine

Alkylating Agents:

Methotrexate (abbreviated MTX and formerly known
as amethopterin.mp.)
Mycophenolate Mofetil
Mycophenolic Acid
Cyclophosphamide (also known as cytophosphane.mp.)

Chlorambucil
Inhibitors of tlymphocyte signaling
(Calcineurin Inhibitors)

Brand Name
Imuran
Azasan
Rheumatrex
Trexall
Cellcept
Myfortic
Cytoxan
Endoxan
Cytoxan
Neosar
Procytox
Revimmune
Leukeran

Cyclosporine

Gengraf
Neoral
Sandimmune

Tacrolimus (also FK-506 or fujimycin)

Prograf
Advagraf
Protopic
Rapamune

Sirolimus (rapamycin)

Using these terms enabled the development of a comprehensive search strategy for each
database, which can be found in the Appendix C. The original search was performed in
June 2012, and it continued to gather articles via monthly updates until March 2013.
Searches were not restricted by publication type, date or language. To ensure all relevant
studies were identified, unpublished studies were also searched through manual searches
of electronic abstracts and dissertations from the American Academy of Ophthalmology
and the Association for Research in Vision and Ophthalmology meetings. To further
ensure all studies relevant to the systematic review were included, bibliographies of
eligible studies and relevant systematic reviews retrieved in the literature search were
manually screened.
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5.2 Eligibility Criteria
With the help of ophthalmologists within the Canadian Uveitis Society, the study
eligibility criteria were established by identifying key components that needed to be
fulfilled to answer our study’s question: how immunosuppressive treatments affect
patients with non-infectious idiopathic uveitis. The key components consisted of patients,
Intervention, Comparison, Outcomes and study design (or PICOS). These terms needed
to be fleshed out completely before we could answer question. PICOS is a helpful tool to
help focus on what is important to our question and create the appropriate eligibility
criteria. Our eligibility criteria was:
Participants: As discussed in section 3.4, we looked at studies that specifically examined
non-infectious idiopathic uveitis patients. This would ensure that the patients who were
studied were the patient population that we wanted to look at, and would allow for
homogeneity within the study population. Patients with uveitis that was not exclusively
idiopathic in nature were included. Studies with fewer than 50% of patients with diseases
other than non-infectious idiopathic uveitis were included in order to capture existing
evidence from mixed populations (see Appendix D for the list of diseases that were
excluded).
The focus was on posterior and intermediate uveitis patients, as they were the 2 locations
of uveitis where it was most unclear regarding treatment efficacy. Studies solely focused
on anterior uveitis patients were excluded because they are easier to treat, and there is
little equipoise regarding treatment choices. If posterior or intermediate uveitis patients
accounted for 50% or more of the patients examined within a study, then that study was
included.
Interventions: The studies that examined any 1 of the 3 main groups of
immunosuppressive treatment (ie, antimetabolites, alkylating agents, inhibitors of tlymphocytes) were included. The treatment must have been orally administered (which is
the most common method of administering immunosuppressive treatment) to ensure
homogeneity, because some patients can be receive treatment via other means, such as
injections.
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Outcomes: Measured via changes in visual acuity (VA) and/or inflammation grade,
relapse rate, corticosteroid-sparing rate, and adverse events. As discussed in section 1.4,
these outcomes were specific to determining the effectiveness of the treatment given to
patients and what was used in different studies to describe effectiveness. And as
discussed in section 3.5, the primary main outcome of measure used for the meta-analysis
was change in VA, measured in logMAR. The rest of these outcomes were used for
descriptive purposes under the systematic review.
Study Design: All study designs were included, except narrative reviews. There were no
restraints on year of publication, as any treatment given in the past or present would be
administered in a similar fashion. Also, we only looked at studies from the English
language. Also, studies that were done in either North America, Western Europe, Hong
Kong, Japan, New Zealand, Australia or Singapore, were included. This was done as
developing countries may not have similar clinical practices as these countries, and
would further the clinical heterogeneity.
Therefore, this study included primary studies that assessed the effectiveness (measured
via changes in visual acuity (VA) and/or inflammation grade, relapse rate, corticosteroid
sparing rate, and adverse events) of treatments (antimetabolites, alkylating agents, tlymphocyte inhibitors) for patients with non-infectious idiopathic uveitis.

5.3 Article Screening
Two levels of screening were performed to eliminate articles that did not meet the
inclusion criteria. Level 1 consisted of screening through the titles and abstracts to seek
out articles potentially relevant to the study. From the articles included in level 1, the fulltext of the articles were retrieved to more closely assess inclusion and exclusion criteria
for level 2 screening. Two reviewers screened citations (AC and HS) and full-text articles
(SS and HS) in an independent fashion, and to examine inter-rater agreement using
Cohen’s kappa coefficients. The kappa values were interpreted as follows: 0.40 to 0.59
reflected fair agreement, 0.60 to 0.74 reflected good agreement, and ≥0.75 reflected
excellent agreement.112, 113 Once the screening was conducted, the 2 reviewers reconciled
the discrepancies through discussion. Both levels of screening were done in duplicate to
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increase accuracy and reduce measurement bias. An experienced ophthalmologist (WH)
was consulted to resolve any remaining disagreements.
Studies were excluded if: (i) greater than 50% of the patients were diagnosed with any of
the diseases listed under Appendix D, (ii) location of disease was mainly anterior uveitis
(greater than 50% of patients), (iii) studies having less than 5 patients with idiopathic
uveitis, (iv) studies were conducted in developing countries, (v) the treatment was not
given orally, (vi) not a primary study, and (vii) studies did not provide the outcome of
interest. The entire list of inclusion/exclusion criteria for both level 1 and level 2 can be
found in Appendix D.

5.4 Data Extraction for Descriptive Statistics
To extract data from the eligible studies, we created a data extraction form. Two
reviewers (HS and AC) dependently conducted a “trial pilot” of the extraction form on a
subset of the eligible studies. Based on the changes in the pilot study, the final version of
the data extraction form was developed (see Appendix E). For the purpose of this thesis,
the data extracted from the studies was organized by the treatment given to the majority
of patients in a particular study. The following information was collected in the final data
extraction form:
Study Characteristics: included the study design, setting/data source, and the accrual
period of the study and sample size. This was relevant because it gave an idea of the
types of studies we examined.
Participant Characteristics: As mentioned in section 3.4, the patient characteristics
included the number of patients with idiopathic uveitis (sample size), mean age, standard
deviation of age and/or the maximum and minimum age range, frequency of female
patients, mean follow-up time in months, mean follow-up standard deviation and/or
maximum and minimum range for follow-up time, primary cause of uveitis, with
majority having idiopathic uveitis, frequency of patients with the primary cause, primary
location of diseases (could be posterior uveitis, intermediate, panuveitis, or a combination
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of them), frequency of patients with primary location of disease, and lastly, which if any
previous treatments were given to patients before the immunosuppressive treatment.
It was important to collect these characteristics for the purposes of describing the findings
in our study. They allowed us to understand the patient characteristics, and allow for
comparisons to be made between patients from different treatment groups. So, where
possible only data from idiopathic patients were extracted from the studies, if the results
were of the entire patient population, then we made sure that 50% or greater of the
patients were idiopathic in nature, which was a part of our article screening process.
Baseline Characteristics (Before Treatment): included location, cause and type of uveitis,
and any previous treatment given. This allowed us to ensure homogeneity was present
within patient populations, as most of the data collected should have been similar.
Treatment: included treatment given, dosage, and length of treatment time. These
variables were important to obtain, so a study with a particular treatment could be
compared to another with the same treatment, knowing that the dosages were similar.
Outcomes (after treatment): As discussed in section 1.4, outcomes measuring
effectiveness included reduction in severity of disease indicated by frequency of patients
that improved or maintained Visual Acuity and/or inflammation grade, reason for
discontinuation, steroid usage, clinically-relevant adverse events and the frequency of
patients that experienced each adverse event, and anything else the study used to measure
outcome. For the purposes of the systematic review, all outcomes that were present in the
study were extracted for descriptive purposes.
Relapse rate, corticosteroid-sparing rate, and adverse events were extracted for
descriptive analysis as opposed to meta-analysis. However, relapse rate and
corticosteroid-sparing rate were not included in the final descriptive statistics due to a
lack of sufficient data.
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5.5 Data Extraction for Meta-analysis
For this study, the primary outcome for the meta-analysis, as outlined in section 3.5, is
presented in the form of pre-/post-logMAR with the respective standard deviations. This
allowed us to use the unstandardized mean difference or raw mean difference because the
summary data was in a meaningful scale. An SMD index was not used because we knew
that some studies used different scales, which we accounted for and standardized.
However, most of the data used the logMAR scale, and the studies that did not were
converted to logMAR. Thus, raw mean difference was used. The unit of analysis is the
pre-/post-logMAR. The advantage to this design is that each pair serves as its own
control, reducing the error term and increasing the statistical power. Also, regardless of
study design, the computed effect size and variance from each study could be included in
the same analysis, since the scale is the same. The conversion of scales to logMAR was
done in MS Excel, before being imported into Stata.
On the extraction form found in Appendix D, pre-VA and post-VA, or change in VA,
were extracted as well. Alongside the VA itself, the respective standard deviations were
also extracted. The majority of the data collected were taken for descriptive purposes, and
pre- and post-VA became useful for the meta-analysis. As described in section 1.4.2, VA
can be measured in different scales and due to the high correlation between the scales VA
can be interchanged. Thus, using Table 9, VA which was not in logMAR was converted
to logMAR scale and also as a rule of thumb the formula to convert from decimal to
logMAR is –log10(Decimal).80
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Table 9: Visual Acuity Conversion Chart
20 ft.

6m

Decimal

4m

Log MAR

20 / 630

6 / 190

0.032

4 / 125

+1.5

20 / 500

6 / 150

0.04

4 / 100

+1.4

20 / 400

6 / 120

0.05

4 / 80

+1.3

20 / 320

6 / 95

0.06

4 / 63

+1.2

20 / 250

6 / 75

0.08

4 / 50

+1.1

20 / 200

6 / 60

0.1

4 / 40

+1.0

20 / 160

6 / 48

0.125

4 / 32

+0.9

20 / 125

6 / 38

0.16

4 / 25

+0.8

20 / 100

6 / 30

0.2

4 / 20

+0.7

20 / 80

6 / 24

0.25

4 / 16

+0.6

20 / 63

6 / 19

0.32

4 / 12.5

+0.5

20 / 50

6 / 15

0.4

4 / 10

+0.4

20 / 40

6 / 12

0.5

4/8

+0.3

20 / 32

6 / 9.5

0.63

4 / 6.3

+0.2

20 / 25

6 / 7.5

0.8

4/5

+0.1

20 / 20

6/6

1.0

4/4

0

20 / 16

6 / 4.8

1.25

4 / 3.2

-0.1

20 / 12.5

6 / 3.8

1.6

4 / 2.5

-0.2

20 / 10

6/3

2.0

4/2

-0.3

As discussed in section 1.4.2., in order for analysis to be conducted on VA, logMAR is
the most reliable and precise scale because of its logarithmic nature, which offers a more
accurate estimate of VA compared to other scales used to measure VA. On the logMAR
scale, better vision means a lower logMAR value (ie, a -0.01 change in logMAR means
an improvement in visual acuity).
In studies that did not record the measure of visual acuity outcome directly, it was
extrapolated from the graphs within the studies. This was done using online software
called graph digitizer™, which allowed us to input the data from the x-axis and the y-axis
to re-create the graphs to scale.114 Then, by manually clicking on the graph at the point of
importance, the software produced the pre- and the post-value of VA for the missing data.
In addition, for data reported as means, standard deviation was also recorded. If standard
deviation was not reported for outcome measures, raw data was extracted from graphs
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and used to calculate standard deviation where available. The standard deviation of age
was also found for studies that did not report it, using range, which is another measure of
variability. In some cases, we also attempted to gather missing information by contacting
the study authors.

5.6 Quality Assessment
We used the Downs and Black scale to evaluate the risk of bias in the included studies.
Deek et al (2003)115 conducted a systematic review where they identified 182 quality
assessment tools for assessing non-randomized studies. From 182, 14 tools were
considered the “best tools” according to their pre-specified criteria, but only 5 were
considered suitable for systemic reviews. From the 5, 2 tools, the Newcastle-Ottawa scale
and the Downs and Black scale, were found to be able to differentiate between the
reporting bias, selection bias and external bias. From these, Downs and Black scale
provides a numeric score for overall study quality that is easy to interpret.
We used the Downs and Black scale to access methodological quality and evaluate the
risk of bias in the studies we included, because it has excellent test-retest reliability (r =
0.88), inter-rater reliability (r = 0.75) and internal consistency (Kuder-Richardson 20 r =
0.89).116 The Downs and Black scale can be used to assess both randomized and nonrandomized studies. It contains 27 questions, divided among the following 5 subsections:
a.

Reporting (10 questions): Is the information provided in the study sufficient for the
reader to make an unbiased assessment of the findings?

b.

External Validity (3 questions): Examines the extent to which the findings of the
study subjects can be generalized to the population.

c.

Internal Validity/Bias (7 questions): Examines whether the measurement of the
intervention and outcome of the study are biased.

d.

Internal Validity/Confounding (6 questions): Examines whether selection bias is
present within the study.
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e.

Power (1 question): Assesses whether the negative findings in the study are due to
chance.

Total scores usually range from 0 to 31; however, we adapted the final question relating
to power from a scoring scale of 0 to 5 to a scale of 0 to 1. Other studies have modified
the Downs and Black, however, it should be noted that when changing or modifying the
tool, it compromises the reliability and validity.117 Thus our modifications could have
comprised the reliability and validity. The modified Downs and Black scale (maximum
score of 28) in other studies is evaluated with grade of “excellent” if studies scored 24–28
points, “good” for 19–23 points, “fair” for 14–18 points or “poor” if <14 points. For our
study we took the frequency that was translated from the grades provided by Tully et al
(2015)117 to give meaning to our results, and differentiate the quality of our studies.
A study scored 1 if a power or sample size calculation was conducted, while 0 was
assigned if no calculation was done. Therefore, our adapted Downs and Black scale for
RCT ranged from 0 to 27, with a higher score indicating higher study quality. The quality
of an RCT would be “excellent” if the a frequency of 83% to 100% was obtained,
“good” would be 65% to 82%, “fair” if frequency would be 51% to 64% points or “poor”
if <50%.
For observational studies, 3 questions from the internal validity section were removed,
along with 2 questions from the selection bias section, as they were topic sensitive and
pertained mainly to randomized trials. Questions 14-16 were removed from internal
validity, because they pertained to whether the patients and those measuring the main
outcome were blinded by the intervention given. In the majority of the studies we
examined, patients were given treatment due to the severity of the disease and both the
administrator and the patient knew which treatment they received. Questions 23 and 24
were removed from selection bias, because they referred to patients being randomized,
which did not take place in the majority of the observational studies. Therefore, our
adapted Downs and Black scale for observational studies ranged from 0 to 22. The
quality of an observational would be “excellent” if the a frequency of 83% to 100% was

58

obtained, “good” would be 65% to 82%, “moderate” if frequency would be 51% to 64%
points or “poor” if <50%.
For the purpose of this thesis, when organizing the figures, the 4 categories were
displayed with the frequency of studies that had been assigned “yes” or “1” in a particular
category, instead of looking at individual questions and their respected frequencies. This
was done because it allowed us to assess the quality of the study using the 4 main
categories that encompass the individual questions. The Downs and Black tool116 is
attached in Appendix F.

5.7 Meta-analysis
Summary Effect Size
All extracted outcomes were treated as continuous data. VA, measured as a logMAR
value, and inflammation grade, measured on SUN’s grading scheme for anterior chamber
cells and its variations, were reported as pre- and post-means. However, not many studies
had pre- and post-inflammation grade on one scale that could be standardized, so we
were unable to conduct a meta-analysis on inflammation grade. As discussed in Chapter 4
section 4.2.1, since the effect size was reported on a meaningful scale (logMAR), and all
studies were converted to the same scale, we were able to perform a meta-analysis
directly on the raw mean difference (D), rather than requiring a standardized mean
difference (Cohen’s d). The explanation behind the computing of the raw mean score is
that the scale is intuitively meaningful (ie, blood pressure, which is a known
measurement scale, similar to logMAR for VA). Because the unit of analysis is the pair
(ie, pre- and post-logMAR), the advantage of this design is that each pair serves as its
own control, reducing the error term and increasing the statistical power. The calculations
for the effect size and its variance were done via STATA, which required individual
pre/post VA and pre/post SD data. So, it was important that all studies had the individual
data in order for the analysis to be undertaken.
So, in studies where only the change in standard deviation and mean visual acuity were
given, we imputed the data using the average pre-VA from the studies that had the data to
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obtain the missing VA, and the post-VA was inferred using the change in VA that the
particular study had provided.
To perform meta-analysis, both the pre- and post-VA and the individual standard
deviation data was required for both pre- and post-means. When possible, missing VA
and standard deviation data was computed using extracted raw data. However, when
studies did not provide sufficient information for individual pre- and post-means and
standard deviations, we had to impute the means and standard deviations for VA, keeping
in the mind the change from pre-VA to post-VA was already calculated or provided, as
was the SD.
With some studies, we knew the mean change, but did not know the specific pre- and
post- values. Since these were required for meta-analysis, we imputed missing pre-visual
acuity as an average of all available pre-data, then used change to infer post- data. We felt
that using mean pre-data fairly estimated the visual acuity of patients prior to treatment,
since the patients had similar conditions and could be used as an indicator of the visual
acuity of patients prior to any treatment.
If a study did not include a change in standard deviation at all, and one could not be
calculated with the raw data, then the Furukawa et al method was used for the missing
pre- and post-SD. Furukawa et al (2006)118 showed that using imputed standard
deviations from other studies in the same meta-analysis resulted in approximately correct
results when compared to non-imputed (actual) standard deviations.4 We reviewed the
possible standard deviation data from other included studies and imputed the highest prestandard deviation as a conservative estimate for missing standard deviations. We
recognized that this would lead to lower weighting of the study within the meta-analysis;
however, we believed that to be a fair trade-off for its inclusion within the results rather
than excluding the study if it did not include standard deviation.

Choice of Fixed vs. Random Effects Analysis
As discussed in section 4.2.4 of Chapter 4, meta-analysis was performed using a random
effects model because we anticipated significant heterogeneity across studies. The
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random effects model appropriately accounts for the differences in observed effects
between studies that are beyond the expected heterogeneity due to sampling error alone.
The studies ranged in areas such as participant mix (eg, juvenile/senile, etc.) and
prescribed treatment and dosage, leading to different possible true effect sizes. Therefore,
we assumed that the reported raw mean differences were simply a random subset of all
possible effect sizes and we assumed the effect sizes were normally distributed. The
random effects model, using the DerSimonian and Laird method, determines the mean
and standard deviation of this distribution, or in other words, the summary effect.

5.8 Sensitivity Analysis of Missing Data
We repeated the analysis while omitting studies that required imputed pre and post VA or
standard deviations. If we saw changes, we checked for any change in heterogeneity; if
none was found, the results were similar to the original analysis, so we reported the
original analysis.

5.9 Heterogeneity
Heterogeneity between studies was visually assessed through paired forest plots.
As stated in section 4.2.5, to quantify the degree of statistical heterogeneity we used the
Cochran Q (X2 test) and the Higgins I2 statistic. Cochran Q allowed us to test the null
hypothesis and obtain an estimate of the excess variance. The I2 statistic is the proportion
of observed dispersion that is real rather than spurious, and it is expressed as a ratio with
a range of 0 to 100%. As a general rule, suggested by Cochrane an I2 value of less than
25% is considered low heterogeneity; I2 between 25 and 50% is moderate heterogeneity;
and I2 greater than 50% is high heterogeneity.119 However, as Higgins and Thompson
(2002) noted there is no universal rule for the definition for mild, moderate and severe
heterogeneity and that these suggestions are tentative.120 So, care must be taken when
concluding with I2 and one should also consider size and direction of the effect alongside
the I2.120,121
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Once quantified, we explored potential sources of heterogeneity using subgroup analysis
and meta-regression. We defined several patient and study characteristics as potential
relevant subgroups and covariates. These are described in the following section.

Subgroup Analysis
As stated in the Cochrane handbook119, it is important to note that our first meta-analysis
is broad, examining the effect size of all the interventions together. However, this is
similar to computing an effect size with apples and oranges, as the treatments are all
different, and so a subgroup analysis was planned for the 3 main classes. A subgroup
analysis can reduce the power, but it allows us to draw a more satisfactory conclusion.
Subgroup analysis was done by dividing the data into subgroups to indirectly identity if
any heterogeneity was associated with any of the subgroups, or if there was positive
change in logMAR due to any of the categories in the subgroup analysis. Because there
were a limited number of studies in each subgroup, it was more appropriate to use a fixed
effects model. Using a random effects model with subgroup analysis would yield poor
precision, whereas the fixed effects model can be assumed to be accurate because the
subgroups are expected to be homogenous.

5.9.1.1

Subgroup Analysis: Type of Immunosuppressive Treatment

To determine the individual effects of the different types of immunosuppressive
treatment on logMAR, we assigned a value of 0 to 4 to each of the different types of
treatment options, for analysis. The effects of individual treatment group on logMAR is
important to understanding if a specific group had a more profound effect on logMAR,
and ultimately on treating uveitis. The treatment types that were added were:
antimetabolites (0), alkylating agents (1), T-lymphocytes inhibitors (2), steroid use only
(3), or a combination of treatments (4).

5.9.1.2

Subgroup Analysis: Type of Primary Location

This analysis was used to determine the effects of the location of uveitis on logMAR. We
assigned a value of 0 to 5 to each of the different types of location of uveitis options, for
analysis. If there was a difference in the subgroups, it allowed us to draw conclusions
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about which location responded better to immunosuppressive treatment. The different
categories examined for the location of uveitis were: intermediate uveitis, posterior
uveitis, panuveitis uveitis, not specified, or combination of the 2 or more of the locations
in the study.

5.9.1.3

Subgroup Analysis: Previous Treatment

This analysis was used to determine whether any previous treatment that was
administered to patients impacted the effectiveness the overall immunosuppressive
treatment had on logMAR. We assigned a value of 0 to 2 to each of the different types of
previous treatment options, for analysis. If there was a difference in the subgroups, it
allowed us to draw conclusions about whether previous treatments affected the overall
logMAR score (for better or worse) after patients were given the immunosuppressive
treatment. The subgroups for previous treatments were: steroids only, not specified, or
combination of steroids and immunosuppressive.

5.9.1.4

Subgroup Analysis: Average Patient Age

This analysis was used to determine if immunosuppressive treatment had differing effects
on logMAR with regards to differences in the average age of patients. We assigned a
value of 0 to 1 to each of the different types of age options, for analysis. If there was a
difference in the subgroups, it allowed us to draw conclusions about which average age
of patients was more positively affected by the treatment, if any. The subgroups for
average age of patients were: either less than or equal to 18 years of average age (0), or
greater than 18 (1). The reason we chose to stratify at 18 years of age is because pediatric
uveitis and adult uveitis can be very different conditions, and thus evaluating whether a
particular treatment is more effective in a younger or older age group is important.
Once the subgroup analysis was complete, we were able to compare the results using (1)
the Z-test, (2) a Q-test for heterogeneity. If there were more than 2 subgroups, the Z-test
was not used, as it is only used when comparing 2 groups. Instead, a Q-test was used to
test the hypothesis.
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Meta-regression
As discussed in Chapter 4, a meta-regression allows us to assess the relationship between
different covariates and effect size.
In our study, most of the covariates were categories. In order to do this in Stata, dummy
variables were coded and used for categorical univariate meta-regression, using the
Knapp and Hartung (2003)107 method to take modifications to the variance into account,
given our use of the random effects model. Thus, we used the t distribution instead of the
normal distribution. In the Knapp and Hartung (2003)107 method of meta-regression, the
restricted maximum likelihood is used to estimate the between-study component of
variance. The restricted maximum likelihood was used over other methods, since it is
allows for greater caution when extrapolating the results for future patients or studies.122
This is because this method results in conservatively wide confidence interval of the
estimated beta coefficient.123 We performed a t-test to assess the null hypothesis of no
effect on logMAR for the different covariates discussed below. A p-value <0.05 (twotailed) was considered statistically significant.
It is important to be aware of the issue of multiple comparisons, in which more than 2
covariates are compared and we want to measure the significance of each covariate
(where the actual alpha may exceed the normal alpha). There is not much consensus as to
which method should be used when dealing with this issue. One way is to conduct a joint
test for all covariates, and obtain a p-value for the overall model, which would assess
whether there is evidence for an association of any of the covariates with the outcome.
However, when a small p-value indicates that there is evidence of that nature, it is hard to
know which and how many of the covariates are implicated. Recently, some other
methods have been established to examine the multiple comparison problems. One such
method is to conduct the permutation test, developed by Higgins and Thompson (2004),
108

to calculate the p-values, as described above. This test allows us to adjust for false

positive findings when there are multiple covariates or variables, by using random
permutations and comparing each t-statistic for every covariate with the largest t-statistic
for any covariate in each random permutation.

64

So, in addition to the meta-regression for each of the covariates, we created dummy
variables, and a univariate random effects model using the Higgins and Thompson
(2004)108 permutation test was done to account for multiple testing.
The following covariates were used in the univariate random effects meta-regression to
assess the impact of uveitis patients receiving immunosuppressive treatment on logMAR:
1) Location of Study: Even though there is no evidence that the practice in North
America is different from other continents and countries, a meta-regression on the
location of study was still done. One category was North America; the other was
any other location included in the study.
2) Year of Publication: We abstracted the year the study was published. Even though
there was no change in practice before or after 2005, we still conducted a metaregression. 2005 was chosen because that was the year the SUN classification was
published, and we speculated that there could be a difference in the studies due to
that publication. There were 2 categories, 1 for studies conducted after 2005 and 1
for studies conducted before.
3) Type of Study: Comparing studies that were observational to RCTs. This was to
understand whether the type of study affects the quality of study, and a change in
logMAR.
4) Sex: We modelled sex distribution based on the percentage of females in the
study population.
5) Mean Age: Mean age was dichotomous, with patients divided into those younger
than 18 and those equal to or older than 18.
6) Location of Disease: There were 5 categories for location of disease: a)
intermediate uveitis, b) posterior uveitis, c) panuveitis uveitis, d) not specified, or
e) combination of the 2 or more of the locations in the study.
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7) Previous Treatment: There were 3 categories for previous treatments given to
patients: a) steroids only, b) not specified, or c) combination of steroids and
immunosuppressives.
8) Primary Treatment: There were 5 categories for the primary treatment given to
patients: a) antimetabolites, b) alkylating agents, c) T-lymphocytes inhibitors, d)
steroid use, or e) a combination of treatments.
A permutation test with 5000 permutations on the covariates p-value was conducted to
alleviate any false negatives that may have been present due to multiplicity.

5.10 Publication Bias
Publication bias could have a pronounced effect on the results of our study, as some
studies could have been missed in our screening phases. This could result in less
information, wider confidence intervals, and less powerful tests. There could be bias due
to larger studies being included and smaller studies being excluded, because they are not
as easy to find. One method to manage publication bias is to use random effects model,
which ensures that all the studies are evenly weighted, but that does not take into account
how much publication bias may exist or how the data would look if those studies were
not missing. Other methods have been developed to determine if publication bias has in
fact taken place, and some methods can even adjust for the bias. These methods use a
funnel plot to identify any asymmetry. To determine whether the asymmetry is due to
chance, there are tests, such as Begg and Mazumdar (1994)109 and Egger et al (1997).110
However, these methods do not provide estimates of the number or characteristics of the
missing studies, nor do they provide an estimate of the underlying (unbiased) effect.
Duval and Tweedie (2000)111 developed the Trim and Fill method to estimate adjusted
effect size, and that is what we used to assess publication bias in our study. The Trim and
Fill method works by removing small studies (trimming), which yields a publication biasadjusted effect size. Because this trimming underestimates the variance, the studies are
then added back with an imputing mirror study (filling), such that the funnel plots
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become symmetrical and the variance is corrected. This allows us not only assess the
presence of publication bias, but also to measure its impact on the observed effect size.

5.11 Software
For systematic review and meta-analysis, we used EPPI version 4.3 (EPPI Centre,
Institute of Education, London, UK; 2013)124 as our reference management program,
used for collection, sorting and screening. Statistical analysis was performed using
STATA 13 (Stata Corp, Austin, TX USA). In STATA special codes were used to do the
random effects meta-analysis (metan, with specification to use the random effects
model). For the meta-regression using the Knapp and Hartung (2003)107 method, we used
the metreg command. With the publication bias, the metatrim command was used.
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Chapter 6
6

Results

6.1 Study Selection
Upon completion of the database search, 2215 articles were included from the databases
and grey literature. No articles were added after extensive snowballing and the grey
literature search. After removing duplicate records, there were 1518 unique articles for
level 1 screening. After level 1 screening was complete, 1248 articles were removed
(kappa for the 2 independent reviewers was 0.89; 95% confidence interval 0.81 to 0.94).
Most articles that were removed during level 1 screening were review articles (over
>80% of the removed articles), biologic treatment (which are not relevant to the study
question), animal studies and/or surgical procedures. The remaining 270 articles were
considered for full article review (ie, level 2).
After level 2, 45 articles satisfied the inclusion criteria (kappa for the 2 independent
reviewers was 0.72; 95% confidence interval 0.65 to 0.79). The 225 excluded articles
were removed for the following reasons: Not English (n=29), fewer than 5 patients
(n=19), location of disease (n=20), not idiopathic uveitis (n=31), other diseases (n=54),
not in humans (n=2), not oral treatment (n=17), not primary article (n=34), not the
outcome considered (n=9), not the treatment considered or not specific enough (n=6),
missing articles (n=4). All of the total 45 studies were used for descriptive outcomes,
however, only 26 articles had sufficient data for the purpose of conducting a metaanalysis. Figure 3 showcases the Prisma diagram that details the selection process.

Identification
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Records identified through
database searching
(n = 2215)

Level 1

Records after duplicates removed
(n = 1518)

Records screened
(n = 1518)

Level 2

Full-text articles
assessed for eligibility
(n = 270)

Full-text articles excluded from
systematic review, with reasons
(n = 225)



Full text articles
removed from metaanalysis
(n= 19)
Included

Records excluded
(n = 1248)



Did not have
the pre and
post VA data
(n=19)

Studies included in
qualitative synthesis
(n = 45 )

Studies included in
quantitative synthesis
(meta-analysis)
(n = 26)
Due to independent
subgroups within
individual studies
(n=32)











Figure 3: Primsa Diagram

Not English (n=29)
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Location of disease
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(n=31)
Other diseases (n=54),
Not in humans (n=2)
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Not primary article
(n=34)
Not the outcome
considered (n=9)
Not the treatment
considered or not specific
enough (n=6)
Missing articles (n=4)
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6.2 Treatment Categories
Of the 45 studies that were included in the systematic review, the antimetabolites
treatment group consisted of 23 studies, which broke down further to specific treatments,
with 12 studies for MMF, followed by 9 studies for MTX, and 2 studies for AZA. All of
these treatments were treating mostly idiopathic uveitis patients (77.6% of the patients
from the studies specifically had idiopathic uveitis). Also, important to note most studies
presented results on the patient level either with subjects or with eyes.
Sixteen studies fell within the inhibitors of T-lymphocyte signalling treatment group,
which broke down to 12 studies for CsA, 3 studies for TAC, and only 1 study that
examined both TAC and CsA. Only 1 study used the alkylating agent, Chlorambucil.
There were 2 studies that looked at multiple treatment groups; BenEzra et al examined
Chlorambucil, AZA and CsA, while Dick et al examined CsA, or CsA plus AZA. There
were 3 studies that examined various combined immunosuppressive treatments. This is
summarized in Table 10.
Table 10: Number of studies for each treatment category
Treatment Class

Treatment

Antimetabolites (n=23)

Azathioprine (n=2)

Methotrexate (n=9)
Mycophenolate Mofetil (n=12)
Alkylating Agents (n=1)

Chlorambucil (n=1)

Inhibitors of t-lymphocyte signaling (n=16)

Cyclosporine (n=12)
Tacrolimus (n=3)

Multiple Treatment Groups (n=2)

--

Combined Immunosuppressive Treatment (n=3)

--
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Inhibitors of T-lymphocyte signalling
6.2.1.1
6.2.1.1.1

Cyclosporine A
Study Characteristics

Twelve studies reported solely on CsA. Seven studies were conducted in the USA, 2 in
Canada, and 3 in the UK. Studies were conducted between 1979 and 2010.
The study designs included: One study was an RCT, 7 studies were prospective cohort
studies, 2 studies were retrospective cohort studies, and 2 studies were retrospective case
series. The total sample size was 711. Study characteristics are summarized in Table 11
on the following page.

6.2.1.1.2

Study Size and Patient Characteristics

Two studies included patients <16 years of age (Kilmartin et al (1998)125 had patients
with an average age of 8.7, while Walton et al (1997)126 had patients aged around 12.9).
In all the other studies, the mean age ranged from 34 to 49 years. Ten of 12 studies
provided gender proportions ranging from 29-63% female. Reported follow up time
ranged from 3 to 227 months, with 2 studies not reporting any follow up. Cause of uveitis
was mainly uveitis with 7 of the 12 studies, where 100% of the patient’s uveitis was
idiopathic in nature. Uveitis type was classified as intermediate in 4 studies, nonclassified in 3 studies, posterior in 2 studies, and mixed in the remaining studies. Six
studies had steroid usage, 2 had steroid combined with immunosuppressive, 1 used
immunosuppressive treatment exclusively, and 3 used no oral drugs. Table 12 presents a
summary of the patient characteristics.

6.2.1.1.3

Descriptive Outcomes

Eight studies did not report how many patients experienced improvement to or
maintained VA. Four studies mentioned frequency of patients that got better, of which,
Walton et al showed 82.1% of patients improved or maintained VA, and Kilmartin et al
(1998)125 showed that 92% of patients had improved or maintained VA. Leznoff et al
(1992)127 reported only 20% of patients improving or maintaining VA, while Rocha et al
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(1997)128 showed 43.75% of patients improving or maintaining VA. Three studies
reported the frequency of patients that had maintained or improved inflammation grade.
Kacmaz et al (2010)129 reported improvement in inflammation grade in 51.9% of patients
overall, ranging from 45.5% to 58.5%. The second study reported that 76% of patients
had maintained or improved inflammation grade, and the third study reported that 49% of
patients had improved or maintained inflammation grade.

6.2.1.1.4

Reason for Discontinuation and Adverse Events

Four studies reported cases of treatment discontinuation due to intolerance (ie, side
effects). In Palestine et al (1985)130, about 30% of patients had to discontinue due to
intolerance. In Rosales (2011)131, 11% of patients had to discontinue because of
intolerance. In Kacmaz (2010)129, renal toxicity was a cause of discontinuation in 4.3% of
patients, while side effects in general were the cause of discontinuation in 11.1% of
patients in Kilmartin et al (1998)125, and within the same study 11.1% of patients
discontinued due to the treatment being ineffective.
Nephrotoxicity was the primary adverse events mentioned in 2 studies. 80% of patients in
1 study experienced nephrotoxicity, and 31.3% of patients experienced it in the other.
Hypertension was the primary adverse event mentioned in 4 studies, ranging from 1980% of patients afflicted. Other adverse events included tremors (40%), increased
creatinine levels (28%), and digestive intolerance in 38% of patients. Table 13
summarizes the descriptive outcomes, including the adverse events.
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Table 11: Cyclosporine A Treatment, Study Characteristics
Citation
Derary et al, 1992132
Isnard et al, 2002133
Leznoff et al, 1992127
Rubin et al, 1993134
Palestine et al, 1985130
Rosales et al*, 2011131
Walton et al, 1997126
Rocha et al, 1997128
Kacmaz et al, 2010129
Kilmartin et al, 1998125
Nussenblatt et al, 1985135
Ramadan et al, 1996136

Design

Setting/Data
source
France
France
Canada
USA
USA
USA
USA
Canada
USA
UK
USA
USA

Accrual Period

Sample
Size
16
41
18
32
60
-75
8
62
373
14
12

PCS
1986 to 1990
PCS
April 1986 to December 1997
PCS
1987
PCS
-PCS
-RCS
January 1992 to October 2010
RCaseS
1983 to 1993
PCS
August 1992 to January 1995
RCS
1979 and 2007
RcaseS
-PCS
-Double-masked,
-RCT
Legend: RcaseS= retrospective case series, RCS= retrospective cohort study, PCS= Prospective cohort study *=
abstract

73

Table 12: Cyclosporine A Treatment, Patient Characteristics
Citation

Derary et al, 1992132
Isnard et al,

2002133

Leznoff et al,

1992127

Mean Age

Age SD

% Female

Mean
Follow-up
SD
--

Prim
Cause

%

Location
of disease

%

56

Mean
Follow-up
(Mo.)
24

45.6

2.7

49

Previous
Treatment

Idio

100

Int or Pos

100

Corticosteroids

10

56

55.4

0.2

Idio

100

Pos

100

None

45

13.5

40

--

--

Idio

100

--

Rubin et al, 1993134

33.8

--

62.5

14

--

Idio

59.4

46.9

Prednisone

Palestine et al, 1985130

35

16.8

--

3

--

Idio

100

Pos, Int,
and Pan
Int

100

--

2011131

Rosales et al*,

Prednisone

42

19.7

54.7

226.8

--

NAU

100

--

--

--

Walton et al, 1997126

12.9

2.5

46.7

44.5

7.3

CU

100

Int

47

Prednisone

Rocha et al, 1997128

39

14

62.5

16

10

Idio

75

Kacmaz et al, 2010129

36.1

19

62.7

10.8

--

Idio

92.4

Pos or Int

45.8

Prednisone+
Immunosuppressive

Kilmartin et al, 1998125

8.7

12.4

28.6

26.8

21.2

PP

55.7

Int

57.1

Systemic steroids

Corticosteroids/
azathioprine
resistant

Nussenblatt et al,
35
16
55.8
-2.3
Idio
50.4
Int
40.4
Immunomodulatory
1985135
Ramadan et al,
35.7
11.2
-13.3
6.6
Idio
100
Pos
100
Corticosteroids
1996136
Legend: SD= Standard Deviation, a= CsA with Ketoconazole, Idio= Idiopathic, NAU= Non-infectious autoimmune uveitis, CU= Chronic uveitis, PP= Pars Planitis, Pos=
Posterior, Int= Intermediate, Pan= Panuveitis, *= Abstract
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Table 13: Cyclosporine A Treatment, Descriptive Outcomes
Citation

IMVA

IMI

Prim.
reason
--

%

Sec. reason

%

--

Discontinuation
Reason
--

Derary et al, 1992132

--

Isnard et al, 2002133
Leznoff et al, 1992127

-20

--

--

--

---

---

---

---

---

Rubin et al, 1993134

--

--

--

--

--

Palestine et al,
1985130

--

49

--

Intolerance

Rosales et al*,
2011131

--

--

--

Walton et al, 1997126

82.1

--

Rocha et al, 1997128

43.8
--

Kacmaz et al,

2010129

Adverse events
prim.
Nephrotoxic

%

%

80

Adverse events
sec.
Hypertension

---

-Increased
hypertension

-20

---

---

--

--

Renal toxicity

31.25

Hypertension

18.75

30

--

P

Parasthesia

--

Gastrointestinal
distress

--

Intolerance

11

--

--

Digestive
intolerance

38

Increase of
creatinine level

28

--

--

--

--

--

Increases in
serum creatinine

53

Hyperplasia

40

--

--

--

--

--

--

Tremor

0.4

--

--

51.9

Side effects

Renal
toxicity

4.3

Hypertension

3.2

--

--

--

21

80

Kilmartin et al,
92
76
-Side effects
11.1 Ineffective
11.1 Hypertrichosis
29
Fatigue
-1998125
Nussenblatt et al,
-----------1985135
Ramadan et al,
-----------1996136
Legend: IMVA= Improving or maintaining Visual Acuity, IMI= Improving or maintaining Inflammation, Prim Reason= Primary, Sec= Secondary, %= Frequency of
patients, *= Abstract
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6.2.1.2
6.2.1.2.1

Tacrolimus
Study Characteristics

There were 3 studies that had administered TAC to patients as the main treatment. Two
of these were conducted in the UK, while location was not specified in the other. The
studies were conducted between 2004 and 2009. The designs of the 3 studies were as
follow: 1 RCT, 1 retrospective case series, and 1 prospective cohort study. The RCT
compared steroid and TAC usage to TAC with steroids. The total sample size was 61.
Study characteristics are summarized in Table 14.

6.2.1.2.2

Study Size and Patient Characteristics

The mean age in the studies ranged from 38 to 40.6 years. The RCT with TAC and
steroid use had an average age of 31.3 years. The gender proportions ranged from 5090.9% females. Only 1 study reported follow up time, which was 45 months. The cause
of uveitis was idiopathic in 67% of the patients. Uveitis type was classified as
intermediate in 1 study and posterior in the other 2 studies, where 1 reported all patients
as posterior, and the other 37.1%. One study only had prior steroids usage, while another
study had both prior steroids and CsA usage, and the last 1 had prior steroid and other
immunosuppressive treatments. Patient characteristics are summarized in Table 15.

6.2.1.2.3

Descriptive Outcomes

Of the 3 studies, only Figueroa et al (2007)137 mentioned the percentage of patients who
improved or maintained VA and inflammation grade. With 80.95% of patients improved
or maintained VA and 54.5% of patients improved or maintained in inflammation grade.

6.2.1.2.4

Reason for Discontinuation and Adverse Events

With the RCT, TAC + steroids, treatment failure accounted for 50% of patients
discontinuing the treatment, while with just TAC in the RCT, 100% of the patients had to
discontinue.
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Lack of efficacy was the cause of discontinuation for the other 2 studies, which
accounted for 36.4% and 24.2% of patients having to discontinue the treatment,
respectively.
In the RCT, 12.5 % of the patient population experienced cramps, and 10.5% experienced
tremors with TAC and steroids in the RCT. Tremors and headaches were the main
adverse events in patients of the other 2 studies, with 72.7% of patients experiencing
hand tremors in Figueroa et al. In addition, 54.5% of patients in Figueroa et al
experienced headaches. Descriptive outcomes, including the adverse events, are
summarized in Table 16.
Table 14: Tacrolimus Treatment, Study Characteristics
Citation
Lee Richard et al,
2012138

Treatment
Steroid +
Tacrolimus
Tacrolimus
Tacrolimus

Design
RCT*

Setting/Data source
UK

Accrual Period
May 2004 to
January 2009

Sample Size
19

16
November 2000 to 15
November 2005
Hogan et al, 2007139
Tacrolimus
RCS
Bristol Eye Hospital,
April 2000 and
11
United Kingdom
April 2004
Legend: RCT*= Randomized, controlled, phase 2b, open-label, dual-center no inferiority trial, PCS= Prospective
Cohort Study, RCS= Retrospective Case Series
Figueroa et al, 2007137

PCS

--
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Table 15: Tacrolimus Treatment, Patient Characteristics
Citation

Treatment

Mean
Age

Age
SD

%Female

Mean
Follow-up
(Mo.)

Mean
Follow-up
SD

Prim.
Cause

%

Location
of
disease

%

Previous Treatment

Lee Richard et al,
2012138

Steroid + Tacrolimus

31.3

--

52.6

--

--

Idio

63.2

Int

42

Prednisone

Tacrolimus

39.8

--

50

--

--

Idio

68.9

Int

62.5

Prednisone

Tacrolimus

40.6

14.7

90.9

45

11.3

Idio

63.6

Pos

100

Pred+CsA

Tacrolimus

38

13.8

72.5

--

--

Idio

70.96

Pos

37.1

Pred+
immunosuppressive

Figueroa et al,
Hogan et al,

2007137

2007139

Legend: Idio= Idiopathic, Pos= Posterior, Int= Intermediate, Pred = Prednisone, %= Frequency of patients

Table 16: Tacrolimus Treatment, Descriptive Outcomes
Citation

Treatment

IMVA

IMI

Reason for
discontinuation

Primary
reason

%

%

50

Primary
Adverse
events
Cramp

%

12.5

Secondary
Adverse
events
Tremor

Lee Richard et al,
2012138

Steroid + Tacrolimus

--

--

Intolerance

Tacrolimus

--

--

Figueroa et al, 2007137

Tacrolimus

80.95

54.5

Treatment failure: 50%
due to drug intolerance
Disease Failure: 100% due
to disease reactivation
Efficacy

Lack of efficacy

100

Cramp

12.5

Tremor

6.3

Efficacy

36.4

Hand tremor

72.7

Headache

54.5

Hogan et al, 2007139

Tacrolimus

--

--

--

Efficacy

24.2

Tremor

8.06

Headache

6.45

Legend: IMVA= Improving or maintaining Visual Acuity, IMI= Improving or maintaining Inflammation, %= Frequency of patients

10.5
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6.2.1.3
6.2.1.3.1

Tacrolimus or Cyclosporine
Study Characteristics

One study compared TAC to CsA in a prospective RCT, which was conducted in the UK
between 2001 and 2003. Study characteristics are summarized in Table 17.

6.2.1.3.2

Study Size and Patient Characteristics

In this study, 19 patients were administered TAC and 18 patients were administered CsA.
The average age of the patients that were given TAC was 48 years, while the average age
for patients that were given CsA was 38 years. 58% of female patients were given TAC
and 56% of female patients were given CsA. The mean follow up for the TAC patients
was 7 months, and it was 4 months for CsA patients. Idiopathic uveitis made up 53% of
the patients that were given CSA, and 57% that were given TAC. All 3 locations were
treated in this study. The previous treatment used in this study was steroids. Patient
characteristics are summarized in Table 18.

6.2.1.3.3

Descriptive Outcomes

The post-VA was maintained or improved in 68% of the patients given TAC and in 67%
of the patients given CsA.

6.2.1.3.4

Reason for Discontinuation and Adverse Events

No mention of discontinuation of treatment was discussed. However, adverse events were
reported for both CsA and TAC. The main adverse events for patients treated with CsA
were fatigue at 56%, and tremors, which occurred in 44% of patients. 37% of the patients
given TAC had paresthesia, and 32% of patients developed tremors after being given
TAC. Descriptive outcomes, including the adverse events, are summarized in Table 19.
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Table 17: Tacrolimus or Cyclosporine A Treatment, Study Characteristics
Citation

Treatment

Murphy et al, 2005140 Tac

CsA

Design

Setting/Data source

Accrual
Period

Sample Size

Prospective
randomized
trial

United Kingdom (Bristol Eye
Hospital [Bristol, England] and
Aberdeen Royal Infirmary
[Aberdeen, Scotland])

May 2001 and 19
April 2003

18

80

Table 18: Tacrolimus or Cyclosporine A Treatment, Patient Characteristics
Citation

Treatment

Mean Age
Age
SD

%Female

Mean
Follow-up
SD
3.5

Prim.
Cause

%

Location of disease

%

%

Previous
Treatment

58

Mean
Follow-up
(Mo.)
7

Murphy et al,
2005140

TAC

48

4.8

Idio

57

100

74

Prednisone

56

4

2.5

Idio

53

Posterior, intermediate
and panuveitis
Posterior, intermediate
and panuveitis

CsA

38

6

100

78

Prednisone

Legend: Idio= Idiopathic, Pos= Posterior, Int= Intermediate, Pred= Prednisnone

Table 19: Tacrolimus or Cyclosporine A Treatment, Descriptive Outcomes
Citation

Treatment

IMVA

%

68

Primary Adverse
event
Paraesthesia

Murphy et al,
2005140

TAC
CsA

%

37

Secondary Adverse
events
Tremors

67

Fatigue

56

Tremors

44

Legend: IMVA= Improving or maintaining Visual Acuity, %= Frequency of patients

32
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Antimetabolites
6.2.2.1
6.2.2.1.1

Mycophenolate Mofetil
Study Characteristics

Studies that administered MMF for uveitis were conducted in Germany (n= 5), other
parts of Europe (n=3), and the USA (n=4). The studies collected patient data from as
early as 1995, and the latest data was collected at the end of 2007. Four studies did not
provide an accrual period. The full paper could not be attained for 1 study (Capriotti et
al18). Eight studies were retrospective case series, 3 were cohort studies, of which 2
studies were prospective cohort studies and 1 was a retrospective cohort study. Study
characteristics are summarized in Table 20.

6.2.2.1.2

Study Size and Patient Characteristics

The total sample size for the MMF studies was 607. The mean age of the patients that
were given MMF across the studies ranged from 8 to 57.3 years. Most studies had a mean
age in the 40s, while 1 study that looked at juvenile idiopathic patients had a mean age of
8 years. In most studies, females accounted for about 50% of the patient population
(ranging from 33% to 68.8%). Mean follow up time reported ranged from 21.4 months to
69.7 months, with 1 study not reporting. One study considered patients with panuveitis,
while the other 10 looked at idiopathic uveitis. There was an average of 73% of
idiopathic uveitis patients.
Uveitis type was classified as intermediate in 4 studies, as mixed posterior and
intermediate in 1 study, and was non-classified in 2 studies. One study divided their
patient population by location of disease, so they had patients with posterior uveitis (n=
23), intermediate uveitis (n=53), and panuveitis (n=6). Five studies had prior steroid
usage, 4 had steroid with immunosuppressive treatment and 1 used immunosuppressive
treatment exclusively. Patient characteristics are summarized in Table 21.
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6.2.2.1.3

Descriptive Outcomes

One measure of effectiveness used was the frequency of patients for whom VA was
improved or maintained. Ten studies demonstrated that MMF was effective in treating
patients, with 76.3% to 94.7% of patients having maintained or improved VA, and with 2
studies not reporting. Seven studies had improvement to inflammation grade, with a
range of 60.9% to 94.2%, with 5 studies not reporting.

6.2.2.1.4

Reason for Discontinuation and Adverse Events

Five studies indicated that MMF was discontinued in 12-35% of patients due to lack of
efficacy. Another 5 studies indicated that lack of efficacy was the most common adverse
effect in patients with MMF use. The secondary adverse event that was quite common
was fatigue. Descriptive outcomes, including the adverse events, are summarized in
Table 22.
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Table 20: Mycophenolate Mofetil Treatment, Study Characteristics
Citation

Treatment

Design

Setting/Data source

Accrual Period

Capriotti et al,
2005*141
Bhat et al, 2009142

MMF

RCaseS

USA

--

Sample
Size
41

MMF

RCaseS

2005 to 2007

7

Neri et al, 2009143

MMF

RCaseS

2003 to 2007

19

Benson et al,
2006144

MMF

RCaseS

2000 to 2006
(consecutive
100 patients)

100

Daniel et al,
2010145
Deuter et al,
2009146

MMF

RCS

Massachusetts Eye
Research and Surgery
Institute
The Eye Clinic of the
Polytechnic University of
Marche
Bristol Eye Hospital’s
Regional Ocular
Inflammatory Service,
United Kingdom
USA

1995 to 2007

236

Mycophenolate
sodium

RCaseS

Germany

--

35

Doycheva et al,
2012147
Zierhut et al,
2011148
Stuebiger et al,
2007149
Forrester et al,
1998150
Siepmann et al,
2006151

MMF

RCaseS

Germany

--

38

MMF

RCaseS

Germany

--

60

MMF

RCaseS

Germany

2000 to 2005

17

MMF

RCS

--

9

MMF

PCS

Aberdeen Royal Hospitals,
Scotland
Germany

51

MMF

PCS

Germany

MMF

PCS

Germany

Between 1998
and 2003
Between 1998
and 2003
Between 1998
and 2003
--

23
6

Llinares-Tello et al, MMF
PCS
USA
12
2004152
Legend: RCaseS= Retrospective Case series, RCS= Retrospective Cohort Study, PCS= Prospective Cohort Study,
*=abstract
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Table 21: Mycophenolate Mofetil Treatment, Patient Characteristics
Citation

Treatment

Mean Age
Age
SD

%Female

Capriotti et al,
2005*141
Bhat et al, 2009142

MMF

--

--

--

MMF

49

2009143

MMF

Neri et al,

Benson et al, 2006144

Mean
Follow-up
(Mo.)
26.8

Mean
Follow-up
SD
--

Prim. Cause

%

Location of %
disease

Previous Treatment

Idio

100

--

Corticosteroids

17.25 57

39.6

9.6

Panuveitis

100

--

Immunomodulatory

32.9

8.9

42.8

30

6

Idio

56.3

Int

21

Steroids, CsA, AZA,
MTX

MMF

39

14.3

65

24

4.75

Idio

61

Pos and Int 71

Pred, CsA, AZA, MTX

2010145

MMF

47.1

19.0

64

21.6

4.5

Idio

100

Int and Pos 51.7

Pred+
46.2% had prior
immunosuppressive
treatment

Deuter et al, 2009146

MMF

42.7

14.5

62.8

68.8

9.6675

Idio

77.1

Int

66

Corticosteroids

Doycheva et al,
2012147
Zierhut et al, 2011148

MMF

42.42 17

68.8

69.7

61.5

Idio

71.1

Int

73.7

Corticosteroids

MMF

40

17.8

61.7

71

4.5

Idio

61.7

Int

68.3

Corticosteroids

Stuebiger et al,
MMF
2007149
Forrester et al, 1998150 MMF

8

2.8

41.2

36

13.75

Idio

64.7

Int

58.8

Prednisolone

39.5

--

78.9

72.7

9

Idio

66.6

Not
specified

Siepmann et al,
2006151

40.1

12.3

49

--

55.75

Idio

80.4

Int

25

--

44.8

11

43.5

--

--

Idio

62.2

Pos

22

--

57.3

8.5

33

--

--

Idio

50

Pan

6

--

Daniel et al,

MMF

Llinares-Tello et al,
MMF
40
16.5 42
21.4
3.5
Idio
67
2004152
Legend: Idio= Idiopathic, Pos= Posterior, Int= Intermediate, Pan= Panuveitis, Pred= Prednisone, %= Frequency of patients

Corticosteroids
+CSa

Corticosteroids
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Table 22: Mycophenolate Mofetil Treatment, Descriptive Outcomes
Citation

Treatment

IMVA

IMI

Primary
Discontinuation
reason

%

Secondary
Discontinuation
reason

%

Primary
Adverse events

%

Secondary
Adverse
events

%

Capriotti et al,
2005*141
Bhat et al, 2009142

MMF

81.1

60.9

Intolerance

16

--

--

--

--

--

--

MMF

64.3

100

Neri et al, 2009143
Benson et al, 2006144
Daniel et al, 2010145

MMF
MMF
MMF

94.7
---

--73.1

--

--

--

Leukopenia

43

-Gastrointestinal
Side Effects

--

--

31.6

Ineffectiveness

9.7

--

Tiredness
Headache
--

26.3

12

Dyspepsia
Gastrointestinal
Gastrointestinal

Deuter et al, 2009146

Mycophenolate
sodium

92.3

94.2

--

--

--

--

Gastrointestinal

14.3

Fatigue

0.1

Doycheva et al,
2012147

MMF

76.3

--

Herpes zoster
dermatitis, kidney
infection, and
gastrointestinal

8.9

--

--

Gastrointestinal

Zierhut et al, 2011148

MMF

81.7

72

Efficacy

35

Inefficacy

20

Gastrointestinal

23.3

Stuebiger et al,
2007149
Forrester et al,
1998150
Siepmann et al,
2006151

MMF

76.5

82.3

--

--

--

--

Headache

MMF

86.7

86.7

--

--

--

--

Myalgia

MMF

100

--

--

--

--

--

Gastrointestinal

100

--

--

--

--

--

--

66.6

--

--

--

--

--

--

Llinares-Tello et al,
MMF
83
-Therapeutic
17
Diarrhoea
2004152
failure
Legend: IMVA= Improving or maintaining Visual Acuity, IMI= Improving or maintaining Inflammation, %= Frequency of patients

--

Fatigue

8.3

23.5

Muscle
pain
Rash

44.4

Fatigue

22.2

Headache

--

--

--

--

--

--

--

25

Agitation

25

11.8
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6.2.2.2
6.2.2.2.1

Methotrexate
Study Characteristics

Of the studies that examined MTX, 7 studies were conducted in the USA, 1 study in
Germany, and the other in Israel. The studies collected patient data from as early as 1986
(Friling et al153), and the latest data was collected in Khan et al in 2008. The full paper
could not be attained for 2 studies, Khan et al (2010)154 and Schmitt et al (1990)155 For
these 2 studies we only had abstracts, however they contained the essential information.
Seven studies were retrospective case series, whereas 1 study was a prospective
randomized pilot study, and the other was randomized control trial, double-masked study.
Study characteristics are summarized in Table 23.

6.2.2.2.2

Study Size and Patient Characteristics

The total sample size for the MMF studies was 691. Across the studies, the mean age of
patients that were given MTX ranged from 16.7 to 49 years. Most studies had a mean age
in the 40s, while 1 study that looked at juvenile idiopathic patients had a mean age of
16.7 years. In all studies, females made up the majority of the patient population (ranging
from 64% to 91%). Mean reported follow up time ranged from 3.9 to 164 months, with 2
studies not reporting
All studies included patients with idiopathic uveitis, with 1 study specifically looking at
juvenile idiopathic uveitis, averaging at 78% of patients having idiopathic uveitis. Uveitis
type was not specified in 5 of the studies, while intermediate, posterior, and mixed were
each reported in 1 study. Seven studies had prior steroid usage, 1 had steroid with
immunosuppressive treatment, and 1 did not specify prior treatment. Patient
characteristics are summarized in Table 24.

6.2.2.2.3

Descriptive Outcomes

One measure of effectiveness used was the frequency of patients for who VA was
improved or maintained. Five studies indicated that MTX was effective in treating
patients, ranging from 76% to 100% of patients experiencing maintained or improved

87

VA, with 4 studies not reporting. The improvement or maintaining of inflammation grade
was exhibited in 2 studies. Yu et al (2005)156 indicated that the inflammation grade for
50% of patients had improved or maintained, while Dev et al (1999)157 indicated that the
inflammation grade for 95% of patients had improved or maintained.

6.2.2.2.4

Reason for Discontinuation and Adverse Events

Five out of 10 studies indicated that MTX was discontinued in some patients due to lack
of efficacy, with frequency ranging from 13% to 48% of patients. With one study having
had patients discontinue treatment due to side effects. Five studies reported adverse
events of MTX. Some patients experienced higher leukopenia (14% of patients), higher
anemia (14%), mild increase in SGOT (13%), minimal increase in creatinine (7%),
fatigue (19%), mild nausea (19%), and gastrointestinal issues (20%). Descriptive
outcomes, including the adverse events, are summarized in Table 25.
Table 23: Methotrexate Treatment, Study Characteristics
Citation

Treatment

Design

Setting/Data
source

Baker et al, 2006158

Methotrexate

Retrospective
case series

Foeldvari et al,
2004159

Methotrexate

Retrospective
case series

Casey Eye Institute
(Portland, Oregon,
USA)
Germany

Friling et al, 2005153

Methotrexate

Retrospective
Case Series

Israel

Khan et al*, 2010154

Methotrexate

Quinones et al,
2010160

Methotrexate

Schmitt et al*,
1990155
Yu et al, 2005156

Methotrexate

Retrospective
Case Series
Prospective
Randomized Pilot
Study
Retrospective
Case Series
Retrospective
Case Series

Dev et al, 1999157

Methotrexate

Foster et al, 2003161

Methotrexate
+Placebo

*abstract

Methotrexate

Retrospective
non-comparative
case series
Randomized
control trial,
Double masked

Accrual Period

Sample
Size

2003

107

467

USA

July 1, 2002 to
December 31,
2002
38 consecutive
children between
1986 to 2002
1997 to 2008

USA

--

.

USA

--

15

Massachusetts Eye
and Ear Infirmary,
USA
USA

1981 and 2001

23

1989 to 1997

11

USA

--

10

15

36
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Table 24: Methotrexate Treatment, Patient Characteristics
Citation

Treatment

Mean
Age

Age
SD

%Female

Mean
Follow-up
(Mo.)

Mean
Follow-up
SD

Prim. Cause

%

Location of
Disease

%

Previous Treatment

Baker et al,
2006158

MTX

49

17.6

70

164.3

--

Idio

58

--

--

Corticosteroids +
immunomodulatory

Foeldvari et al,
2004159
Friling et al,
2005153
Khan et al*,
2010154

MTX

--

--

--

--

--

JIA

100

--

--

Corticosteroids

MTX

--

--

67

3.9

2.8

Idio

100

--

--

Prednisone

MTX

43.5

14.25

64

--

--

Idio

53

100

--

Quinones et al,
2010160
Schmitt et al*,
1990155
Yu et al, 2005156

MTX

34.54

11.75

57

5.44

Idio

85.7

Posterior,
intermediate
and
panuveitis
Intermediate

100

Corticosteroids

idio

53.3

--

--

--

JIA

100

--

--

Corticosteroids

Panuveitis

--

Posterior

--

Corticosteroids
(were resistant)

Dev et al,

1999157

1.2
MTX

47

12

80

9
5.5

MTX

16.7

10

91

7.3

MTX

38

11.5

81.8

<12
months

2
--

Foster et al,
Methotrexa 45
-90
--Idio
70
--2003161
te +Placebo
Legend: Idio= Idiopathic, JIA= Juvenile idiopathic arthritis, Pos= Posterior, Int= Intermediate, Pan= Panuveitis, Pred= Prednisone, *abstract

Methotrexate

89

Table 25: Methotrexate Treatment, Descriptive Outcomes
Citation

Treatment

IMVA

IMI

Baker et al, 2006158

MTX

--

Foeldvari et al,
2004159
Friling et al, 2005153
Khan et al*, 2010154
Quinones et al,
2010160
Schmitt et al*,
1990155

MTX

Yu et al, 2005156
Dev et al, 1999157
Foster et al, 2003161

%

--

Prim. Reason
for discon.
Lack of efficacy

%

16

Sec. reason
for discon.
Adverse
events
--

%

26

Primary
Adverse events
--

76

--

Lack of efficacy

--

MTX
MTX
MTX

87
---

----

--Lack of efficacy

--44

--.

MTX

--

--

Lack of efficacy

13

MTX

86

50

Lack of efficacy

48

36

%

--

Secondary
Adverse events.
--

--

--

--

--

--.

--Higher leukopenia

--14

--Higher anemia

.

--

--

Mild increase in
SGOT (2)

13

7

--

--

Fatigue

19

A minimal
increase in
creatinine (1)
Mild nausea

--

14

19

MTX
90
95
Side effects
---Nausea
14
Cytopenia
Methotrexate 100
-----Gastrointestinal
0.2
--+Placebo
Legend: IMVA= Improving or maintaining Visual Acuity, IMI= Improving or maintaining Inflammation, Prim Reason= Primary, Sec= Secondary, %= Frequency of
patients, MTX= Methotrexate, discon= discontinuation *abstract
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6.2.2.3
6.2.2.3.1

Azathioprine
Study Characteristics

Two studies used solely AZA, and both studies were conducted in the USA, between
1977 and 2008. One study was a case series, while the other was a retrospective cohort
study. Study characteristics are summarized in Table 26.

6.2.2.3.2

Study Size and Patient Characteristics

The total combined number of patients in both studies was 153. Across the studies, the
mean age of patients that were given AZA ranged from 12.6 years to 50.6 years. 88% of
the patients were female in the study with the juvenile patients, while 67.9% of patients
were female in the second study. Reported mean follow-up time ranged from 7.67
months to 84 months. Uveitis type was only classified in 1 study as mixed, while the
other did not specify. One study had prior steroid usage, while the other had steroid with
immunosuppressive treatment. Patient characteristics are summarized in Table 27.

6.2.2.3.3

Descriptive Outcomes

Only 1 of the studies reported on the frequency of patients for who VA was improved or
maintained, which was about 83.3%. The other study was the only one that reported on
inflammation grade, for which about 62.2% of patients had improved or maintained.

6.2.2.3.4

Reason for Discontinuation and Adverse Events

Pasadihika et al (2009)162 indicated that 24% of patients given AZA discontinued
treatment due to side effects, while 15% of patients discontinued treatment due to lack of
efficacy. Descriptive outcomes, including the adverse events, are summarized in Table
28.
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Table 26: Azathioprine Treatment, Study Characteristics
Citation

Treatment

Design

Hemady et al, 1992163

Azathioprine

Case Series

Setting/
Data
source
USA

Pasadhika et al,
2009162

Azathioprine

Retrospective cohort study

USA

Accrual Period

Sample
Size

January 1977 to
September 1989
2005 to 2008

8
145

92

Table 27: Azathioprine Treatment, Patient Characteristics
Citation

Treatment

Mean

Age
SD

%Female

Mean
Follow-up
(Mo.)

Mean
Follow-up
SD

Prim.
Cause

%

Location of disease

%

Previous Treatment

Age
Hemady et al,
1992163

Aza

12.6

5.2

88

84

28

JIA

100

--

--

Corticosteroids

Pasadhika et al,
2009162

Aza

50.6

19.2

67.6

7.67

5.2

--

--

Posterior/Panuveitis
/Intermediate

48.3

Corticosteroids+
40% prior
immunosuppressive

Legend: Prim.= Primary, % = Frequency of patients, JIA= Juvenile idiopathic arthritis

Table 28: Azathioprine Treatment, Descriptive Outcomes
Citation

Treatment

IMVA

IMI

Primary
reason for
discon.

%

Secondary
reason for
discon.

%

Primary
Adverse events

Hemady et al,
1992163

Azathioprine

83.333

--

--

--

--

--

Gastrointestinal

Pasadhika et al,
2009162

Azathioprine

--

62.2 (50.5 to
74.0)

Side Effects

24

Ineffectiveness

15

Gastrointestinal

%

9

Secondary
Adverse events

%

--

--

Bone marrow
suppression

5

Legend: IMVA= Improving or maintaining Visual Acuity, IMI= Improving or maintaining Inflammation, %= Frequency of patients, discon= discontinuation
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Alkylating Agents
6.2.3.1

Chlorambucil

6.2.3.1.1

Study Characteristics

One study explored the use of Chlorambucil. It was a non-comparative interventional
case series conducted in the USA, between 1987 and 2000. Study characteristics are
summarized in Table 29.

6.2.3.1.2

Study Size and Patient Characteristics

There were 28 patients in the study, with a mean age of 28.8 years, and 92.8% female
patients. The mean follow-up was 46 months. Juvenile rheumatoid arthritis patients with
idiopathic uveitis accounted for 66% of the patients. Location of the disease in all
patients was panuveitis. Patients had previously been treated with steroids, CsA, AZA,
and/or MTX. Patient characteristics are summarized in Table 30.

6.2.3.1.3

Descriptive Outcomes

VA was maintained or improved in 82.1% of patients, and the inflammation grade
maintained or improved in 67.9% of the patients.

6.2.3.1.4

Reason for Discontinuation and Adverse Events

Gastrointestinal intolerance and leukopenia accounted for AZA treatment being
discontinued in 14.2% of patients. Descriptive outcomes, including adverse events, are
summarized in Table 31.
Table 29: Chlorambucil Treatment, Study Characteristics
Citation

Treatment

Design

Setting/Data source

Accrual Period

Sample
Size

Miserocchi et al,
2002164

Chlorambucil

Non-comparative
interventional case
series

Ocular
Immunology and Uveitis
Service of the
Massachusetts Eye and
Ear Infirmary

1987 to 2000

28

94

Table 30: Chlorambucil Treatment, Patient Characteristics
Citation

Treatment

Age

Age
SD

%Female

Mean
Follow-up
(Mo.)

Mean
Follow-up
SD

Primary Cause

%

Location of
disease

%

Previous
Treatment

Miserocchi et
al, 2002164

Chlorambucil

28.75

16.3

92.8

46

40.5

Juvenile rheumatoid
arthritis–associated
uveitis

55.7

Posterior/
Panuveitis/
Intermediate

60.7

Pred, CsA,
AZA, MTX

Table 31: Chlorambucil Treatment, Descriptive Outcomes
Citation

Treatment

IMVA

IMI

Reason for
discontinuation

Primary reason
for discon.

%

Secondary
reason
for discon.

%

Primary
Adverse events

%

Secondary
Adverse
events

Miserocchi
Chlorambucil
82.1
67.9 Side effects
Gastrointestinal 7.1
Leukopenia 7.1 Gastrointestinal 7.1 Leukopenia
et al,
intolerance
2002164
Legend: IMVA= Improving or maintaining Visual Acuity, IMI= Improving or maintaining Inflammation, %= Frequency of patients, discon= discontinuation

%

7.1
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Studies with Multiple Treatments
The majority of patients in the studies were idiopathic uveitis patients, with 3 studies
having 100% of the patients being idiopathic in nature. Two studies included individual
patients who were administered multiple treatments in the same study. The first, BenEzra
(1990)165, was a retrospective case series conducted in Israel between 1979 and 1987.
Three treatments were prescribed to patients: Chlorambucil (n=46), AZA (n=23), and
CsA (n=24). The treatment administered to patients prior to Chlorambucil and AZA was
corticosteroids; patients were given corticosteroids with AZA or Chlorambucil before
they were given CsA. VA was maintained or improved in 83% of patients treated with
Chlorambucil, in 50% of patients treated with AZA, and in 90% of patients treated with
CsA. Inflammation grade was maintained or improved in 83% of patients treated with
Chlorambucil. The study did not report any improvement to inflammation grade for
patients treated with AZA and CsA. Lack of efficacy led to treatment discontinuation in
23% of Chlorambucil-treated patients.
The second study, Dick et al (1997)166, was a retrospective case series conducted in
Scotland between 1992 and 1996. The first group contained 54 posterior uveitis patients
with a mean age of 44.6 years. They were administered steroids and CsA. The second
group contained 24 posterior uveitis patients with a mean age of 46.2 years. They were
administered steroids, CsA and AZA. There were no outcomes reported, however,
measurements of pre-treatment and post-treatment VA were reported in the metaanalysis. Study and patient characteristics for multiple treatments are summarized in
Tables 32 and 33, respectively, and descriptive outcomes, including adverse events, are
summarized in Table 34.

96

Table 32: Multiple Treatments, Patient Characteristics
Citation

Treatment

Design

BenEzra,
1990165

Chlorambucil

Prednisone +
Cyclosporine A

Retrospective
Case series
Retrospective
Case series
Retrospective
Case series
Retrospective
case series

Prednisone +
Cyclosporine A + AZA

Retrospective
case series

AZA
CsA
Dick et al,
1997166

Legend: AZA= Azathioprine, CsA= Cyclosporine

Setting/Data
source
Israel

Accrual Period

Scotland, Europe

1979-1987 (patients
followed for 2 years)
1979-1987 (patients
followed for 2 years)
1979-1987 (patients
followed for 2 years)
1992 to 1996

Scotland, Europe

1992 to 1996

Israel
Israel

Sample
Size
46
23
24
54
24
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Table 33: Multiple Treatments, Patient Characteristics
Citation

BenEzra,
1990165

Dick et al,
1997166

Treatment

Mean

Age
SD

%Female

Mean
Follow-up
(Mo.)

Mean
Follow-up
SD

Primary
Cause

%

Location
of disease

%

Age

Previous
Treatment

Chlorambucil

--

--

34

8

4

Idiopathic

67

--

--

Corticosteroids

Azathioprine

--

--

--

--

--

--

--

--

--

Cyclosporine A

--

--

--

--

--

--

--

--

--

--

Prednisone +
Cyclosporine A

54

13.6

--

--

--

Idiopathic

100

Posterior

--

Corticosteroids

Prednisone +
Cyclosporine A +

24

19.9

--

--

--

Idiopathic

100

Posterior

--

Corticosteroids

Azathioprine

Table 34: Multiple Treatments, Descriptive Outcomes
Citation

Treatment

Improved or maintained
VA # 1

Controlling intraocular
inflammation # 1

Primary reason
for discon.

%

BenEzra,
1990165

Chlorambucil

83

83

Lack of efficacy

23

Azathioprine

50

--

--

--

Cyclosporine A

92

--

--

--

--

--

--

--

--

Dick et al,
1997166

Legend: Discon= Discontinuation
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Studies With No Specification Regarding Which
Immunosuppressive Was Used
Three studies only mentioned that immunosuppressives were used as treatment, without
specifying the exact treatment group. Two studies were a retrospective case series, 1 was
a retrospective cohort study. Two studies were conducted in the USA between 1978 and
2005. The total sample size across the 3 studies was 174. Two studies included the ages
of the patients; 1 was conducted with JIA patients, so the mean age was 9 years, with a
range of 1 to 17 years. The other was conducted with panuveitis uveitis patients, where
the mean age was 45 years, with a range of 9 years to 80 years. Gender proportions
ranged from 75.8-82% female. Only 1 study specified the uveitis location classification
as panuveitis. Corticosteroids were used as prior treatment in all 3 studies. One study
reported that VA was maintained or improved for 100% of patients. None of the studies
reported on treatment discontinuation or adverse events. Study and patient characteristics
for non-specific immunosuppressive treatments are summarized in Tables 35 and 36,
respectively, and descriptive outcomes are summarized in Table 37.
Table 35: Immunomodulators, Study Characteristics
Citation

Treatment

Design

Setting/Data source

Michel et al,
2002167

Immunomodulators

USA

Kump et al,
2006169
Throne et al,
2006168

Immunomodulators

Retrospective,
non-comparative,
interventional
case series
Retrospective
Case Series
Retrospective
Cohort Study

Immunosuppressive
drug therapy

USA
Ocular Immunology
at the Wilmer Eye
Institute

Accrual
Period
1978 to 2000

Sample
Size
19

1985 through
2003
January 1984
and June 2005

89
66

99

Table 36: Immunomodulators, Patient Characteristics
Citation

Treatment

Age

Age
SD

%Female

Mean
Follow-up
(Mo.)

Mean
Follow-up
SD

Primary Cause

%

Location of
disease

%

Previous
Treatment

Michel et al,
2002167

Immunomodulators

9

4.5

82

35.52

--

Juvenile
idiopathic
arthritis

53

--

--

--

Kump et al,
2006168

Immunosuppressive
drug therapy

45

17.8

75.8

--

--

Panuveitis

100

Panuveitis

100

Corticosteroids

Throne et al,
2006169

Immunomodulators

--

--

78.9

72.7

55.8

Panuveitis

100

--

--

Corticosteroids

Table 37: Immunomodulators, Descriptive Outcomes
Citation

Treatment

Improved or
maintained VA # 1

Michel et al,
2002167

Immunomodulators

--

Kump et al,
2006168

Immunosuppressive drug therapy

--

Throne et al,
2006169

Immunomodulators

100

100

6.3 Risk of Bias within Studies
The quality of the studies included in this systematic review was analyzed using a
modified Downs and Black checklist. Of the 45 studies we looked at, only 41 were
included in the assessment; the 4 excluded studies were abstracts.

Randomized Controlled Trials
When we applied the modified Downs and Black checklist, the median score for the
quality of the 5 RCT studies was 60%, with an interquartile range of 7%. The risk of bias
in the RCTs is presented in Figure 4 on the following page.
The RCT studies included additional questions specifically about randomization and
blinding of patients.
Only 2 of the 5 RCT studies did all of the following: randomized and blinded patients to
the treatment, listed confounders, blinded those measuring the main outcome, and
randomized intervention assignment that was concealed from the patients and staff until
the recruitment was complete.
Three studies had adequate adjustment for confounding in analysis; losses of patients to
follow-up were not taken into account, and no power calculation was done. Of the 10
reporting bias questions, 7 questions were answered yes in all 5 studies. The 3 questions
pertaining to external validity were answered yes in all studies. Of the 7 internal validity
bias questions, 1 question was answered yes for all studies, while 2 other questions were
answered yes for only 3 studies. As for selection bias, only 1 of the 6 questions had a yes
from all studies, and was poorly rated in the studies overall.

Observational Studies
After using the checklist on the 37 observational studies, the median score for the quality
of the studies was 48%, with an interquartile range of 5%. The risk of bias in the
observational studies is presented in Figure 4.
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Three questions from the internal validity section were removed, and 2 questions from
the selection bias section were removed, as they pertained mainly to randomized trials.
The principal confounders were clearly described in 10% of studies. Patients that were
lost to follow-up were described in 12.5 % of studies. 15% of studies listed the
probability values for the main outcomes, 5% indicated follow-up of patients was the
same for all study participants, and 17.5% used appropriate statistical tests to assess the
main outcomes.
Of the 10 reporting bias questions, 7 questions were answered yes in >80% of studies.
The 3 questions pertaining to external validity were answered with yes in >80% of
studies. Of the 4 internal validity bias questions, 1 question was answered yes in >80% of
studies. As for selection bias, only 1 of the 4 questions had a yes in 87.5% of studies.

0.32

Selection Bias

0.30
0.19

Internal Validity

0.46
0.97

External Validity

1.00
0.72

Reporting Bias

0.80
0

0.2

0.4

0.6

0.8

Frequency of quality questions that scored a "yes"
Observational Studies Quality Checklist

RCT Quality Checklist

Figure 4: Risk of Bias and Internal/External Validity

1

1.2
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6.4 Meta-analysis
Results of Individual Studies
Majority of the patients were idiopathic uveitis patients, with posterior or intermediate
uveitis, this can be seen with the data from the systematic review. As discussed in section
5.5, VA was used as the primary outcome to measure efficacy. VA was measured using
logMAR in some studies, while in other studies VA was converted to logMAR from
other scales. Inflammation grade change was not reported among enough studies having a
standardized scale for inflammation grade to allow for any meaningful conclusions. Table
38 indicates the results from the 26 individual studies.
For our study, we had independent subgroups within a study, which allowed them to be
viewed as independent studies. Because of this, the count of studies went from 26 to 32.
However, 6 studies had some missing data, either with pre- and post-logMAR, or preand post-logMAR standard deviation, thus it was extrapolated, and these studies are
noted in bold print in Table 38.
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Table 38: Results of Individual Studies: pre- and post-logMAR
Study
Year
N
Prim Treatment
Prev
Age (year) Loc
Pre-logMAR
Pre-SD Post-logMAR
Post-SD
Friling R et al153
2005
15
MTX
Steroids
10.5
Into
0.357
2.18
0.052
0.103
Lee Richard et al138
2012
19
Steroid + Tac
Steroids
32.3
Pos
0.57
2.18
0.561
2.42
Lee Richard et al138
2012
16
Tac
Steroids
41.8
Pos
0.57
2.18
0.579
2.245
Murphy et al140
2005
19
tac
Steroids
49
Pan
0.335
0.225
0.248
0.304
Murphy et al140
2005
18
CsA
Steroids
38
Pan
0.45
0.289
0.326
0.302
Quinones et al160
2010
7
MTX
Steroids
34.5
Int
0.57
2.18
0.514
2.292
Rosales et al131
2011
75
CsA
Steroids
42
NS
0.57
2.18
0.47
2.61
Walton et al126
1998
15
CsA
NS
12.9
Int
0.176
0.265
0.218
0.262
Yu et al156
2005
23
MTX
Steroids
16.7
NS
0.968
0.824
0.803
0.974
Bhat et al142
2009
7
MMF
Imm
49
Pan
0.52
0.72
0.43
0.77
Dev et al157
1999
11
MTX
Steroids
38
Pos
0.415
0.491
0.23
0.361
Kump et al169
2006
89
Comb
NS
5.7
NS
0.471
0.42
0.403
0.393
Rocha et al128
1997
8
CsA
Imm
39
Pan
1.19
0.97
1.04
1.02
Neri et al143
2009
19
MMF
Imm
32.9
Int
0.34
0.14
0.67
0.18
Deuter et al146
2009
35
MMF
Steroids
42.7
Comb
0.38
0.47
0.38
0.51
Figueroa et al137
2007
11
Tac
Imm
40.6
Pos
0.868
0.623
0.913
0.652
Hogan et al139
2007
62
Tac
Imm
38
Pos
0.297
0.322
0.233
0.319
Kilmartin et al125
1998
14
CsA
Steroids
8.7
Int
0.5688
0.561
0.405
0.539
Miserochhi et al164
2002
28
Chlorambucil
Imm
28.8
Comb
0.776
0.761
0.63
0.844
Siepmann et al151
2006
51
MMF
NS
40.1
Int
0.458
0.33
0.293
0.299
Siepmann et al151
2006
23
MMF
NS
44.8
Pos
0.545
0.352
0.465
0.39
Siepmann et al151
2006
6
MMF
NS
57.3
Pan
0.613
0.273
0.546
0.368
Doycheva et al147
2012
38
MMF
Steroids
42.4
Int
0.564
0.509
0.427
0.547
Hemady et al163
1992
8
Aza
Steroids
12.6
NS
0.834
0.664
0.551
0.527
Dick et al166
1997
54
Steroids + CsA
Steroids
45.6
Pos
0.593
0.68
0.549
0.654
Dick et al166
1997
24
Steroids + CsA + AZA
Steroids
47.2
Pos
0.489
0.624
0.615
0.683
Ramadan et al136
1996
6
CsA
Steroids
35.7
Pos
0.57
2.18
0.67
2.306
Ramadan et al136
1996
6
CsA + Ketoconazole
Imm
35.7
Pos
0.57
2.18
0.697
2.21
Forrester et al150
1998
9
MMF
Imm
39.5
NS
0.584
2.18
0.452
1.02
Nussenblatt et al135
1985
52
CsA
Imm
35
Int
0.824
0.47
0.571
0.455
Stuebiger et al149
2007
17
MMF
Steroids
8
Int
0.57
2.18
0.464
2.45
Rubin et al134
1993
32
CsA
Steroids
33.8
Comb
0.877
0.496
0.52
0.422
*Pre- and post-logMAR and logMAR SD were used to calculate change in logMAR, and the change in SD in Stata and excel. The bolded studies were missing either
logMAR SD (n=1) or pre-/post-logMAR (n=5); the highest SD for the missing SD and mean pre-/post-logMAR was used for missing pre/post data.
Legend: Prim= Primary, Prev= Previous treatment, Loc= Location of disease, pre or post-logMAR= logMAR before or after primary treatment, SD= Standard deviation,
MTX= Methotrexate, TAC= Tacrolimus, CsA= Cyclosporine, MMF= Mycophenolate Mofetil, Comb= Combination of treatments given at the same time/or patients with
different locations, AZA= Azathioprine, Imm= Immunomodulatory, NS= not specified, int= Intermediate uveitis, pos= positive uveitis, pan= panuveitis
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Primary Analysis
The summary of the results from the pooled meta-analysis and the subgroup analysis is
shown in Table 39. Figure 5 below displays the forest plots of random effects pooled
meta-analysis of the weighted mean difference in logMAR, where a negative change in
logMAR is improvement in vision and positive change in logMAR is deteriorated vision.
The studies with an asterisk (*) on them, are studies that have independent subgroups
within the study. From the forest plot, it is also important to note that I+V means fixed
effect model, whereas D+L means random effects model, and IMM means
immunosuppressive treatments.
Since 6 studies had missing pre- and post-SD data, we imputed SD by using the highest
SD reported among the overall results. The total sample size was 817 patients across all
32 analyzed studies. In the pooled random effects analyses, the immunosuppressive
treatment was significantly associated with a decrease in change in logMAR (WMD 0.107 with 95% CI of -0.152 to -0.061, p= 0) and the I2 was 0%, p=0.987. Of note, 25
studies (78.3%) reported that immunosuppressive treatment reduced logMAR.

Sensitivity Analysis
Out of the 26 studies, 6 had extrapolated data, so they were removed to conduct a
sensitivity analysis. From the overall total of 32 studies, 8 studies were removed because
they did not have the pre-/post-VA or SD, leaving only 24 studies in the sensitivity
analysis. The adjusted WMD was similar to the WMD from the original pooled data that
included the 8 studies (WMD -0.107 with 95% CI of -0.155 to -0.062, p=0). The I^2 of
the sensitivity analysis was 0% as well. This can be seen in Figure 6 below.

Subgroup Analysis
6.4.4.1

Subgroup Analysis by Age

Ten studies included patients with a mean age younger than 18 years. Twenty-two studies
included patients that were older than or equal to 18 years old. For patients older than or
equal to 18 years old, immunosuppressive treatment had a positive statistically significant
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impact on logMAR, with vision improving by -0.147 logMAR (WMD -0.147, 95% CI 0.208 to -0.097, p=0, I2=0%, p=0.990). For patients younger than 18 years, there was a
slight increase in logMAR, but it was not significant (WMD -0.052, 95% CI -0.122 to
0.015, p=0.128 and I2=76.5% p=0.954). This can been seen in Figure 7.

6.4.4.2

Subgroup Analysis by Location

Nine studies containing intermediate uveitis patients indicated that patients had improved
vision, with a WMD of -0.146 logMAR, which was statistically significant (95% CI 0.226 to -0.0666, p=0, I2=0%, p=0.677). Ten studies containing posterior uveitis patients
had a WMD of -0.069, which was not significant (95% confidence interval -0.15 to 0.01
p=0.191, I2=0% p=0.996). Five studies containing patients with panuveitis had a WMD
of -0.10, p=0.098 (95% CI - 0.22 to 0.018, I2=0%). Three studies included a combination
of all 3 locations, and the patients that had uveitis in 1 of the 3 locations experienced
improved vision, with a WMD of -0.172 and a p-value of 0.021 (95% CI -0.419 to 0.074,
I2= 57.9% p= 0.093). It should be noted that the p-value for the z-score was calculated
using the fixed effects model. Since there was heterogeneity present in this subgroup, the
random effects model was used to test the significance of the results, because it takes into
account the between-study variance. The random effects model had a broader CI, which
was not statistically significant. Finally, there were 3 studies that did not specify the
location of uveitis; they had a WMD of -0.081 (95% CI -0.192 to 0.031 p=0.157, I2=0%).
Heterogeneity was found in 1 of the 5 categories, which was the combination of
locations, which showed an I2 measure of 57.8%, but it was not significant. This can been
seen in Figure 8.

6.4.4.3

Subgroup Analysis by Treatment

Fourteen studies that used antimetabolites as the primary treatment indicated that patients
had a statistically significant improvement in vision, with a WMD of -0.131 change in
logMAR, p=0.001 (95% CI -0.211 to -0.050, I2=0%). Fifteen studies where patients were
given T-cell inhibitors as the primary treatment showed a statistically significant
improvement in vision, with a WMD of -0.109, p=0.001 (95% CI -0.172 to -0.045,
I2=0%, p=0.680). In one study, in which patients were given an alkylating agent, the
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WMD was -0.146, p=0.497 (95% CI -0.567 to 0.275). Two studies, where patients were
given a combination of various immunosuppressive treatments had a WMD of -0.050,
p=0.497 (95% CI -0.163 to 0.064, 0% p=0.328). This can been seen in Figure 9.

6.4.4.4

Subgroup Analysis by Previous Treatment

All 3 categories: steroids, not specified, and a combination of steroids and
immunomodulatory treatment demonstrated a statistically significant improvement in
vision after primary treatment was given. However, there was no heterogeneity in any of
the categories. Fifteen studies that had given only steroids as the previous treatment had a
WMD of -0.120, p=0.002 (95% CI -0.198 to -0.042, I2=0%). Five studies within
unspecified previous treatments had a WMD of -0.100, p=0.018 (95% CI -0.157 to 0.018, I2=0%), while the treatments with steroids plus various immunosuppressive
treatment had a WMD of -0.120, p=0.008 (95% CI -0.209 to -0.031, I2=0%). This can
been seen in Figure 10.
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Study

Year

N

Primary Treatment Class

WMD (95% CI)

Bhat et al.
2009 7 Anti-Metabolites
Deuter et al.
2009 35 Anti-Metabolites
Dev et al.
1999 11 Anti-Metabolites
Dick et al.*
1997 54 T-Cell Inhibitors
Dick et al.*
1997 24 Combination of Treatments
Doycheva et al.
2012 38 Anti-Metabolites
Figeroa et al.
2007 11 T-Cell Inhibitors
Forrester et al.
1998 9 Anti-Metabolites
Friling R et al.
2005 15 Anti-Metabolites
Hemady et al.
1992 8 Anti-Metabolites
Hogan et al.
2007 62 T-Cell Inhibitors
Kilmartin et al.
1998 14 T-Cell Inhibitors
Kump et al.
2006 89 Combination of Treatments
Lee Richard et al.* 2012 19 T-Cell Inhibitors
Lee Richard et al.* 2012 16 T-Cell Inhibitors
Miserochhi et al. 2002 28 Alkylating Agents
Murphy et al.*
2005 19 T-Cell Inhibitors
Murphy et al.*
2005 18 T-Cell Inhibitors
Neri et al.
2009 19 Anti-Metabolites
Nussenblatt et al. 1985 52 T-Cell Inhibitors
Quinones et al.
2010 7 Anti-Metabolites
Ramadan et al.* 1996 6 T-Cell Inhibitors
Ramadan et al.* 1996 6 T-Cell Inhibitors
Rocha et al.
1997 8 T-Cell Inhibitors
Rosales et al.
2011 75 T-Cell Inhibitors
Rubin et al.
1993 32 T-Cell Inhibitors
Siepmann et al.* 2006 51 Anti-Metabolites
Siepmann et al.* 2006 6 Anti-Metabolites
Siepmann et al.* 2006 23 Anti-Metabolites
Stuebiger et al.
2007 17 Anti-Metabolites
Walton et al.
1998 15 T-Cell Inhibitors
Yu et al.
2005 23 Anti-Metabolites
I-V Overall (I-squared = 0.0%, p = 0.987)
D+L Overall

-0.09 (-0.87, 0.69)
0.00 (-0.23, 0.23)
-0.19 (-0.55, 0.18)
-0.04 (-0.30, 0.21)
0.13 (-0.24, 0.50)
-0.14 (-0.37, 0.10)
0.05 (-0.49, 0.58)
-0.13 (-1.70, 1.44)
-0.31 (-1.41, 0.80)
-0.28 (-0.87, 0.30)
-0.06 (-0.18, 0.05)
-0.16 (-0.57, 0.24)
-0.07 (-0.19, 0.05)
-0.01 (-1.47, 1.46)
0.01 (-1.52, 1.54)
-0.15 (-0.57, 0.27)
-0.09 (-0.26, 0.08)
-0.12 (-0.32, 0.07)
-0.30 (-0.82, 0.22)
-0.25 (-0.43, -0.08)
-0.06 (-2.40, 2.29)
0.10 (-2.44, 2.64)
0.13 (-2.36, 2.61)
-0.15 (-1.13, 0.83)
-0.10 (-0.87, 0.67)
-0.36 (-0.58, -0.13)
-0.17 (-0.29, -0.04)
-0.07 (-0.43, 0.30)
-0.08 (-0.29, 0.13)
-0.11 (-1.66, 1.45)
0.04 (-0.15, 0.23)
-0.17 (-0.69, 0.36)
-0.11 (-0.15, -0.06)
-0.11 (-0.15, -0.06)

-2
IMM improves Vision

0

%
Weight
(I-V)
0.34
3.90
1.59
3.25
1.50
3.65
0.72
0.08
0.17
0.60
16.17
1.24
14.42
0.10
0.09
1.16
7.12
5.52
0.75
6.51
0.04
0.03
0.03
0.22
0.35
4.04
13.78
1.53
4.47
0.08
5.79
0.76
100.00

2
IMM worsens Vision

Figure 5: Pooled random effects (D+L) Meta-analysis of change in logMAR for idiopathic uveitis patients given
immunosuppressive treatments (IMM)
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Study

Year

WMD (95% CI)

Bhat et al.
2009
Deshka et al.
2012
Deuter et al.
2009
Dev et al.
1999
Dick et al.*
1997
Dick et al.*
1997
Figeroa et al.
2007
Forrester et al.
1998
Friling R et al.
2005
Hemady et al.
1992
Hogan et al.
2007
Kump et al.
2006
Miserochhi et al. 2002
Murphy et al.*
2005
Murphy et al.*
2005
Neri et al.
2009
Nussenblatt et al. 1985
Nussenblatt et al. 1993
Rocha et al.
1997
Siepmann et al.* 2006
Siepmann et al.* 2006
Siepmann et al.* 2006
Walton et al.
1998
Yu et al.
2005
I-V Overall (I-squared = 0.0%, p = 0.854)
D+L Overall
-2

-0.09 (-0.87, 0.69)
-0.14 (-0.37, 0.10)
0.00 (-0.23, 0.23)
-0.19 (-0.55, 0.18)
-0.04 (-0.30, 0.21)
0.13 (-0.24, 0.50)
0.05 (-0.49, 0.58)
-0.16 (-0.57, 0.24)
-0.31 (-1.41, 0.80)
-0.28 (-0.87, 0.30)
-0.06 (-0.18, 0.05)
-0.07 (-0.19, 0.05)
-0.15 (-0.57, 0.27)
-0.09 (-0.26, 0.08)
-0.12 (-0.32, 0.07)
-0.30 (-0.82, 0.22)
-0.25 (-0.43, -0.08)
-0.36 (-0.58, -0.13)
-0.15 (-1.13, 0.83)
-0.17 (-0.29, -0.04)
-0.07 (-0.43, 0.30)
-0.08 (-0.29, 0.13)
0.04 (-0.15, 0.23)
-0.17 (-0.69, 0.36)
-0.11 (-0.15, -0.06)
-0.11 (-0.15, -0.06)
0

IMM improves Vision

%
Weight
(I-V)
0.34
3.68
3.93
1.60
3.28
1.51
0.73
1.25
0.17
0.60
16.30
14.53
1.17
7.18
5.57
0.76
6.56
4.08
0.22
13.89
1.54
4.50
5.84
0.76
100.00

2
IMM worsens Vision

Figure 6: Sensitivity Analysis (Removal of 6 studies): pooled random effects (D+L) meta-analysis of change in logMAR
for idiopathic uveitis patients given immunosuppressive treatments (IMM)
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Figure 7: Fixed effects (I+V) subgroup analysis by age examining the change in logMAR for idiopathic uveitis patients
given immunosuppressive treatments (IMM)
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Figure 8: Fixed effects (I+V) subgroup analysis by location of disease examining the change in logMAR for idiopathic
uveitis patients given immunosuppressive treatments (IMM)
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Figure 9: Fixed effects (I+V) subgroup analysis examining the change in logMAR for idiopathic uveitis patients given
the different immunosuppressive treatment (IMM) classes
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Figure 10: Fixed effects (I+V) subgroup analysis by previous treatments examining the change in LogMAR for
idiopathic uveitis patients given immunosuppressive treatments (IMM)
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Table 39: Summary of Pooled Meta-analysis and Subgroup Analysis examining the change in logMAR for treating
idiopathic patients with immunosuppressive treatments
Meta-analysis on:

Subgroup

Number of
Studies*
32

WMD
Significance test of WMD = 0
(95% CI)
(p-value)
Pooled
--0.107
z= 4.61
(-0.152 to -0.061)
(p=0.0)
Sensitivity
-24
-0.107
z= 4.61
(-0.153 to -0.062)
(p= 0.0)
Age
Greater than or equal to 18 22
-0.147
z=4.79
(-0.208 to -0.087)
(p=0.0)
Less than 18
10
-0.053
z=1.52
(-0.122 to 0.015)
(p=0.128)
Previous Treatment Immunmodulatory
9
-0.120
z=2.64
(-0.209 to -0.031)
(p=0.008)
Steroids
15
-0.120
z= 3.03
(-0.198 to -0.042)
(p=0.002)
Not Specified
5
-0.087
z=2.37
(-0.157 to -0.015)
(p=0.018)
Location of Disease Panuveitis
5
-0.100
z= 1.65
(--0.218 to 0.018)
(p=0.098)
Combination of Locations
3
-0.172
z=2.31
(-0.419 to 0.074)
(p=0.021)
Posterior Uveitis
10
-0.057
z=1.31
(-0.143 to 0.029)
(p=0.191)
Intermediate Uveitis
9
-0.146
z=3.57
(-0.226 to -0.066)
(p=0.0)
Not Specified
3
-0.081
z=1.42
(0.194 to 0.031)
(p=0.157)
Primary Treatment
Anti-Metabolites
14
-0.131
z= 3.18 (p=0.001)
Class
(-0.211 to -0.050)
T-cell Inhibitors
15
-0.109
z= 3.36 (p=0.001)
(-0.172 to -0.045)
Combination of Treatments 2
-0.050
z= 0.86 (p=0.392)
(-0.163 to 0.064)
Alkylating Agents
1
-0.146
z=0.68 (p=0.497)
(-0.567 to 0.275)
Legend: WMD= Weight Mean Difference, *Number of studies including the independent subgroups in some studies (n=32)

Test of heterogeneity, I^2
(p-value)
0% (p= 0.987)
0% (p=0.854)
0% (p=0.990)
0% (p=0.954)
0% (p=0.859)
0% (p=0.962)
0% (p=0.482)
0% (p=0.998)
57.9% (p=0.093)
0% (p=0.996)
0% (p=0.677)
0% (p=0.962)
0% (p=0.999)
0% (p=0.680)
0% (p=0.328)
--(only 1 study)
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Meta-regression
Even though there was no heterogeneity found in the pooled analysis, meta-regression
was still undertaken, as it was predefined on the onset of the study. There were 8
univariate random effect meta-regressions that we conducted. Furthermore, since there
was heterogeneity found, which was found to be not significant, it was wise to have
undertaken a meta-regression. As seen in Table 40 below, none of the pre-specified
covariates were found to be significant and no heterogeneity was found in any of the
covariates (as can be seen with the 0% I2 value).
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Table 40: Results from fitting 8 random effect univariate meta-regression models
that examined the effects of covariates on treatment effectiveness measure, logMAR
Metaregression on:

Covariate

Location of
Study
Year of study

North America (1) vs.
Other (0)
After 2005 (1) vs.
before or on 2005 (0)
Observational (1) vs.
RCT (0)
%Female Distribution

Type of Study
%Female

Mean Age

Greater than or equal
to 18 (1) vs.
Less than 18 years old
(0)

Regression
Coefficients
(95% CI)
-0.0410
(-0.145 to 0.0627)
0.0389
(-0.0578 to 0.136)
0.0373
(-1.36 to 0.210)
0.000667
(-0.0285 to
0.00418)
-0.0941
(-0.189 to 0.0132)

I^2

Adjusted
R^2

T2

0.426

Joint
Pvalue
--

0%

.%

0.0067

0.364

--

0%

.%

0

0.663

--

0%

.%

0

0.700

--

0%

.%

0

0.053

--

0%

.%

0

0.751

0%

.%

0.00139

--

-0%

---

--

0%

--

0%

.%

0%

--

--

--

Pvalue

Previous
Treatment
Immunmodulatory*
Steroids
Not Specified

-0.00658
(-.129 to 0.142)
0.0436
(-0.0916 to 0.180)

-0.922
0.515

Location of
Disease

0.531
Panuveitis
Combination of
Locations*
Posterior Uveitis
Intermediate Uveitis
Not Specified

0.0774
(-0.1223 to 0.278)
--

0.435

0.120
(-0.0615 to 0.301)
0.0957
(-.101 to .292)
0.0957
(-0.101 to 0.292)

0.187

0%

--

0.722

0%

--

0.327

0%

--

0%

.%

0.000621

--

--

--

0%

--

--

--

Primary
Treatment

--

0.744
Anti-Metabolites
T-cell Inhibitors
Combination of
Treatments*
Alkylating Agents

*Not included due to collinearity

0

0.0957
(-0.2371 to 0.724)
-0.630
(-0.208 to 0.0821)
--

0.285

0%

0.381

0%

-0.987
(-0.560 to 0.361)

0.664

--

--

--
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Publication Bias
Publication bias was assessed using Duval and Tweedie’s trim and fill method. Once the
algorithm was complete there was no trimming to be done, however, there was 1 study
that was filled in, which can be seen in Figure 11 in the study that has a square around it.
This indicates that a study was added to make the funnel plot symmetrical and less
biased.

Filled funnel plot with pseudo 95% confidence limits

theta, filled

2

0

-2

-4
0

.5

1

1.5

s.e. of: theta, filled

Figure 11: Publication bias, with Duval and Tweedie (2000)111 Method: Funnel plot
with pseudo 95% confidence limits
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Chapter 7
7

Discussion

7.1 Systematic Review
This study is unique in that it is the first systematic review and meta-analysis conducted
on immunosuppressive treatments given to non-infectious idiopathic uveitis patients
(averaging 78% of the patients having idiopathic uveitis with all the studies combined).
There were 2251 citations screened using the inclusion/exclusion criteria. The 45 studies
included in the systematic review were found to have moderate quality of evidence
according to the Downs and Black checklist. The 45 studies were divided into different
immunosuppressive treatment groups.
Also, most studies were done on the subjects that analyzed both eyes of each patient
rather than each eye individually. Issues with measuring per eye could lead to
discrepancies and heterogeneity, if they do not correlate the outcome between eyes.
Recently, Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group (2015)97
was very careful to make this distinction accounting for the likely correlation in
responses between eyes from subjects with disease in both eyes. This distinction needs to
be there or else it could lead to heterogeneity if not accounted for.
The patient and study characteristics were very similar among the various
immunosuppressive treatment groups, with the antimetabolites having the greatest
number of studies (23) and a sample size comprising of 1451 patients. The treatment
group with the second greatest number was the inhibitors of T-lymphocyte signalling,
with 15 studies and 772 patients. Given their similarity in size, these 2 treatment groups
could be compared fairly but are limited to descriptive statistics as no statistical inference
was carried out. The year, the type, and the location of where the studies were conducted
were similar across the different treatment groups. In most treatment groups the
frequency of patients that had idiopathic uveitis were similar along with factors such as
age. In most studies, location of uveitis in patients was almost evenly divided between
posterior uveitis and intermediate uveitis, and majority were idiopathic in nature. This
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enabled a systematic review to focus on studies that were specific to our question, and
allowed for as much homogeneity that could be facilitated with the data available.
The antimetabolite treatment group showed the most positive effect on VA: in 5 studies
with MTX, VA improved or maintained in 88% of the patients with a sample size of 526
patients, while in 10 studies with 271 patients given MMF, VA improved or maintained
in 85.5% of patients. In 4 studies with 474 patients given CsA, which belonged to the
inhibitors of T-cell signalling treatment group, VA improved or maintained in 59.5% of
the patient population. In 1 study, 81% of patients who received TAC, another treatment
belonging to the same treatment group, improved or maintained VA. These findings
suggest that MTX and MMF, which belong to the antimetabolite treatment group, are the
most effective in treating uveitis patients
Inflammation grade, which is a more direct measure of improvement from uveitis, also
maintained or improved with antimetabolite treatment, with MTX having a positive effect
on 72.5% of the patient population in 2 studies, and MMF on 77.5% of the patient
population in 7 studies. However, the frequencies presented cannot be used as the sole
means to detect efficacy, as a more analytical approach should be used to assess efficacy
of the different treatment groups. But, in past narrative reviews, due to the heterogeneity
in patient types and outcomes measures, no real comparison was ever done. While our
systematic review of smaller patient groups and different treatments allows these values
to be compared descriptively, definitive conclusions are difficult to make.
Discontinuation rates were low for both MTX and MMF, with lack of efficacy as the
main reason for the treatments being discontinued. MTX contained 6 studies, with 13%
to 48% of patients discontinuing treatment, while the 5 MMF studies indicated that 12%
to 35% of patients discontinued treatment. CsA was discontinued mainly due to
intolerance and side effects (specifically renal toxicity). This accounted for 11% to 30%
of patients discontinuing in the 5 studies that used CsA. The RCT with TAC indicated
that treatment failure lead to discontinuation of treatment in 50% of patients. Lack of
efficacy was another reason some of the patients that were given TAC were removed
from the study. MTX and MMF caused mild adverse events in about 14% of patients,
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while CsA and TAC had a greater number of patients for whom adverse events could be
harmful, such as renal toxicity. This corresponds with many studies that suggest CsA can
cause severe side effects, and larger doses of CsA can be more harmful to patients.

7.2 Quality Assessment
The quality of the studies was examined using the Downs and Black checklist, which
indicated that there were some low quality papers present (10%). However, the majority
of the papers were of moderate quality. All studies were included in the meta-analysis
and systematic review. The systematic review also indicated that many of the studies
were not of high quality, as evident from the literature search of the systematic review.
The methodological quality of included studies in the meta-analysis was at least
moderate. As discussed in section 5.6, the median score of observational studies being
48%, indicated that the quality of the studies were “poor to moderate”. However, the
internal validity of the observational studies was very poor, with 19% of studies having
scored a “yes” in the validity section. This suggests that there is a bias in intervention
measures for the primary outcome. This was either due to the fact that the analysis related
to the measure of choice for the VA scale or alternatively, how they analyzed the
patients’ data, such as per eye or subject level. This could indicate that there was in fact
heterogeneity related to our meta-analysis, when comparing intervention groups and the
outcomes. However, most of these validity questions were specific to randomized control
trials, and having case series and cohort studies could limit how interventions are dealt
with and measured, but does not mean that it would cause major discrepancies that would
hinder our results.
A meta-regression of the types of studies were compared (RCTs and observational
studies), and although nothing significant was found, there was a slight difference
between the change in logMAR between the 2 groups, with RCTs demonstrating a more
positive effect on logMAR post-treatment. However, it is important to note that there was
no heterogeneity between the 2 groups (12= 0%). This further strengthened our
confidence in the results.
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7.3 Meta-analysis and Subgroup Analysis
There were 26 studies included in the meta-analysis, dealing with change in logMAR,
once idiopathic uveitis patients are given immunosuppressive treatments. Of these, 5
studies did not include either pre-treatment or post-treatment logMAR, but did include
the change in logMAR, which was added postoperatively by using the mean pre-logMAR
calculated by the 20 studies that were present in the meta-analysis. Also, the pre- and
post-SD was missing from 1 study, so we had to use the highest SD given in 1 of the 26
studies, which allowed for a conservative value for the missing SD. The studies with
missing pre- and post- data did in fact demonstrate a change in logMAR and the
respective SD, so we did not make up values, but used the information provided and
extrapolated the data, which is advised when partial data is missing.
Some of the studies had independent subgroups (ie, 1 study included a subset of patients
treated with antimetabolites and another subset of patients treated with T-cell inhibitors),
which were included as individual studies, increasing the total study count to 32 studies.
From these 32 studies, 78.3% indicated a reduced logMAR (improved vision) when
patients were given immunosuppressive treatments. Using the weighted mean difference
in the overall use of treatment of any kind indicated a reduction in logMAR of -0.11,
which was significant (p=0). This suggests that there was an improvement in vision with
a change in 1.5 lines or -0.11 logMAR. Generally speaking a clinically relevant change
in vision may be described as 2 lines or -0.2 logMAR.
The sensitivity analysis, when the studies with missing data were removed and the
analysis was run again on only 24 studies, supported these results as well. Even with the
removal of those studies, there was no difference in the overall effect, which was still
significant. There was also no difference in heterogeneity. These results support results
found in the existing literature, which indicate that immunosuppressive treatments are
effective in treating patients with inflammatory eye disease.
While our results indicated there was no heterogeneity, it was not significant. To better
understand this, we conducted a subgroup and meta-regression to verify that
heterogeneity was not present and to evaluate whether any of the subgroup categories
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were more positively or negatively affected by the immunosuppressive treatment (for
example, did treatment affect different age groups differently, or did location of the
disease have an impact on effect size).
The results from the subgroup analysis for age indicated that individuals greater than or
equal to 18 years of age were affected more positively by the treatment than patients
under 18 years of age. Patients in the former group also demonstrated a statistically
significant change in logMAR of -0.147 with a p-value of 0. The heterogeneity in patients
greater than 18 years was 0%, which indicates that the different treatment groups had a
similar effect on this patient subgroup. This suggests that any immunosuppressive
treatment is likely to be effective for patients older than 18 years, and that the results are
statistically significant. In contrast, even though patients younger than 18 years
experienced improvement in vision, the improvement was not statistically significant. In
this thesis, 10 of the studies we examined contained patients below 18 years of age. Six
studies used antimetabolites, and they indicated that antimetabolites may not be
appropriate for patients younger than 18 years. (Most of these patients were JIA with
uveitis, and some were uveitis patients with no JIA involved, which could also explain
the non-significance).
Results from the subgroup analysis of previous treatment given to patients was also
important, as patients that were given just steroids before receiving the treatment of
choice had a statistically significant positive change in logMAR (WMD= -0.120, p=0.002
with I^2=0%). This was also seen in patients given steroids and other immunosuppressive
treatments before receiving the treatment of choice (WMD= -0.120 p=0.008).
Furthermore, studies that did not specify also showed a statistically significant positive
change. This could be explained by the fact that no matter which treatment they were
previously given, what mattered at the end was the impact the primary treatment had on
patients.
Subgroup analysis by location indicated that the only category that contains heterogeneity
is the combination of locations patient group (I^2=57.9%, p=0.093). This could be
explained by the fact that there were 3 different groups of patients within a study, and
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since there were only 3 studies in the subgroup, it could have resulted in the
heterogeneity seen in the subgroup analysis. Also, interestingly, intermediate uveitis was
shown to be the group most effectively treated by immunosuppressive treatment, and it
was statistically significant (WMD= -0.146. p=0). This means that patients with
intermediate uveitis have a better chance of responding to treatment from any of the
treatment groups, more so than the other 2 locations. However, as is noted in Figure 8,
there were 6 studies where intermediate uveitis patients were given antimetabolites,
whereas patients with posterior uveitis were mainly given T-cell inhibitors. This suggests
that antimetabolite treatment may play a role in why intermediate uveitis patients
demonstrated a greater change in logMAR, and thus improvements in vision, or it may
suggest that it is easier to treat patients with intermediate uveitis than those with posterior
uveitis.
Subgroup analysis by treatment found that patients given antimetabolites were more
positively (WMD= -0.131, p=0.001) treated then patients given inhibitors of T-cell
signalling (WMD= -0.109, p=001). This finding is similar to descriptive outcomes found
in the systematic review with frequencies, which indicated that antimetabolites are more
effective in maintaining or improving VA in patients. However, comparing the pre- and
post-logMAR treatment is a more accurate measure of the number of patients who got
better after treatment was administered. This supports the subgroup analysis of location
of disease discussed above, as intermediate uveitis patients also responded positively
when treated with immunosuppressive treatments, and since they were given
antimetabolites, it seems fair to conclude that antimetabolites were more effective overall
than other treatments. However, it is interesting to note that both subgroup treatment
groups experienced a statistically significant positive effect on vision. This suggests that
being given either of the 2 treatments is beneficial to patients, with antimetabolites
having a slight advantage in treating patients, especially those with intermediate uveitis.
Since the other 2 treatment groups only contained 1 to 2 studies, it is not fair to compare
those groups.
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7.4 Meta-regression
With the meta-regression, although there was no heterogeneity to begin with, some doubt
remained because it was not statistically significant in the pooled meta-analysis. After
running the meta-regression, none of the covariates were found to be associated with
change in logMAR. Furthermore, there was no heterogeneity found in the regression
models with all the covariates. We also determined joint p-values, as the meta-regression
was done with multiple categories with a covariate, for example, primary treatment had a
joint p-value of 0.744, which indicates that there is very little evidence the change in
logMAR differs among the 4 categories. The same conclusion can be drawn for all the
covariates that we examined. This suggests that the heterogeneity of 0% found in the
pooled analysis was accurate to a certain extent, since the goal of a meta-regression is to
investigate the heterogeneity between results of multiples studies and one or more
characteristics of a study can alter that heterogeneity. Since no heterogeneity was found,
meta-regression was not necessary for this study, but it added a layer of further
understanding by indicating that heterogeneity was not present.
Finally, although it was stated in the methods that a permutation test would be done,
since none of the covariates had a significant p-value, a permutation test was not needed.

7.5 Publication Bias
For publication bias, we used the trim and fill method, as mentioned earlier. Three
iterations were needed, which enabled us to identify and fix the asymmetry by adding 1
extra study to balance out the others, as can be seen in Figure 11. The addition of the
extra study made the WMD = -0.110, 95% CI -0.155 to -0.065.
As can be seen in the funnel plot, everything is within symmetry. This suggests that there
were no extreme positive studies that could have caused deviation. However, imputation
was required to create more symmetry. In other words, our selection of studies may have
been unbiased and mainly symmetrical with regards to the underlying common effect, but
we used the trim and fill method to be certain that any existing asymmetry was addressed.
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In conclusion, this study found that there was no heterogeneity in the pooled analysis, nor
was there any heterogeneity in the subgroup analysis or the meta-regression. This
indicates that the population group was fairly homogeneous and could be compared from
one study to another. Another interesting take away is that all treatments seemed to be
effective at treating uveitis, with antimetabolites and T-cell inhibitors reporting
statistically significant results. However, antimetabolites were more effective at treating
patients, demonstrating a greater change in logMAR then T-cell inhibitors.

7.6 Strengths
Meta-analysis is a powerful tool that can assist researchers when an overwhelming
amount of information is present, even when the field of study is quite narrow. However,
there can be drawbacks to conducting a meta-analysis, and it can be controversial if not
done correctly. Methodology is the most important attribute in both a systematic review
and a meta-analysis. Even a slight deviation or violation of the methods could lead to
misleading results and bias.
Our study adhered to all possible guidelines and rules of thumb from the search strategy
in the way our meta-regression was done, with consideration of all caveats. All work was
done very carefully, from the search strategy, to the article capturing and screening, to the
data abstraction, to the analysis. Careful analysis of the data was important to ensure
reliable results. The Cochrane Collaboration and the PRISMA guidelines were followed
to ensure that the meta-analysis was completed and reported with precision (see
Appendix A and B).
This is the first systematic review and meta-analysis undertaken on the treatments given
to patients that specifically have non-infectious idiopathic uveitis. We screened 2251
citations using the inclusion/exclusion criteria. Unlike previous narrative and systematic
reviews, our systematic review developed a meticulous search strategy with the help of
an information specialist. There were 6 scientific databases used to collect relevant
articles, and a comprehensive search of grey literature was also done. Strict
inclusion/exclusion criteria were developed specific to our research question, and the
studies were independently screened by 2 reviewers, in order to reduce potential bias.
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The inclusion/exclusion criteria were created to ensure homogeneity in both the studies
and the patient population. The patient population was homogenous, according to the
following criteria: primary treatment given to the patients was orally administered in all
studies, studies were limited by the type of previous treatments given, the locations of
uveitis were mainly intermediate and posterior uveitis, and the disease was specific to
idiopathic uveitis. The heterogeneity from the patient population was only in the primary
treatment given to the patients.
Unlike previous reviews, our study also used a quality assessment tool, the Downs and
Black checklist. The checklist is one of the only validated checklists for methodological
quality of observation studies. We used the checklist for all 45 studies, of which, the 28
used in the meta-analysis were moderate studies, with some RCTs as well. This suggests
that the studies that remained for our analysis were strong enough to ensure the integrity
of the results.
Alongside the systematic review, it was very important for the meta-analysis to adhere to
the strict guidelines and accurately conduct the analysis. We anticipated that the pooled
meta-analysis would have heterogeneity because all the studies were pooled together.
However, there was a specific factor in the heterogeneity, which was the primary
treatment, and therefore we needed other tests to investigate where the heterogeneity
came from. We used subgroup analysis and meta-regression to test and quantify the
heterogeneity. All precautions and rules were followed to ensure the integrity of the
results. The subgroup analysis was conducted even with the subgroups that had fewer
than 5 studies. Another method used to investigate the heterogeneity and to bypass the
subgroup analysis problem was a meta-regression. Here, while many methods were
considered, the best method for our meta-analysis was the Knapp and Hartung univariate
meta-regression. Finally, we also planned to conduct a permutation test to ensure no false
negative p-values were present in the initial test.

7.7 Limitations
Even though publication bias was found through the trim and fill method, with very
minimal changes, there were no non-English studies used in our study, which is one
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limitation that could lead to publication bias. Future studies should attempt to include
non-English studies.
The quality of the 45 studies used in this systematic review was mild to moderate, only
stating frequencies of improvements to visual acuity and inflammation grade, but
otherwise not having much statistical basis. However, the 28 studies that we used for the
meta-analysis contained more robustness in their methodology, which helped to
compensate for the overall quality of the 45 studies.
Some of the data that was collected in the extraction sheets was not used in the analysis,
in particular, the dosage, which could have played an important role in understanding the
heterogeneity. However, dosage was left out because the dosages for treatment groups
could not be compared, as different treatment groups required different dosages. Another
limitation is that some of the subgroups contained fewer than 5 studies, which can cause
bias. Generally, small subgroups such as this should not be compared to other subgroups,
however, using meta-regression on these subgroups helped to alleviate the issue when
assessing the data.
Also, we could have had methodological heterogeneity with our primary outcome. It has
been found that there is a clear correlation between the scales measuring VA. The
regression analysis revealed a significant correlation between the visual acuity scores on
the 2 charts (R2 = 0.8839) with a slope significantly different from 1 (P < .0001).
However, it is also been noted that the Snellen method is not as reliable as the logMAR
method when measuring for VA. This could lead to heterogeneity as our study had a
variation on measuring VA. Though we standardized the scales to logMAR, the initial
method used to measure VA could have led to methodological heterogeneity. Future
studies should test to see whether the difference in scales resulted in different results,
using either a subgroup or meta-regression analysis.
Also, important to note is that even though most studies conducted on the subject level, it
should be important to ensure that the methodology used by the studies allowed for
correlation if there was two observations done per individual. Thus, in future studies, we
should be stricter on the methodology of the studies, so we can ensure that studies that do
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report two observations per individual, account for correlation and thus would lead to less
error within the study and higher quality of the study for internal validity.
Another limitation is that heterogeneity was not pooled by treatment group, because there
were not enough studies in each treatment group to conduct a subgroup analysis or metaregression on each treatment group separately. When subgroup analysis or metaregression was conducted it was conducted on the pooled data. However, due to the lack
of studies, we were unable to conduct more specific analysis, such as examining the
heterogeneity of the covariates or subgroups that were examined in the pooled data, for
each primary treatment group. This may limit the interpretation of the results and
introduce complications regarding the main question this thesis wanted to answer.
In addition to the above, no analysis was conducted on the outcome of inflammation
grade, even though it is a better measure of improvement in the severity of uveitis. Again,
this was a result of not having enough studies containing the information necessary to
conduct a meta-analysis on this outcome. While this reduces the applicability of the
results, it is a good starting point.
Finally, one of the most significant limitations of a meta-analysis is the fact that any
results obtained from the subgroup analysis and meta-regression are observational in
nature. Any statistically significant or non-statistically significant result cannot be used to
draw any concrete conclusions, but could be used to make an observation. This is
important to keep in mind since power to detect heterogeneity in effect sizes or between
covariates or subgroups is very low. In other words, failure to obtain a statistically
significant difference among subgroups should never be interpreted as evidence that the
effect is the same across subgroups. The same can be said for obtaining a statistically
significant result. Simple failure to obtain a statistically significant effect for a covariate
should never be interpreted as evidence that there is no relationship between the covariate
and the effect size.
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7.8 Possibilities for future research
In future studies, there are a few elements that can be taken into consideration to ensure
better results that are more viable for converting to policy. One is the inclusion of nonEnglish studies. If we had included studies from other languages, it would have increased
our meta-analysis by 29 studies. Another is the inclusion of biologics as a treatment
group. Finally, our study did not include an analytical comparison of adverse events.
Future studies should include this element, which would facilitate a deeper understanding
about the effectiveness of different treatments. In addition to including the above
elements, future studies should also conduct a cost-effectiveness analysis, which is a key
element for creating policy. Including a cost-effectiveness model, done in accordance
with CUS and COS, would be the final step in ensuring a comprehensive study that can
be used to inform policy and further our understanding about off-label treatments and
their ability to treat uveitis patients.

7.9 Conclusion
This systematic review and meta-analysis were conducted with the utmost care and
accuracy. Idiopathic non-infectious uveitis patients that received 1 of 3 different
treatment groups were the primary patient population this study examined. There were
specific criteria used to determine which studies were included in the systematic review
and meta-analysis. This study helped to paint a better picture about the different
treatments administered to patients with non-infectious idiopathic uveitis. All treatments
were found to be effective in the pooled analysis, with a logMAR of -0.11. Furthermore,
there was an indication in the subgroups analysis that treatment was particularly
efficacious in patients over 18, patients with intermediate uveitis, patients treated with
antimetabolites, and patients pretreated (usually with steroids). Finally, there was
minimal heterogeneity present, which was explained in the subgroup analysis. Future
studies, especially those that include a cost-effectiveness analysis, will allow us to draw
better conclusions about the most effective treatments for non-infectious idiopathic
uveitis.
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Appendices
Appendix A: Meta-analysis of Observational Studies in Epidemiology (MOOSE)
Checklist
Page #
Reporting of background should include:
Problem definition
Hypothesis statement
Description of study outcome(s)
Type of exposure or intervention used
Type of study designs used
Study population
Reporting of search strategy should include:
Qualifications of searchers (eg, librarians and investigators)
Search strategy, including time period included in the synthesis and keywords
Effort to include all available studies, including contact with authors
Databases and registries searched
Search software used, name and version, including special features used (eg, explosion)
Use of hand searching (eg, reference lists of obtained articles)
List of citations located and those excluded, including justification
Method of addressing articles published in languages other than English
Method of handling abstracts and unpublished studies
Description of any contact with authors
Reporting of methods should include:
Description of relevance or appropriateness of studies assembled for assessing the hypothesis
to be tested
Rationale for the selection and coding of data (eg, sound clinical principles or convenience)
Documentation of how data were classified and coded (eg, multiple raters, blinding, and
interrater reliability)
Assessment of confounding (eg, comparability of cases and controls in studies where
appropriate)
Assessment of study quality, including blinding of quality assessors; stratification or
regression on possible predictors of study results
Assessment of heterogeneity
Description of statistical methods (eg, complete description of fixed or random effects models,
justification of whether the chosen models account for predictors of study results, dose-response
models, or cumulative meta-analysis) in sufficient detail to be replicated
Provision of appropriate tables and graphics
Reporting of results should include:
Graphic summarizing individual study estimates and overall estimate
Table giving descriptive information for each study included
Results of sensitivity testing ( eg, subgroup analysis)
Indication of statistical uncertainty of findings
Reporting of discussion should include:
Quantitative assessment of bias (eg, publication bias)
Justification of exclusion (eg, exclusion of non-English-language citations)
Assessment of quality of included studies
Reporting of conclusions should include:
Consideration of alternative explanations for observed results
Generalization of the conclusions (ie, appropriate for the data presented and within the domain
of the literature review)
Guidelines for future research
Disclosure of funding source
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Appendix B: Preferred Reporting Item for Systematic Reviews and Meta-analysis (PRISMA) guidelines
Section/topic

#

Checklist item

Reported
on page #

1

Identify the report as a systematic review, meta-analysis, or both.

--

2

Provide a structured summary including, as applicable: background; objectives; data sources; study
eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results;
limitations; conclusions and implications of key findings; systematic review registration number.

ii

Rationale

3

Describe the rationale for the review in the context of what is already known.

33-34

Objectives

4

Provide an explicit statement of questions being addressed with reference to participants,
interventions, comparisons, outcomes, and study design (PICOS).

52

TITLE
Title
ABSTRACT
Structured
summary
INTRODUCTION

METHODS
Protocol and
registration
Eligibility
criteria
Information
sources
Search
Study
selection
Data
collection
process
Data items

5

Indicate if a review protocol exists, if and where it can be accessed (eg, Web address), and, if
available, provide registration information including registration number.
6 Specify study characteristics (eg, PICOS, length of follow-up) and report characteristics (eg, years
considered, language, publication status) used as criteria for eligibility, giving rationale.
7 Describe all information sources (eg, databases with dates of coverage, contact with study authors to
identify additional studies) in the search and date last searched.
8 Present full electronic search strategy for at least one database, including any limits used, such that
it could be repeated.
9 State the process for selecting studies (ie, screening, eligibility, included in systematic review, and, if
applicable, included in the meta-analysis).
10 Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and
any processes for obtaining and confirming data from investigators.

--

11 List and define all variables for which data were sought (eg, PICOS, funding sources) and any
assumptions and simplifications made.

53-55,
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56-57
55-56
152-157
52-53
52-55

151

Risk of bias in
individual
studies
Summary
measures
Synthesis of
results
Risk of bias
across studies
Additional
analyses
RESULTS

12 Describe methods used for assessing risk of bias of individual studies (including specification of
whether this was done at the study or outcome level), and how this information is to be used in any
data synthesis.
13 State the principal summary measures (eg, risk ratio, difference in means).

56

14 Describe the methods of handling data and combining results of studies, if done, including measures
of consistency (eg, I2) for each meta-analysis.
15 Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias,
selective reporting within studies).
16 Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta-regression), if
done, indicating which were pre-specified.

52-55

Study
selection
Study
characteristics
Risk of bias
within studies
Results of
individual
studies
Synthesis of
results
Risk of bias
across studies
Additional
analysis
DISCUSSION

17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons
for exclusions at each stage, ideally with a flow diagram.
18 For each study, present characteristics for which data were extracted (eg, study size, PICOS, followup period) and provide the citations.
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item
12).
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data
for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.

66

21 Present results of each meta-analysis done, including confidence intervals and measures of
consistency.
22 Present results of any assessment of risk of bias across studies (see Item 15).

116

23 Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta-regression [see
Item 16]).

108-116

Summary of
evidence
Limitations

24 Summarize the main findings including the strength of evidence for each main outcome; consider
their relevance to key groups (eg, healthcare providers, users, and policy makers).
25 Discuss limitations at study and outcome level (eg, risk of bias), and at review-level (eg, incomplete
retrieval of identified research, reporting bias).

117-128

54

65
60-64

76-100
101
104, 116

101

126-128

152

Conclusions

26 Provide a general interpretation of the results in the context of other evidence, and implications for
future research.

130-131

27 Describe sources of funding for the systematic review and other support (eg, supply of data); role of
funders for the systematic review.

--

FUNDING
Funding
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Appendix C: Search Strategies

MEDLINE (Ovid)
Timespan:
Ovid MEDLINE(R) 1946 to July Week 1, 2012
Ovid MEDLINE(R) Daily Update July 13, 2012
Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations July 13, 2012

SEARCH STRATEGY (Blue = Keywords

/ Red = MeSH)

1 Uveitis or "Ocular inflammat$" or "Intraocular inflammat$"
2 Uveitis/ OR intermediate uveitis/ OR Uveitis, Anterior/ OR Uveitis, Posterior/
3 1 OR 2
(Immunosuppress$ or immunomodulat$) ADJ2 (agent$1 or treatment$1 or
4 drug$1 or therap$)
Immunosuppressive Agents/ or Immunosuppression/ or Immunologic
5 Factors/
6 4 OR 5
Antimetabolite$ or Azathioprine or Methotrexate or "Mycophenolic Acid" or
Alkylating Agent$ or Cyclophosphamide or Chlorambucil or Cyclosporine or
Tacrolimus or Sirolimus or Rapamycin or amethopterin OR "Mycophenolate
Mofetil" OR cytophosphane OR FK-506 OR fujimycin OR Imuran OR Azasan
OR rheumatrex OR cellcept OR trexall OR myfortic OR cytoxan OR endoxan
OR cytoxan OR neosar OR procytox OR revimmune OR chlorambucil or
leukeran or "calcineurin inhibitor$" or gengraf or neoral or sandimmune or
7 prograf or advagraf or protopic or rapamune
Antimetabolites/ or Azathioprine/ or Methotrexate/ or Mycophenolic Acid/
or Alkylating Agents/ or Cyclophosphamide/ or Chlorambucil/ or calcineurin
8 inhibitor/ or Cyclosporine/ or Tacrolimus/ or Sirolimus/ or Rapamycin/
9 7 OR 8
10 3 AND (6 OR 9)
Results = 1822
Explanation of Syntax Used:
-

the dollar sign ($) finds all variations of word endings (i.e, comput$ finds computer, computing,
etc.)
the number sign (#) finds words that may appear with or without an extra letter (ie, computer#
finds computer or computers)
the Adjacency Operator (ADJ ) searches for 2 or more words that appear within a specified
number of words (or fewer) of each other and in any order (ie, "tax ADJ5 reform" would find
instances of "tax reform" as well as "reform of income tax")
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EMBASE (Ovid)
Timespan: Embase 1980 to 2012 Week 28

SEARCH STRATEGY (Blue = Keywords

/ Red = EMTREE Terms)

1 Uveitis or "Ocular inflammat$" or "Intraocular inflammat$"
2 Uveitis/ OR intermediate uveitis/ OR Uveitis, Posterior/
3 1 OR 2
(Immunosuppress$ or immunomodulat$) ADJ2 (agent$1 or treatment$1 or
4 drug$1 or therap$)
Immunosuppressive Agent/ or Immunosuppressive Treatment/ or
5 immunomodulating agent/
6 4 OR 5
Antimetabolite$ or Azathioprine or Methotrexate or "Mycophenolic Acid" or
Alkylating Agent$ or Cyclophosphamide or Chlorambucil or Cyclosporine or
Tacrolimus or Sirolimus or Rapamycin or amethopterin OR "Mycophenolate
Mofetil" OR cytophosphane OR FK-506 OR fujimycin OR Imuran OR Azasan OR
rheumatrex OR cellcept OR trexall OR myfortic OR cytoxan OR endoxan OR
cytoxan OR neosar OR procytox OR revimmune OR chlorambucil or leukeran or
"calcineurin inhibitor$" or gengraf or neoral or sandimmune or prograf or
7 advagraf or protopic or rapamune
Antimetabolites/ or Azathioprine/ or Methotrexate/ or Mycophenolic Acid/ or
Alkylating Agents/ or Cyclophosphamide/ or Chlorambucil/ or Cyclosporine/ or
8 Tacrolimus/ or Sirolimus/ or Rapamycin/
9 7 OR 8
10 3 AND (6 OR 9)
Results = 3786
Explanation of Syntax Used:
-

the dollar sign ($) finds all variations of word endings (i.e, comput$ finds computer, computing,
etc.)
the number sign (#) finds words that may appear with or without an extra letter (ie, computer#
finds computer or computers)
the Adjacency Operator (ADJ ) searches for 2 or more words that appear within a specified
number of words (or fewer) of each other and in any order (ie, "tax ADJ5 reform" would find
instances of "tax reform" as well as "reform of income tax")
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CINAHL (EBSCO)
Timespan: 1982-present

SEARCH STRATEGY (Blue = Keywords

/ Red = CINAL Subject Terms)

1 Uveitis or "Ocular inflammat*" or "Intraocular inflammat*"
(MH "Uveitis") OR (MH "Uveitis, Anterior") OR (MH "Uveitis,
2 Intermediate") OR (MH "Uveitis, Posterior")
3 1 OR 2
(Immunosuppress* or immunomodulat*) N2 (agent# or treatment# or
4 drug# or therap*)
(MH "Immunosuppressive Agents") OR (MH "Immunosuppression") OR
5 (MH "Immunologic Factors")
6 4 OR 5
Antimetabolite# or Azathioprine or Methotrexate or "Mycophenolic Acid"
or Alkylating Agent# or Cyclophosphamide or Chlorambucil or Cyclosporine
or Tacrolimus or Sirolimus or Rapamycin or amethopterin OR
"Mycophenolate Mofetil" OR cytophosphane OR FK-506 OR fujimycin OR
Imuran OR Azasan OR rheumatrex OR cellcept OR trexall OR myfortic OR
cytoxan OR endoxan OR cytoxan OR neosar OR procytox OR revimmune
OR chlorambucil or leukeran or "calcineurin inhibitor#" or gengraf or
7 neoral or sandimmune or prograf or advagraf or protopic or rapamune
(MH "Antimetabolites") OR (MH "Azathioprine") OR (MH "Methotrexate")
OR (MH "Mycophenolate Mofetil") OR (MH "Mycophenolic Acid") OR (MH
"Cyclophosphamide") OR (MH "Alkylating Agents") OR (MH
8 "Cyclosporine") OR (MH "Sirolimus")
9 7 OR 8
10 (3) AND (6 OR 9)
Results = 89
Explanation of Syntax Used:
-

the asterisk sign (*) finds all variations of word endings (i.e, comput* finds computer,
computing, etc.)
the number sign (#) finds words that may appear with or without an extra letter (ie, computer#
finds computer or computers)
the Near Operator (N ) searches for 2 or more words that appear within a specified number of
words (or fewer) of each other and in any order (ie, "tax N5 reform" would find instances of
"tax reform" as well as "reform of income tax")
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COCHRANE LIBRARY
Timespan:
EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2012
EBM Reviews - ACP Journal Club 1991 to July 2012
EBM Reviews - Database of Abstracts of Reviews of Effects 3rd Quarter 2012
EBM Reviews - Cochrane Central Register of Controlled Trials July 2012
EBM Reviews - Cochrane Methodology Register 3rd Quarter 2012
EBM Reviews - Health Technology Assessment 3rd Quarter 2012
EBM Reviews - NHS Economic Evaluation Database 3rd Quarter 2012

SEARCH STRATEGY (all keywords)
1 Uveitis or "Ocular inflammat$" or "Intraocular inflammat$"
(Immunosuppress$ or immunomodulat$) ADJ2 (agent$1 or treatment$1 or
2 drug$1 or therap$)
Antimetabolite$ or Azathioprine or Methotrexate or "Mycophenolic Acid" or
Alkylating Agent$ or Cyclophosphamide or Chlorambucil or Cyclosporine or
Tacrolimus or Sirolimus or Rapamycin or amethopterin OR "Mycophenolate
Mofetil" OR cytophosphane OR FK-506 OR fujimycin OR Imuran OR Azasan
OR rheumatrex OR cellcept OR trexall OR myfortic OR cytoxan OR endoxan
OR cytoxan OR neosar OR procytox OR revimmune OR chlorambucil or
leukeran or "calcineurin inhibitor$" or gengraf or neoral or sandimmune or
3 prograf or advagraf or protopic or rapamune
5 1 AND (2 OR 3)
Results = 85
Explanation of Syntax Used:
-

the dollar sign ($) finds all variations of word endings (i.e, comput$ finds computer, computing,
etc.)
the number sign (#) finds words that may appear with or without an extra letter (ie, computer#
finds computer or computers)
the Adjacency Operator (ADJ ) searches for 2 or more words that appear within a specified
number of words (or fewer) of each other and in any order (ie, "tax ADJ5 reform" would find
instances of "tax reform" as well as "reform of income tax")
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BIOSIS Previews
Timespan: 1926-present (updated 2012-07-13)

SEARCH STRATEGY
Topic=(Uveitis or "Ocular inflammat*" or "Intraocular inflammat*")
AND
Topic=((Immunosuppress* or immunomodulat*) NEAR/1 (Agent& or Treatment$ or drug$ or
therap*))
AND
Topic=(Antimetabolite$ or Azathioprine or Methotrexate or "Mycophenolic Acid" or
Alkylating Agent$ or Cyclophosphamide or Chlorambucil or Cyclosporine or Tacrolimus or
Sirolimus or Rapamycin or amethopterin OR "Mycophenolate Mofetil" OR cytophosphane
OR FK-506 OR fujimycin OR Imuran OR Azasan OR rheumatrex OR cellcept OR trexall OR
myfortic OR cytoxan OR endoxan OR cytoxan OR neosar OR procytox OR revimmune OR
chlorambucil or leukeran or "calcineurin inhibitor$" or gengraf or neoral or sandimmune or
prograf or advagraf or protopic or rapamune)
AND
AND Concept Codes=(Pathology - Inflammation "and" inflammatory disease OR Pathology Inflammation "and" inflammatory disease)
Results = 112
Explanation of Syntax Used:
-

the asterisk sign (*) finds all variations of word endings (i.e, comput* finds computer,
computing, etc.)
the dollar sign ($) finds words that may appear with or without an extra letter (ie, computer$
finds computer or computers)
the Near Operator (N) searches for 2 or more words that appear within a specified number of
words (or fewer) of each other and in any order (ie, "tax N5 reform" would find instances of
"tax reform" as well as "reform of income tax")
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Web of Science
Timespan: 1898-present (updated 2012-07-13)
includes Citation Databases:
Science Citation Index Expanded (SCI-EXPANDED) --1945-present
Social Sciences Citation Index (SSCI) --1898-present
Arts & Humanities Citation Index (A&HCI) --1975-present
Conference Proceedings Citation Index- Science (CPCI-S) --1990-present
Conference Proceedings Citation Index- Social Science & Humanities (CPCI-SSH) --1990present

SEARCH STRATEGY
Topic=(Uveitis or "Ocular inflammat*" or "Intraocular inflammat*")
AND
Topic=((Immunosuppress* or immunomodulat*) NEAR/1 (Agent& or Treatment$ or drug$ or
therap*))
AND
Topic=(Antimetabolite$ or Azathioprine or Methotrexate or "Mycophenolic Acid" or
Alkylating Agent$ or Cyclophosphamide or Chlorambucil or Cyclosporine or Tacrolimus or
Sirolimus or Rapamycin or amethopterin OR "Mycophenolate Mofetil" OR cytophosphane
OR FK-506 OR fujimycin OR Imuran OR Azasan OR rheumatrex OR cellcept OR trexall OR
myfortic OR cytoxan OR endoxan OR cytoxan OR neosar OR procytox OR revimmune OR
chlorambucil or leukeran or "calcineurin inhibitor$" or gengraf or neoral or sandimmune or
prograf or advagraf or protopic or rapamune)
Results = 275
Explanation of Syntax Used:
-

the asterisk sign (*) finds all variations of word endings (i.e, comput* finds computer,
computing, etc.)
the dollar sign ($) finds words that may appear with or without an extra letter (ie, computer$
finds computer or computers)
the Near Operator (N) searches for 2 or more words that appear within a specified number of
words (or fewer) of each other and in any order (ie, "tax N5 reform" would find instances of
"tax reform" as well as "reform of income tax")
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Appendix D: Study Eligibility Criteria
Level 1 Screening:
1. Does the study look at non-infectious idiopathic uveitis in humans?
2. Is it a primary study?
3. Does the study look at immunosuppressive treatments: antimetabolites, alkylating
agents, T-lymphocytes inhibitors?
4. Was the study conducted in North America, Western Europe, Hong Kong, Japan,
New Zealand, Australia, and Singapore?
*Answer to all questions must be a yes in order to be included for level 2 screening.
Level 2 Screening:
1. Does the study look at non-infectious idiopathic uveitis (keep studies that have
50% or more of patients with non-infectious idiopathic uveitis or Juvenile
rheumatoid arthritis associated with uveitis)? Studies with 50% or more patients
with these diseases were excluded from study:
- Behects disease
- Vogt-Koyanagi-Harada
- HLA B27
- Serpiginous choroiditis
- Cystoid macular oedema
- Atopic keratoconjunctivitis
- Vasculitis
- ocular cicatrical Pemphiod
- Wegener's granulomatosis
- Sclerosis
- Sarcoidosis
2. Location of disease either posterior or intermediate or panuvitis. If 50 % or more
patients have anterior uveitis, the study is excluded.
3. Is it a primary study?
4. More than 5 patients?
5. The study population had oral treatment given
6. Does the study look at immunosuppressive treatments: antimetabolites, alkylating
agents, T-lymphocytes inhibitors?
7. Does the study report any one of these outcomes: Visual acuity, inflammation
grade, relapse rate, corticosteroid sparing rate and/or adverse events?
8. Was the study conducted in North America, Western Europe, Hong Kong, Japan,
New Zealand, Australia, and Singapore?
9. Is the study in English?
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Appendix E: Data Extraction Form

Reviewer’s Initial:
(Please check the second page if terminology is unclear)
Study Identification

Method

Participant Characteristics

Baseline Characteristics

Treatment

Outcomes
(After treatment)

(Before Treatment)
Citation (author,
year):

Study
objective:
Study
design:
Site(s):

Location of Uveitis:

Treatment given:

Pre and Post Visual Acuity

Cause of Uveitis:

Dosage (per week):

(given either in % or the
number of patients)

Type of Uveitis:

Length of time:

Severity of Uveitis:
Measured via inflammation
grade

Concurrent Treatment:

Or/And

Length of time:

Geographic location (of study):

Visual Acuity (LogMAR):

Mean Follow Up (months):

Any condition alongside Uveitis:

Is steroid give
concurrently?
Yes
No

N (Full) =
Ni (idiopathic uveitis) =
Mean age:
% Female:
Race/ethnicity (and %):

Inclusion
criteria:

Exclusion
criteria:

Lost to follow up:

Dosage (per week):

Any previous treatment given:
If yes, what dosage:

Reduction in Severity
Via:
Visual Acuity:
Or/and
Inflammation grade:
Steroid Usage:
Discontinuation of Steroids
completely
Or
Reduction in dosage of
steroids
Dosage was reduced to:

If so, which type:
Length of time:
What dosage:

Data
collection
technique:

Date(s) of
data
collection:

N (Full) = total number of patients considered. Ni= Total number of patients with idiopathic uveitis

Number of people that
relapsed once within the
followup period:
Number of people that
relapsed more than once:
Adverse events (list them
with the number of patients
that had the individual
adverse event):
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Appendix F: Downs and Black Checklist for Study Quality
Checklist for measuring study quality

6.

Reporting
1.

Is the hypothesis/aim/objective of the study
clearly described?

yes

1

no

0

2.

Are the main outcomes to be measured clearly
described in the Introduction or Methods
section?
If the main outcomes are first mentioned in the
Results section, the question should be
answered no.

yes

1

no

0

3.

Are the characteristics of the patients included
in the study clearly described?
In cohort studies and trials, inclusion and/or
exclusion criteria should be given. In casecontrol studies, a case-definition and the
source for controls should be given.

yes

1

no

0

4.

yes

2

partially

1

no

0

5.

yes

1

no

0

7.

Does the study provide estimates of the random
variability in the data for the main outcomes?
In non-normally distributed data the interquartile range of results should be reported. In
normally distributed data the standard error,
standard deviation or confidence intervals
should be reported. If the distribution of the
data is not described, it must be assumed that
the estimates used were appropriate and the
question should be answered yes.

yes

1

no

0

8.

Are the interventions of interest clearly
described?
Treatments and placebo (where relevant) that
are to be compared should be clearly described

Are the main findings of the study clearly
described?
Simple outcome data (including denominators
and numerators) should be reported for all
major findings so that the reader can check the
major analyses and conclusions. (This question
does not cover statistical tests which are
considered below.)

Have all important adverse events that may be a
consequence of the intervention been reported?
This should be answered yes if the study
demonstrates that there was a comprehensive
attempt to measure adverse events. (A list of
possible adverse events is provided.)

yes

1

no

0

9.

Are the distributions of principal confounders in
each group of subjects to be compared clearly
described?
A list of principal confounders is provided.

Have the characteristics of patients lost to
follow-up been described?
This should be answered yes where there were
no losses to follow-up or where losses to
follow-up were so small that findings would be
unaffected by their inclusion. This should be
answered no where a study does not report the
number of patients lost to follow-up.

yes

1

yes

1

no

0

no

0
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10. Have actual probability values been reported
(e.g. 0.035 rather than <0.05) for the main
outcomes except where the probability value is
less than 0.001?
yes

1

no

0

should demonstrate that the intervention was
representative of that in use in the source
population. The question should be answered
no if, for example, the intervention was
undertaken in a specialist centre
unrepresentative of the hospitals most of the
source population would attend.
yes

1

External validity

no

0

All the following criteria attempt to address the
representativeness of the findings of the study and
whether they may be generalized to the
population from which the study subjects were
derived.

Unable to determine

0

11. Were the subjects asked to participate in the
study representative of the entire population
from which they were recruited?
The study must identify the source population
for patients and describe how the patients
were selected. Patients would be
representative if they comprised the entire
source population exists. Where a study does
not report the proportion of the source
population from which the patients are
derived, the question should be answered as
unable to determine.

Internal validity — bias
14. Was an attempt made to blind study subjects to
the intervention they have received?
For studies where the patients would have no
way of knowing which intervention they
received, this should be answered yes.
yes

1

no

0

Unable to determine

0

15. Was an attempt made to blind those measuring
the main outcomes of the intervention?

yes

1

no

0

yes

1

Unable to determine

0

no

0

Unable to determine

0

12. Were those subjects who were prepared to
participate representative of the entire
population from which they were recruited?
The proportion of those asked who agreed
should be stated. Validation that the sample
was representative would include
demonstrating that the distribution of the main
confounding factors was the same in the study
sample and the source population.

16. If any of the results of the study were based on
“data dredging”, was this made clear?
Any analyses that had not been planned at the
outset of the study should be clearly indicated.
If no retrospective unplanned subgroup
analyses were reported, then answer yes.
yes

1

yes

1

no

0

no

0

Unable to determine

0

Unable to determine

0

13. Were the stay, places, and facilities where the
patients were treated, representative of the
treatment the majority of patients receive?
For the question to be answered yes the study

17. In trials and cohort studies, do the analyses
adjust for different lengths of follow-up of
patients, or in case-control studies, is the time
period between the intervention and outcome the
same for cases and controls?
Where follow-up was the same for all study
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patients the answer should yes. If different
lengths of follow-up were adjusted for by, for
example, survival analysis the answer should be
yes. Studies where differences in follow-up are
ignored should be answered no.
yes

1

no

0

Unable to determine

0

18. Were the statistical tests used to assess the main
outcomes appropriate?
The statistical techniques used must be
appropriate to the data. For example nonparametric methods should be used for small
sample sizes. Where little statistical analysis
has been undertaken but where there is no
evidence of bias, the question should be
answered yes. If the distribution of the data
(normal or not) is not described it must be
assumed that the estimates used were
appropriate and the question should be
answered yes.
yes

1

no

0

Unable to determine

0

19. Was compliance with the intervention/s reliable?
Where there was non-compliance with the
allocated treatment or where there was
contamination of one group, the question
should be answered no. For studies where the
effect of any misclassification was likely to bias
any association to the null, the question should
be answered yes.
yes

1

no

0

Unable to determine

0

20. Were the main outcome measures used accurate
(valid and reliable)?
For studies where the outcome measures are
clearly described, the question should be
answered yes. For studies which refer to other
work or that demonstrates the outcome
measures are accurate, the question should be
answered as yes.

yes

1

no

0

Unable to determine

0

Internal validity — confounding (selection bias)
21. Were the patients in different intervention
groups (trials and cohort studies) or were the
cases and controls (case-control studies)
recruited from the same population?
For example, patients for all comparison groups
should be selected from the same hospital. The
question should be answered unable to
determine for cohort and case-control studies
where there is no information concerning the
source of patients included in the study.
yes

1

no

0

Unable to determine

0

22. Were study subjects in different intervention
groups (trials and cohort studies) or were the
cases and controls (case-control studies)
recruited over the same period of time?
For a study which does not specify the time
period over which patients were recruited, the
question should be answered as unable to
determine.
yes

1

no

0

Unable to determine

0

23. Were study subjects randomized to intervention
groups?
Studies which state that subjects were
randomized should be answered yes except
where method of randomization would not
ensure random allocation. For example
alternate allocation would score no because it
is predictable.
yes

1

no

0

Unable to determine

0
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24. Was the randomized intervention assignment
concealed from both patients and health care
stay until recruitment was complete and
irrevocable?
All non-randomized studies should be
answered no. If assignment was concealed from
patients but not from stay, it should be
answered no.
yes

1

no

0

Unable to determine

0

25. Was there adequate adjustment for confounding
in the analyses from which the main findings
were drawn?
This question should be answered no for trials
if: the main conclusions of the study were based
on analyses of treatment rather than intention
to treat; the distribution of known confounders
in the different treatment groups was not
described; or the distribution of known
confounders differed between the treatment
groups but was not taken into account in the
analyses. In non-randomized studies if the
effect of the main confounders was not
investigated or confounding was demonstrated
but no adjustment was made in the final
analyses the question should be answered as
no.
yes

1

no

0

Unable to determine

0

26. Were losses of patients to follow-up taken into
account?
If the numbers of patients lost to follow-up are
not reported, the question should be answered
as unable to determine. If the proportion lost to
follow-up was too small to affect the main
findings, the question should be answered yes.
yes

1

no

0

Unable to determine

0

Power
27. Did the study have sufficient power to detect a
clinically important event where the probability
value for a difference being due to chance is less
than 5%?
Sample sizes have been calculated to detect a
difference of x% and y%.
Size of smallest intervention group
A

<n1

0

B

n1–n2

1

C

n3–n4

2

D

n5–n6

3

E

n7–n8

4

F

n +

5
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